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Abstract 
 
Cognitive function in the brain is controlled by neurotransmitters whose release is 
tightly controlled. When normal levels are perturbed deficits in function can be observed 
both in humans and in animal models. The cholinergic system, acting via muscarinic or 
nicotinic receptors, modulates neurotransmitter release.  
The aim of this thesis was to investigate the identity of the nicotinic acetylcholine 
receptor (nAChR) subtypes involved in modulating noradrenaline (NA) release, in rodent 
frontal cortex (FC) and hippocampus (HC). Comparisons were made both in vitro and 
in vivo using pharmacological tools. 
In vitro, acute application of nicotinic agonists evoked release of previously loaded 
[3H]-NA from prisms of rat FC and HC. There was a 2000-fold more potent response to 
β2* selective nAChR agonist 5-iodo-A85380 in FC than HC. A greater response to choline 
in HC than FC, combined with a lack of response to selective α7 ligands supports α3β4* 
nAChRs as the main mediator of nicotinic stimulated NA release in vitro in HC. A 
proportion of the release in each region was mediated via a potentially excitatory action of 
GABA. The profile of responses was unchanged after the acute or chronic administration of 
nicotine in vivo.  
In vivo microdialysis experiments were designed to test whether the nAChR 
subtype differences in vitro were representative of differences in vivo. 5-iodo-A85380 
administered by reverse dialysis increased NA levels to a greater extent in FC than HC, 
supporting differences in the nAChR composition involved in NA regulation between these 
two regions. Targeted stimulation of these different nAChR subtypes could allow 
exploitation of this disparity to improve function with novel compounds such as those 
described in Chapter 2. 
Overall the studies described in this thesis show that there are differences in the 
subtype of nAChRs involved in NA release from terminal fields of FC and HC both in vitro 
and in vivo.  
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1. Introduction 
1.1. The mammalian brain and its anatomical and functional 
subdivisions  
Throughout the evolution of mammals and primates there has been an increase in 
brain size relative to body size; however this has been greatest in the human lineage. 
Deviation from a correlation of the size of the brain in relation to body size however is 
thought to be an overly simplistic measure (Jerison and Count, 1955). This increase in size 
has not been uniform across all brain structures. The human brain is unique in its structure, 
with greatly enlarged cerebral hemispheres. The expansion of the cerebral cortex and the 
degree of folding are now thought to be important factors in the increased capacity for 
adaptation our large brain allow us. The degree of encephalisation has been linked to the 
perceived intelligence across vertebrate species. Reptiles for example have a lower 
encephalisation quotient (EQ) than mammals. Within mammalian species carnivores have 
higher EQ than insectivores, with simians and Homo sapiens having the highest. 
Interestingly dolphins have a similar EQ to humans.  
The earliest suggestions that specific brain functions could be associated with 
different brain regions came from the pseudoscience of phrenology, where the shape of 
different parts of the skull was linked to personality traits. Although this is not now an 
accepted theory the notion of regional specification remains. Study of patients with brain 
injuries through trauma, stroke or disease allowed the early mapping of function to specific 
regions in the brain. Extension of these cases by study of selective lesions of areas of the 
brain in animal models has allowed a more detailed map to be created, although many 
functions are so complex that they cannot be mapped to a specific brain region but depend 
on circuits linking two or more regions. Functional mapping using imaging techniques has 
also become possible in recent years in both human and animal models. Techniques such as 
functional magnetic resonance imaging (fMRI) measure the hemodynamic response in 
relation to activity (Ogawa et al 1990). The measurement of uptake of radiolabelled 
2-deoxy-glucose by positron emission tomography (PET) scanning allows location of 
regions with increased glucose utilisation and therefore assumed increase in function 
(Baron et al, 1982). These techniques allow the functional mapping of brain function under 
physiological conditions and without lesions, giving additional information on the duration 
and pattern of responses under a range of conditions (Miller et al, 1987; Goebel et al, 
1998). This thesis focuses on a comparison of two regions, frontal cortex and hippocampus, 
which will be discussed in greater detail below. 
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1.1.1. Prefrontal cortex 
The prefrontal cortex (PFC) is an important region of the brain to study due to its 
role in executive control of behaviour (Goldman-Rakic, 1996). Executive function involves 
decision making, and the ability to override instinctual or habitual responses. This region of 
the brain is proportionally larger in humans in comparison with other species, giving rise to 
the higher cognitive functions.  
All of the major psychiatric disorders have involvement of the PFC, in fact a deficit 
in executive function in one form or another is the hallmark of a psychiatric disorder 
(Fogel, 1994). Frontal lobotomy, where connections to and from the PFC are severed, was 
used as a treatment for psychiatric disorders, and often left patients with little ability to 
function in normal society. Functions such as decision making were affected, and 
attentional processes and cognition were also damaged. 
Damage to the PFC often causes deficits in executive function, with Phineas Gage 
a notable example. After an accident fired an iron rod through his brain, damaging his left 
frontal lobe, Gage became aggressive and impulsive (Harlow, 1868 reprinted 1993; 
Macmillan, 1986) although reports of the case are likely to have been exaggerated. Brain 
injuries suffered to the PFC such as from car accidents are known to be linked to 
behavioural changes, which may take years to recover from (Miller, 2000). Again these 
changes seem to arise from lack of control over executive function, with aggression and 
lack of ability to concentrate. These symptoms can persist long after other aspects of 
recovery (such as relearning motor skills) have been completed. 
1.1.1.1. Location and structure of PFC 
The PFC is the anterior part of the frontal lobe of the brain, stimulation of which 
does not lead to motor responses (Figure 1-1). For this reason it is also sometimes referred 
to as the non-motor cortex. In humans and other primates PFC is highly developed. There is 
some debate on a precise definition of the PFC, and on if this definition translates between 
species, especially between primates and rodent models (see Preuss, 1995). Many 
definitions depend on the arrangement of cellular layers within the cortex, with a granular 
layer IV, however this is absent in the rat (Preuss, 1995). This definition has been expanded 
to include some non-granular regions in the frontal cortex, allowing similarities with rodent 
brain to be identified. Reciprocal connections with other brain regions are now thought to 
be important for PFC function and therefore specification (Figure 1-1; Arnsten, 2009). In 
particular, a major projection from the thalamic mediodorsal nucleus is present which 
reaches both granular and non-granular regions in the primate cortex. These projections are 
also present in rodent brain, suggesting a similarity of the non-granular region of non-motor 
cortex across mammalian species (Leonard, 1969).  
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Figure 1-1 Functional subdivisions of the frontal cortex 
The frontal cortex has extensive connections with other brain regions and subdivisions are highly 
connected. This region regulates higher order decision making and planning. From Arnsten, 2009 
with permission. 
Studies of catecholamine distribution show that primate PFC is richly innervated 
by the dopaminergic system, with non-primates also showing innervation from 
dopaminergic nuclei. The distribution of this innervation is broadly similar to the 
mediodorsal nucleus projection (Divac et al, 1978). These projections do not distinguish 
this region from other parts of the FC (Preuss and Goldman-Rakic, 1991), however 
connections from PFC to the basal forebrain have been shown in both primate and non-
primate species (Figure 1-1; Groenewegen et al, 1997). 
The PFC is involved in delay-task performance in both primates and non-primates, 
suggesting a functional similarity of the region across species. Due to the difficulty in 
achieving a precise definition of the PFC across species the broader term FC will be used 
within this thesis. Emphasis on functional as opposed to structural homology generally 
shows more translatability of the definition of FC across species, and therefore allows the 
use of rodents as a practical and useful model for aspects of FC function (Preuss, 1995). 
1.1.1.2. Interrogation of FC function 
Examination of executive function and activity of the FC is possible due to 
development of behavioural tests, however none of these is perfect and can only give a 
surrogate for aspects of FC functioning. For many of the tasks multiple brain regions are 
involved, although attempts have been made to separate the roles of these regions. Another 
issue is that animals do not communicate in the way that we do, inferences must be made 
from observing behaviour and extrapolating to cognition. With studies in humans, of 
course, language can be used as well as behavioural measures giving a fuller picture, albeit 
 - 5 - 
with more limited experimental regimens. Some of the common behavioural tests that rely 
on FC function, at least in part, are outlined below. 
Five-choice serial reaction time task 
The five-choice serial reaction time task (5CSRTT) requires a nose poke or lever 
press on one of five locations in response to a cue. Usually the cue is a light above the 
appropriate response location. This task can be used to assess attention, reaction time, 
accuracy of responses and impulsivity in the form of prepotent responding. The duration of 
the light presentation and the time between trials can be varied to increase the power of the 
test. The 5CSRTT is a useful tool in the investigation of attention deficit hyperactivity 
disorder (ADHD) as several aspects of attention can be investigated simultaneously. This 
task is further reviewed in Robbins (2002). This task has been further refined with the 
addition of a ‘No-Go’ condition to allow the separation of motor impulsivity from 
behavioural disinhibition (Young et al, 2009; 2011). Performance in go/no-go tasks has 
been localised to specific FC subregions (Chikazoe et al, 2010). 
Attentional set shifting/ Wisconsin card sorting task 
In humans and primates this task involves the sorting of a series of cue cards into 
groups. They may be sorted by colour, shape or the number of symbols present. Once the 
rule for sorting has been learned an interdimensional shift, where, for example, two new 
colours are the relevant cues, takes place. Reversals then take place, where the previously 
correct answer is now incorrect. The most cognitively challenging aspect of the task is the 
extradimensional shift, where the previously relevant dimension (colour/shape) is no longer 
relevant. The animal version of the task requires some modification, but involves digging in 
bowls for food rewards, with odour and digging medium as the variables for the task 
(Birrell and Brown, 2000). Perseveration is the persistent repetition of an action, often in a 
manner which cannot be controlled. This symptom is in some psychiatric disorders such as 
autism and obsessive compulsive disorder. Perseveration of responding for the incorrect 
dimension is common in schizophrenia models, and is separate from learning of the initial 
task and so not a deficit in ability to learn. McGaughy et al (2008) showed that 
noradrenergic but not cholinergic deafferentation to the FC impaired attentional set shifting, 
with the extradimensional shift greatly affected. 
1.1.1.3. Summary 
FC is an important brain region as it is involved in many disorders, with particular 
impact on attentional tasks and executive function. FC does not act in isolation; it receives 
inputs from many other brain regions and acts to integrate signals to balance cognition and 
emotion. Another region of the brain known to be important in learning and memory tasks 
is the hippocampus. 
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1.1.2. Hippocampus 
The hippocampus (HC) has been widely studied due to its roles in learning and 
memory. It forms part of the limbic system and has an important role in consolidation from 
short to long term memory and spatial navigation. Damage to the HC can cause anterograde 
amnesia, the inability to form new memories. A well known case of this is that of H.M. 
(named as Henry Gustav Molaison since his death in 2008). After bilateral removal of his 
HC to relieve severe epilepsy H.M. was unable to form new episodic memories although he 
was able to learn new skills albeit with no knowledge of having done so (case review in 
Corkin, 2002). Learning in picture recognition tasks was seen, possibly due to part of the 
ventral perirhinal cortex being spared. H.M. was impaired in spatial tasks, showing an 
important association between HC and spatial ability, although he was able to draw a map 
of the floor plan of his residence, suggesting that repeated exposure can allow this deficit to 
be partially overcome (Kolb and Wishaw, 1996; Corkin, 2002).  
The role of the HC in spatial tasks is well established (Morris et al, 1982; Deiana et 
al, 2011). Place cells, which fire when the animal is in a certain location in the 
environment; have been shown in rodents (O’Keefe, 1976; Moser et al, 2008). They 
interact with head direction cells and grid cells in the entorhinal cortex helping to form 
cognitive maps. These maps may be egocentric (with self as a reference point in relation to 
intramaze cues) or allocentric (with self in relation to objects in 3-dimensional space). The 
HC is involved in the learning of allocentric spatial representations (Deiana et al, 2011). 
 
Figure 1-2 The location of the hippocampus 
A diagram of the human brain with the hippocampus, amygdala and other areas of the limbic system 
indicated. There are extensive connections between the HC and other parts of the limbic system 
leading to roles in emotion and motivation. Reproduced from Joseph, 2000. 
 - 7 - 
1.1.2.1. Location and structure  
The hippocampus is located in the medial temporal lobe, beneath the cortical 
surface (Figure 1-2). The majority of HC cell bodies are glutamatergic, with around 10 % 
GABAergic interneurons, however much of the innervation in the HC is noradrenergic, 
originating from the locus coeruleus. Afferent pathways from other regions of the brain 
contribute innervation by dopamine, serotonin, acetylcholine, GABA and glutamate. Each 
of these transmitter systems can interact with the others, and autoreceptor modulation of 
responses also takes place leading to great complexity within the HC (for full review see 
Vizi and Kiss, 1998). Table 1-1 summarises the afferent and efferent pathways of the main 
HC neurotransmitter systems. The main interactions that are important in the context of this 
thesis are those of the noradrenergic and cholinergic systems, specifically the actions of 
ACh mediated by nicotinic acetylcholine receptors. Nicotinic acetylcholine receptors 
(nAChRs) have been shown to elicit noradrenaline (NA) release by presynaptic 
mechanisms (1.3.2). 
Table 1-1 Major hippocampal transmitter systems  
ND- not determined. Reproduced from Vizi and Kiss (1998) with permission with additional 
information from Shohamy and Adcock, 2010. 
Transmitter 
system 




















100 % Interneurons 




- 15 % - 
5HT Raphe-hippocampal - 21 % - 
DA VTA-hippocampal - ND - 
 
There are large bidirectional connections between the ventral HC and the amygdala 
(Figure 1-3; Kishi et al, 2006), a region linked to stress and emotion. These projections and 
the knowledge of involvement of noradrenaline in both HC and amygdala suggest a role for 
ventral HC in emotional responses. As place fields are present across the whole HC this 
role may be to do with goal directed behaviours and the motivational significance of an area 
(Fanselow and Dong, 2010). Stress is known to trigger reinstatement of drug seeking; links 
between noradrenaline, amygdala and HC may therefore be implicated in this behaviour 
(1.2.2; Belujon and Grace, 2011). 
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Figure 1-3 euronal connectivity of the ventral HC 
Abbreviations: ACB, nucleus accumbens; AMY, cortical-like amygdalar areas (nuclei); BST, bed 
nuclei of the stria terminalis; CEA, central amygdalar nucleus; LSr, v, the rostral and ventral parts of 
the lateral septal nucleus; MEA, medial amygdalar nucleus; MPF, medial prefrontal cortex; 
SUBv, the ventral subiculum. From Fanselow and Dong, (2010) with permission. 
1.1.2.2. Examining the HC 
Separating procedural and episodic memory is relatively simple in humans 
although, as the case of H.M. shows, there are links between these. In animals these aspects 
are more difficult to separate and so many of the tasks available make some assumptions 
about what precisely is measured. Most tasks that are affected by HC manipulation in 
animal models are spatial in nature. 
Morris water maze 
This task involves the animal being placed in a tub of opaque water; within which 
there is a hidden platform which allows escape (Morris, 1981). The criteria measured are 
the time and distance swum to reach the platform. Both extra-maze (e.g. symbols on walls) 
and intra-maze cues are used although it was shown that starting position had little effect on 
the speed to locate the platform (Morris, 1981). Animals with hippocampal lesions do not 
learn the location of a hidden platform in the Morris water maze, whilst escape to a visible 
platform is unaffected (Morris et al, 1982). The role of the hippocampus in this model 
includes self-localisation and route replay (Redish and Touretzky, 1998).  
Radial arm maze 
This is a maze with a central platform surrounded by a variable number of arms, 
which can be blocked, baited or left open and unbaited. Animals must navigate to food 
rewards placed at the ends of arms. In the simplest forms of the test the animal must 
remember which arms have already been visited in the current test session, as this the most 
efficient way to visit all arms and therefore collect all food rewards. More complex versions 
of the test involve removing animals from the maze between arm entries to extend the time 
that previously visited arms must be remembered. Procedural or reference memory 
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(learning arms that are consistently unbaited) and episodic or working memory 
(remembering which arms have been visited in the current session) can be separated to a 
certain extent in this task, with pharmacological interventions shown to affect one 
component or the other. Bouffard and Jarrard (1988) showed that HC lesions affect both 
reference and working spatial memory. 
Odour span task  
This is a non-match to sample task, where increasing numbers of differently 
scented pots are presented, with a food reward in the novel scented pot. The previously 
presented pots do not remain in the same locations between trials, to separate spatial 
working memory from the odour span. Animals with damage to the hippocampus perform 
this task normally, but with poor performance if a delay is introduced, suggesting that this 
form of working memory does not rely on HC (Dudchenko et al, 2000). Indeed H.M. 
retained close to normal performance in working memory tasks (1.1.2). This suggests that 
working memory for lists of previously presented stimuli is slightly different to spatial 
working memory, and so some rodent tasks may not be ideal for separating these factors. 
1.1.2.3. Summary 
The HC is involved in learning and memory tasks, in particular the consolidation of 
memory and in spatial mapping. Ablation of the HC or perturbations of its function lead to 
anterograde amnesia and dysfunction in spatial tasks. Projections between HC and 
amygdala suggest a role for HC in emotional responses and stress, with mediation via the 
catecholaminergic systems likely to be important. 
1.2. Catecholamines 
1.2.1. Dopamine 
Although originally thought to be merely a precursor to noradrenaline (Figure 1-4), 
following the discovery of its neurotransmitter properties the role of dopamine (DA) in the 
brain has been widely studied (Carlsson et al, 1957; 1958; Benes 2001). DA has strong 
links to movement and reward in the striatum, attention in the FC and many other processes 
(Floresco and Magyar 2006; Scultz 2002; Thomas and Beal, 2007). 
 
Figure 1-4 Synthesis pathway of dopamine and noradrenaline 
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Figure 1-5 Major dopaminergic pathways in the rat brain 
The caudate putamen (CPu) or dorsal striatum (light blue) is innervated by dopaminergic neurons 
from the substantia nigra pars compacta (SNc, light orange) forming the nigrostriatal pathway and, 
to a lesser extent, from the ventral tegmental area (VTA, orange, dashed line). Two major dopamine 
pathways originate in the VTA; the mesolimbic pathway that terminates in the nucleus accumbens 
(NAcc, dark blue) and the mesocortical pathway in the prefrontal cortex (green). From Livingstone 
and Wonnacott (2009), with permission. 
DA acts via well defined pathways that give dense innervation of specific regions 
of the brain. Neurons from the ventral tegmental area (VTA) project to the ventral striatum 
(or nucleus accumbens, NAcc) in the mesolimbic pathway and also to the FC forming the 
mesocortical pathway (Bjorklund and Dunnett, 2007; Figure 1-5). The dorsal striatum 
(caudate putamen, CPu) is innervated by dopaminergic neurons from the substantia nigra 
pars compacta (SNc,) forming the nigrostriatal pathway and, to a lesser extent, from the 
VTA. 
DA receptors are metabotrophic G-protein coupled receptors that fall into two main 
classes, D1-like (D1 and D5) and D2-like (D2-4). Stimulation of D1-like receptors activates 
adenylyl cyclase and thereby increases cAMP production. D2-like receptors are inhibitory; 
activation inhibits the formation of cAMP. The distribution of the receptors is distinct but 
overlapping, D1 receptors are found in the striatonigral neurons and D2 in the striatalpallidal 
and as autoreceptors, inhibiting the further release of DA. Density of D2 receptor 
availability as measured by PET has been inversely linked with propensity to abuse drugs 
both in humans and in animal models. It is seen that lower basal D2 receptor availability 
precedes drug taking and increases impulsivity, however decreases in D2 availability can 
also be induced after drug administration (reviewed by Nader and Czoty, 2005). This 
suggests that a lower basal D2 availability increases impulsivity and therefore propensity to 
administer drug and the drug administration then causes a decrease in D2, which feeds back 
to an increased likelihood of further drug use. Phasic firing of dopaminergic neurons 
indicates differences between actual and predicted rewards (Scultz, 2002) and may be 
hijacked by drugs of abuse. Most drugs of abuse increase striatal DA, but by different 
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mechanisms. Some cause increased firing of dopaminergic neurons but others increase DA 
by inhibiting or reversing dopamine transporters or by decreasing metabolism. 
Amphetamine-based drugs that reverse the DA transporter have high abuse liability as there 
is no dose ceiling effect and their actions on catecholaminergic systems are very powerful 
(Heal et al, 2009a). Other drugs such as nicotine act to increase DA by promoting its 
release. These different mechanisms of action will be explored in Chapter 3.  
In striatum DA is also involved in motor control, but the mechanism varies. Motor 
processes are enabled by tonic dopaminergic firing as opposed to phasic changes. There is 
an optimal level of DA for correct functioning. Levels of DA that are too low are found 
during Parkinson’s disease (PD) and cause poverty of movement. Other symptoms include 
depression, apathy and cognitive problems (Krishnamoorthy and Craufurd, 2011). A 
common model of PD is treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP). This potent toxin destroys dopaminergic neurons in the substantia nigra and so 
causes symptoms of PD. Motor deficits are not seen unless there is an almost complete 
lesion, so low numbers of neurons can compensate for substantial losses. Noradrenaline has 
also been suggested to play a role in PD (see 1.2.2). Levels of DA that are too high in 
striatum cause hyperactivity (Gainetdinov et al, 1999). Increased DA levels have also been 
linked with schizophrenia and mania. 
 
Figure 1-6 Inverted U shaped influences of catecholamines on FC function 
Both NA A) and DA B) must be present at optimal levels for optimal FC function. There are 
increasing levels of catecholamine release with arousal level with low levels during fatigue, optimal 
phasic release during alert conditions and high levels during stress. The examples are patterns of FC 
neuronal firing from monkeys performing a delayed response spatial working memory task with the 
preferred direction (PD) on the left of each example, and non-preferred direction (NPD) on the right. 
Figure adapted from Arnsten (2011) with permission. 
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DA in the FC is involved in attention and working memory tasks, with low levels 
during fatigue or depletion leading to poor performance (Arnsten, 2011; Figure 1-6). 
Optimal performance and FC neuron firing is found at moderate DA levels, with levels that 
are too high (under stress or after drug administration) causing the FC to become 
disengaged (Cools and D’Esposito, 2011). Disengagement of the FC can cause cognitive 
inflexibility seen as perseverance in the WCST (1.1.1.2) and often noted in schizophrenics. 
Schultz (2002) has attributed the modulation of executive function by DA to its roles in FC.  
1.2.2. oradrenaline 
Noradrenaline is produced from dopamine by dopamine-β-hydroxylase (Figure 
1-4). In contrast with the well studied role of dopamine within the nervous system, less 
focus has been directed upon noradrenaline (NA) recently. The role of NA has been shown 
to include attribution of salience to stimuli, attentional control, executive functioning in the 
FC and modulation of the responses of the DA system. Neurons releasing NA arise from 
the locus coeruleus (LC; Figure 1-7) and project across the brain. NA release from nerve 
terminals is exocytotic, and requires Ca2+; termination of signalling is by reuptake.  
 
Figure 1-7 oradrenergic pathways in the brain 
The main noradrenergic pathways in the rat brain. Abbreviations A, amygdala; AON, anterior olfactory 
nucleus; AP-VAB, ansa peduncularis–ventral amygdaloid bundle system; BS, brainstem nuclei; C, cingulum; 
CC, corpus callosum; CER, cerebellum; CTT, central tegmental tract; CTX, cortex; DB, dorsal bundle; DPS, 
dorsal periventricular system; F, fornix; FC, frontal cortex; FR, fasiculus retroflexus; H, hypothalamus; HF, 
hippocampal formation; LC, locus coeruleus; ML, medial lemiscus; MT, mamillothalamic tract; OB, olfactory 
bulb; PT, pretectal area; RF, reticular formation; S, septum; SC, spinal cord; ST, stria terminalis; T, tectum; TH, 
thalamus. From Sara, 2009 with permission. 
Similarly to DA receptors NA receptors are G protein coupled. The actions of the 
β adrenergic receptors are mediated by Gs coupled to adenylyl cyclase and GTP leading to 
the formation of cAMP and then activation of PKA which can phosphorylate a variety of 
proteins (Figure 1-8). The actions of β1 and β2 receptors oppose one another, which may be 
due to the different distribution, with β2 on glial and β1 on neuronal cells. The α2 subtype 
of NA receptor is coupled to Gi instead of Gs, and so inhibits the cAMP/PKA pathway. This 
is important as it is present presynaptically where it acts as an inhibitory autoreceptor 
(reviewed by Starke, 2001). The postsynaptic α1 adrenoceptor acts rather differently and is 
excitatory through activation of intracellular Ca2+ stores via IP3 (Figure 1-8). 
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Figure 1-8 A receptor subtypes 
Increasing levels of NA stimulates receptors with different affinities that activate different 
intracellular pathways. AC, adenylyl cyclase; LC, locus coeruleus; PLC, phospholipase C; IP3, inositol 1,4,5- 
triphosphate; DAG, diacylglycerol. Adapted from Ramos and Arnsten (2007) with permission 
Regulation of NA is extremely important, as its influence on cognition has an 
inverted U shape, with optimal functioning at moderate levels of NA, as seen for DA 
(Arnsten, 2011; Figure 1-6). Low NA levels, through fatigue, depletion or antagonism 
impair performance and cause poor attention. The subtype with the highest affinity is α2 
and so moderate levels of NA enhance FC cognitive function. Higher NA levels (such as 
during stress) stimulate α1 and β1 receptors, causing disengagement of the FC (Figure 1-6 
and Figure 1-8).  
Attention deficit hyperactivity disorder (ADHD) is characterised by deficits in 
attention and impulse control. It has been linked to several genetic variants, including some 
in catecholaminergic systems; in particular DA receptor genes, the DA transporter (DAT) 
and the NA transporter (NET; Arime et al, 2011). Low FC DA and NA in comparison with 
control are seen as a result of the dysfunction of the transporters (reviewed in Prince, 2008; 
Levy, 2009). One animal model of ADHD is the spontaneous hypertensive rat, with the 
DAT knockout mouse also used by some groups (Meneses et al, 2011; Arime et al, 2011). 
The main classes of drug prescribed for ADHD are stimulants and catecholamine 
reuptake inhibitors although α2-adrenoceptor agonists and monoamine oxidase inhibitors 
are also used. The efficacy and safety of these pharmacological treatments is further 
discussed in Heal et al (2009a). Briefly, these drugs act to increase FC NA and DA to 
optimal levels, although the administration of high doses can cause levels that are too high 
and thus suboptimal performance on attentional tasks. Stimulant medications are more 
efficacious than reuptake inhibitors, but with a higher abuse liability (1.2.1). All of the 
medications currently available for ADHD influence both DA and NA transmission and 
improve aspects of FC function. The role of nAChR agonists as possible alternative ADHD 
treatments has been investigated for several drugs in recent years (1.4).  
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NA has also been considered in conditions such as Parkinson’s disease (PD). 
Although usually thought to be characterised by loss of nigrostriatal DA neurons (1.2.1) 
there is also a loss of NA neurons arising from LC in PD (Marien et al, 2004; 
Rommelfanger and Weinshenker, 2007). A neurotoxic lesion of DA neurons with MPTP is 
the usual PD animal model, but this does not model the motor deficits well in rodent 
models (Tillerson et al, 2002). The dopamine-β-hydroxylase knockout mouse (dbh-/-) 
which is unable to produce noradrenaline from dopamine has abnormalities in coordinated 
movement (Rommelfanger et al, 2007), and this is not exacerbated by MPTP treatment. 
The motor impairment is also seen in NA-lesioned animals and could be improved by the 
restoration of NA or by DA agonist treatment. These data suggest a synergistic effect of 
DA and NA loss during the early stages of PD, possibly opening up new treatment options. 
Noradrenergic transmission also has a role in the positive rewarding effects of drug 
taking, dbh-/- mice do not show conditioned place preference for morphine, although place 
preference for food rewards (a natural stimulus) is the same as for wild-type, suggesting 
that that there is no effect on learning. Place preference was found in these animals for 
morphine if NA signalling was rescued in the central nervous system (Jasmin et al, 2006). 
Highly salient natural stimuli induce a greater release of FC NA than low salience stimuli. 
Selective FC NA depletion with DSP-4 has been shown to impair CPP induced by these 
highly salient stimuli to a greater extent than for stimuli with low salience (Ventura et al, 
2008). This suggests that NA is particularly important in regulating responses to natural 
stimuli when they are of high salience, the responses to many drugs of abuse are higher 
than for natural stimuli and so the FC NA system is likely to be involved in responses. 
NA is also increased in withdrawal from addicting substances. Destruction of the 
LC reduces physical symptoms during withdrawal from opiates (Maldonado and Koob, 
1993). Noradrenergic neurons project to the amygdala, causing the release of corticotrophin 
releasing hormone, further activating the release of NA. This feed forward mechanism 
during withdrawal is aversive, leading to anxiety and increasing drug seeking in order to 
relieve craving. The shift from the hedonic reward-seeking to the negative relief-seeking 
mode is an important factor in the theory of drug addiction (compulsive behaviour) and 
drug taking (Koob, 2009). The involvement of NA and modulation of emotional centres in 
the brain goes some way to explain how stress can trigger relapse to drug seeking in a 
variety of paradigms (reviewed in Steketee and Kalivas, 2011). 
Many factors are known to influence the release of NA, and hence influence the 
conditions mentioned. One of these factors is the administration of nicotine. NA has a 
number of modulatory effects in various brain regions; a greater understanding of the 
regulation of NA in various brain regions by nicotinic receptors may contribute towards a 
greater understanding of nicotine’s effects. 
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1.3. Nicotinic Acetylcholine Receptors 
In the Western world tobacco smoking is the leading preventable cause of 
premature death, contributing to an estimated 5 million deaths per year from smoking 
related illnesses such as cancers and vascular and chronic lung diseases (WHO, 2009). Only 
4-6% of those who attempt to quit are successful in doing so (RCP, 2007) despite a range of 
therapies being available to assist quit attempts. Nicotine is the main addictive component 
of tobacco products, and exerts its effects via the nicotinic acetylcholine receptor (nAChR). 
Aside from the physical symptoms, one of the many reasons given for failure (or 
unwillingness) to quit smoking is perceived effects on cognition during nicotine withdrawal 
(Beaver et al, 2011). This, along with reports that patients with schizophrenia, depression, 
ADHD and other disorders affecting cognition smoke more, has led to research into the 
cognitive enhancing effects of nicotine. Data support an enhancement of cognition by 
nicotine in abstinent smokers, with varying reports of the effects in non-smokers (Snyder et 
al, 1989; Wignall and de Wit, 2011). Not all studies with human subjects have found 
improvements in cognitive performance with nicotine, suggesting that improvements are 
stronger when there is suboptimal function, such as during nicotine withdrawal. Many of 
the cognitive responses to nicotine have been shown to follow an inverted U-shape curve, 
as seen for catecholamines (Figure 1-6). This suggests that the cognitive benefits may be 
due to optimisation of neurotransmitter function. These data suggest that there may be 
benefits to nicotine treatment in other groups with cognitive impairment, especially as 
cognitive components are often an unmet treatment need in psychological disorders such as 
schizophrenia and depression. The addictive nature and side effects of nicotine mean that it 
is not an ideal drug and so drug design has focussed on nAChR subtype-selective 
compounds as possible therapeutic agents. This is made possible by knowledge of the 
structure, function and localisation of nAChRs within the brain. 
1.3.1. Structure of nAChRs 
The nAChR is found not only at the neuromuscular junction but also in the 
peripheral and central nervous systems, where it is more important in terms of addiction 
and withdrawal. The nAChR is a pentameric ligand gated ion channel of the cys-loop 
family (reviewed in Sine and Engel, 2006). In muscle nAChRs are formed from two 
alpha-1 subunits in combination with one each of beta-1, gamma and delta subunits with α 
subunits being defined by the presence of a pair of adjacent cysteine residues in the 
N-terminal domain that contribute to the ligand binding site. In CNS the nAChR consists of 
alpha (α2-10) and beta (β2-4) subunits. In the mammalian brain the α2-7 and β2-4 nAChR 
subunits are found. The pentameric channel can either be homomeric (α7) or heteromeric 
comprising combinations of α and β subunits with the ligand binding site at the interface 
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between two subunits. The most common heteromeric nAChR in the mammalian brain is 
the α4β2*, where * indicates the possibility of other subunits (Lukas et al, 1999). The 
α3β4* subtype is also found, as well as more complex subtypes e.g. α3/α6α4β2* (1.3.2). 
The α7 subunit can contribute both primary and complementary faces of the binding site 
and so is found as a homomeric pentamer (Figure 1-9). Although found throughout the 
brain there was little evidence of nAChRs mediating synaptic communication until their 
role in modifying transmission via a presynaptic localisation was shown (McGehee et al, 
1995). The cellular localisation of nAChRs is further discussed below (1.3.2). 
 
Figure 1-9 Example subunit stoichiometries of neuronal nAChRs 
Neuronal nAChRs are either heteromeric (A) or homomeric (B). The agonist binding site (red dot) is 
between the alpha subunit and the adjacent subunit.   
The binding site is at the interface between pairs of subunits and is comprised of 
residues from the primary and complementary faces. A number of important residues have 
been identified as being involved in ligand binding and these are highly conserved (Figure 
1-10). Most of the conserved residues are present on the primary face of the binding site on 
the alpha subunit. The beta subunit contributes the complementary face and a number of 
less well conserved residues have also been identified, which are thought to be involved in 
conferring specificity to different receptor subtypes. The fifth subunit in a heteromeric 
receptor can be either alpha or beta and is usually thought to be structural (Figure 1-9), 
although functional roles of this accessory subunit have been postulated (1.3.3). The 
subtypes of nAChR differ in their affinities for ligands and so can be distinguished from 
one another. For example receptors containing α4 subunits have higher affinity for nicotine 
than those containing α3 subunits (Fenster et al, 1997). The significance of receptor 
composition will be discussed below (2.6.3.3).The interactions of several ligands (both 
agonists and antagonists) have been mapped by Parthiban et al (2010) and are shown below 
using the α7 nAChR residues (Table 1-2). Numbering of the conserved residues differs 
between subunits and from the acetylcholine binding protein (AChBP) hence the 
differences between Figure 1-3 and Table 1-2 (see Appendix 1for table summarising these 
differences). 
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Figure 1-10 Conserved residues in the Ach binding pocket 
A number of important residues around the Ach binding site have been identified. A) A schematic to 
show the loops contributing important residues from the primary (orange) and complementary (blue) 
faces of the binding site. B) X-ray crystallography structure of the ligand binding site in AChBP in 
complex with nicotine. Important residues are in stick structure and coloured according to the same 
scheme as A. From Changeux and Taly, (2008), with permission. 
The difference in the effect of mutations on the binding of different drugs suggests 
that the residues that ligands interact with can differ. The main interactions for a selection 
of ligands are shown below (Table 1-2). Alterations to the structure of the ligand can 
strengthen or disrupt the bonds between ligand and receptor. Exploiting this can lead to the 
development of new selective ligands, however the interactions must be well modelled, 
which is only the case for the most highly conserved residues. Modelling selectivity is more 
difficult as there is variability between species as well as between subunits near the binding 
pocket in the non-conserved residues, meaning that the validation of selective drugs is 
hampered if they are to be developed for clinical use. 
Table 1-2 Interacting residues from neuronal α7 nAChR 
Those residues that are important for binding across all ligands listed are indicated in bold. Adapted 
from Parthiban et al (2010) with permission 
Ligand Interacting residues 
Agonists  
Acetylcholine 
Tyr91, Ser146, Trp147, Tyr186, Cys188, Cys189, Tyr193, Trp53, 
Leu117 
icotine 
Tyr91, Ser146, Trp147, Ser148, Cys188, Cys189, Tyr193, Trp53, 
Leu107, Leu117, Tyr116 
Epibatidine Trp147, Tyr186, Cys188, Cys189, Tyr166, Gln115, Leu117, Leu109 
Antagonists  
Mecamylamine Cys188, Cys189, Tyr193, Trp147, Leu117, Glu115, Leu107 
DHβE  Tyr147, Tyr186, Cys188, Cys189, Tyr166, Gln115, Leu117, Leu109 
B A 
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1.3.2. Distribution and localisation 
NAChRs are found throughout the mammalian brain, with higher densities in 
cortex, hippocampus and striatum than cerebellum. Early studies using autoradiographic 
techniques found little correlation between binding sites for [3H]-nicotine and 
[125I]-α-bungarotoxin (α-Bgt; Clarke et al, 1985). This led to the supposition that these were 
labelling different populations of nicotinic receptor, which are now known to be the 
high-affinity heteromeric subtypes and α7 for nicotine and α-Bgt respectively.  
 
Figure 1-11 Autoradiographic nicotinic binding sites in rat brain 
Serial sections were incubated with [3H]-Acetylcholine (left), [3H]-Nicotine (middle) or 
[125I]-bungarotoxin (right). Non-specific binding was determined in an excess of unlabelled nicotine 
(10 µM for nicotine, 1 mM for α-Bungarotoxin) or carbachol (100 µM for Ach). Abbreviations; APT, 
Anterior pretectal area; Arc, arcuate hypothalamic nucleus; AV, anteroventral thalamic nucleus; BL, basolateral 
amygdaloid nucleus; BM, basomedial amygdaloid nucleus; DA, dorsal hypothalamic area; DG, dentate gyrus; 
DLG, dorsal lateral geniculate nucleus; DM, dorsomedial hypothalamic nucleus; En, endopiriform nucleus; 
Hi, hippocampus; ICPC, intracommisural nucleus of the posterior commisure; IMCPC, interstitial 
magnocellular nucleus of the posterior commissure; LP, lateral posterior thalamic nucleus; Me, medial 
amygdaloid nucleus; MHb, Medial habenular nucleus; mt, mammiliothalamic tract; OPT, olivary pretectal 
nucleus; PCo, posterior cortical amygdaloid nucleus; PH, posterior hypothalamic nucleus; PM, paramedian 
lobule; PMCo, posteromedial cortical amygdaloid nucleus; PT, paratenial thalamic nucleus; Re, reuniens 
thalamic nucleus; Rt, reticular thalamic nucleus; STh, subthalamic nucleus; VL, ventrolateral thalamic nucleus; 
VLG, ventral lateral geniculate nucleus; VM, ventromedial hypothalamic nucleus; VPM, ventral parabrachial 
nucleus. From Clarke et al (1985), with permission. 
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Binding patterns for [3H]-ACh, [3H]-Nicotine and [125I]-α-Bgt in sections of rat 
brain showing hippocampal and cortical regions are shown in Figure 1-11 (Clarke et al, 
1985). The proportion of different nAChR subtypes varies between different brain regions 
with the FC containing mostly α4β2* and the HC having a higher proportion of α7 (Clarke 
et al, 1985). More complex subtypes such as the α3/α6α4β2 have been shown to be present 
in the striatum (Livingstone et al, 2009). Epibatidine (Epi) is a nicotinic agonist with high 
potency at heteromeric nAChRs (Marks et al, 1998). A study immunoprecipitating [3H]-Epi 
bound nAChRs with a variety of subunit specific antibodies has shown that the majority of 
the nAChRs in a variety of regions of the rat nervous system are comprised of α4 and β2 
subunits (Figure 1-12; Gotti and Clementi, 2004). All the regions examined also contained 
some α5 subunits, and HC, superior cervical ganglia and retina had α3 and β4 subunits 
present. The α6 and β3 subunits were expressed in striatum and retina with expression of α2 
almost exclusively in retina. Immunoprecipitation of α7 was not included due to the 
absence of a suitable antibody. 
 
Figure 1-12 Distribution of nAChRs in rat nervous system 
Immunoprecipitation analysis of [3H]-Epi labelled nAChRs expressed in rat cortex, hippocampus, 
striatum, retina and superior cervical ganglia. The level of Ab immunoprecipitation is expressed as 
the percentage of [3H]-Epi labelled receptors immunoprecipitated by the indicated antibodies, taking 
the amount of receptors present in the Triton X-100 extract solution before immunoprecipitation as 
100%. From Gotti and Clementi (2004) with permission. 
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As well as brain region distribution, the cell types upon which nAChRs occur are 
important in determining consequences of their activation. Jones et al (2001) showed 
extensive colocalisation of tyrosine hydroxylase (TH) and β2 subunit antibodies in sections 
from rat substantia nigra. Within striatal synaptosomes there was some overlap of TH and 
β2 staining, with additional synaptosomes showing TH staining alone. This shows a 
presynaptic localisation of β2* nAChRs in dopaminergic neurons in striatal areas, in 
agreement with functional data discussed below. 
The α7 nAChR is found localised to axon-dendritic synapses in association with the 
neuronal membrane in tissue from HC. In the ventral tegmental area (VTA) most α7 
nAChRs were found in somatodendritic and presynaptic locations, with the majority of 
presynaptic receptors found on glutamatergic axon terminals. Receptors were also 
associated with dopaminergic neurons but not with astrocytes (Jones and Wonnacott, 
2004). The presence of α7 nAChRs on LC noradrenergic neurons was shown by Bitner and 
Nikkel (2002), with a number of small, possibly GABAergic, α7 positive cells also present. 
The same work also found a population of α7 positive serotonergic cells in dorsal raphe, 
again with a population of putatively GABAergic cells also positive for α7 nAChRs (Bitner 
and Nikkel, 2002). Dehkordi et al (2007) showed extensive expression of α7 and α4 
subunits in GABAergic neurons in rostral ventral medulla. 
1.3.3. Function  
Upon binding of the endogenous ligand, acetylcholine, or exogenous ligand such as 
nicotine, the probability of the ion channel opening increases and allowing Na+ and Ca2+ 
influx and K+ efflux, causing a depolarisation within the cell. Both presynaptic and 
preterminal localisations of nAChRs have been found. Presynaptic nAChRs elicit 
neurotransmitter release at the synapse by virtue of Ca2+ influx through the receptor 
(McGehee et al, 1995). The Ca2+ influx through nAChRs can also elicit responses from 
voltage operated calcium channels (VOCCs) or Ca2+ induced Ca2+ release (CICR) from 
intracellular stores (Figure 1-13A), giving larger rises in intracellular Ca2+ than would result 
from receptor opening alone. As well as vesicular neurotransmitter release this increase in 
calcium can trigger a variety of intracellular signals (Figure 1-13B) leading to both short 
and long term effects.  
Many ACh release sites in the brain are non-synaptic, giving a low concentration of 
ACh within the extracellular space. This ACh is unlikely to diffuse into synapses and 
activate presynaptic nAChRs. A large number of nAChRs are located preterminally, that is 
not directly in the synaptic region. Preterminal nAChRs have been shown to be involved in 
neurotransmitter release at the synapse, via a tetrodotoxin sensitive mechanism (Lena et al, 
1993).  
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Figure 1-13 Intracellular Ca
2+
 signalling 
A) Different mechanisms by which nAChR stimulation increases intracellular calcium. 
B) Intracellular signalling pathways affected by Ca2+. Adapted from Dajas-Bailador and Wonnacott 
(2004), with permission  
Preterminal nAChRs can also elicit neurotransmitter release non-synaptic sites; 
transmitters must diffuse away from the release site to activate receptors and may be 
involved in volume transmission. The increase in intracellular Ca2+ through preterminal 
nAChRs is also a mediator of VOCCs and CICR as seen for presynaptic localisations. 
1.3.4. Structure and gating 
Each nAChR subunit has four membrane spanning domains, termed M1 to M4 and 
a large N-terminal domain. The M2 region of each subunit lines the central pore and there 
is an intracellular loop between M3 and M4 that contains phosphorylation sites involved in 
receptor regulation (Lopez-Hernandez et al, 2008). Due to its membrane spanning domains 
there are no x-ray crystal structures of the nAChR; however a soluble molluscan 
acetylcholine binding protein (AChBP) from Lymnaea stagnalis, comprising regions 
A 
B 
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homologous to the extracellular binding domains of the nAChR has been crystallised and 
the structure determined at a 2.7 Ǻ resolution (Brejc et al, 2001). This has given insight into 
the locations of residues critical to ligand binding at the subunit interface. A 4 Å resolution 
model of the acetylcholine receptor from Torpedo marmorata muscle has been produced, 
using electron microscopy images and has been shown to have similar topology (Unwin 
2005). A comparison of the structure of the AChBP and Torpedo nAChR is shown below 
(Figure 1-14). The α subunits in the Torpedo structure differ from those in the 
homopentameric AChBP, likely because they represent the closed unbound state and 
indeed a ‘spray-freezing’ technique used by Unwin (2005) has shown that upon ACh 
binding, the α subunit B and C loops are rearranged to more closely resemble those of the 
AChBP in bound form, indicating local structural rearrangement upon ligand binding.  
The N-terminal cys loop consists of a 15 amino acid sequence with a cysteine-
cysteine disulphide bond. This loop is common to a family of ion channel receptors across 
both anion and cation permeable classes and is critical for channel opening and signal 
transduction (Sine and Engel, 2006). Hydrophobic residues on neighbouring pore lining M2 
helices form a tight girdle that prevents ions passing through in hydrated form. As the 
hydration shells of Na+ or K+ ions are not easily lost without polar surfaces to substitute for 
water, this hydrophobic ring forms an energetic barrier to ion permeation (Unwin, 2003). 
Agonist binding leads to a 15 ° rotation of the two muscle α subunits and a concerted 
movement of all 5 M2 helices, widening the pore by 3 Å and allowing cations to pass 
through (Unwin, 2003; Figure 1-15). This mechanism of channel opening by a twisting of 
the subunits has been tested by several models and is further reviewed by Taly (2007). 
 
Figure 1-14 Subunit topology of the AChBP and nAChR 
Ribbon diagrams of A) AChBP from Lymnaea and B) muscle nAChR from Torpedo. The receptor 
has 5-fold rotational symmetry. The α subunits in the Torpedo structure are rotated in comparison to 
the ligand bound AChBP, with an opening of loop C. Adapted from Brejc et al, 2001 and Unwin, 
2005 with permission. 
 
A B 
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Figure 1-15 Model of nAChR channel opening 
Cross section of the gate showing atoms encircling the closed (A) and open (B) pore. This opening is 
modelled by applying 15 ° rotations of the M2 helices (C), resulting in a 3 Å widening of the pore. 
Adapted from Unwin, 2003 with permission. 
Many of the elements in the extracellular domain and the transmembrane domains 
are rigid, whereas there is a more flexible linker region between the two. In α subunits short 
loops joining two β strands dock into a hydrophobic pocket made by the end of the M2 
helices (Unwin, 2003). This gives a direct link through which to transmit the rotational 
movement to the membrane spanning regions. Many mutations implicated in myasthenia 
gravis and autosomal dominant nocturnal frontal lobe epilepsy have been traced to the rigid 
transduction regions of the α subunit, suggesting that they have a direct effect on the 
translation of binding to gating (Taly et al, 2007). 
It is possible for the channel to open briefly without ligand present; this is best 
explained by a model where the different receptor conformations are in equilibrium, with 
ligand binding shifting the equilibrium to favour the open conformation (Figure 1-16). 
Binding of ligand therefore stabilises the open state, with a second ligand molecule further 
stabilising the channel opening. Creation of chimeric receptors has proven experimentally 
that binding at two sites gives optimal channel opening (Andersen et al, 2011). This study 
also showed that each coupling region contributes equally to the open channel stability. A 
C 
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minimal requirement in a homomeric receptor is for a single binding site flanked by two 
active coupling regions, or alternately a single coupling region flanked by two active 
binding sites (Andersen et al, 2011). The addition of a third, desensitised, state is important 
when modelling nAChRs. This is an important mechanism of signal termination. Many 
authors now suggest the existence of a second non-activable desensitised state, where 
ligand binding and channel become functionally uncoupled due to alterations in the 
structure of the coupling domain (daCosta and Baenziger, 2009). 
 
Figure 1-16 A Monod-Wyman-Changeux model for nAChRs 
C, O and D are closed, open and desensitised receptor forms respectively. A represents the agonist 
concentration. The equilibrium constants are represented on the appropriate arrows. From Grosman 
and Aerbach, 2001 with permission. 
As well as differences in ligand sensitivity, nAChR subtypes have differing 
calcium permeability and gating and desensitisation kinetics; this can be affected by both 
the alpha and beta components. Receptors containing β2 desensitise more quickly than 
those containing β4 (Nelson and Lindstrom, 1999). Recovery from desensitisation also 
varies with α3 containing receptors recover more quickly than those containing α4; 
similarly β2 recover quicker than β4 (Fenster et al, 1997). The homomeric α7 nAChR has 
the fastest rates of desensitisation and recovery. The α5 subunit does not form a binding site 
and does not coassemble with beta subunits alone; however it will assemble into a 
pentamer with α3β2 or α3β4 combinations (Wang et al, 1996). This role as a structural 
accessory subunit does not change the binding affinity of receptors although the presence of 
α5 causes faster desensitisation (Wang et al, 1996). There is also an effect of α5 on single 
channel properties in α3β4 nAChRs, with a larger channel conductance found (Nelson and 
Lindstrom, 1999). 
1.3.5. Summary 
The stimulation of neuronal nAChRs causes a rotation of the M2 helices, opening 
the channel pore and allowing an influx of Ca2+ and a depolarisation within the cell. Due to 
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the subcellular distribution of the receptors this can lead to intracellular signalling (Figure 
1-13B) or, more relevantly to the current work, neurotransmitter release. The consequences 
of this release of neurotransmitter have already been discussed (1.2). The ability to 
influence neurotransmission by targeting nAChRs leads to the possibility of nicotinic drugs 
being used as therapies for a wide range of diseases. 
1.4. Health and disease 
The most obvious involvement of nicotine in disease is its role in addiction to 
tobacco. Nicotine replacement therapy is widely used in assisting smoking cessation, 
however as the mode of administration tend to give a slower pharmacokinetic profile than 
tobacco use, and the prevalence of side effects other treatments have been investigated. 
Partial nicotinic agonists (e.g. cytisine) are used as smoking cessation therapies with the 
premise that they will give some stimulation of receptors, lessening withdrawal, whilst also 
decreasing reinforcement upon tobacco use and so preventing relapse. There are often side 
effects of these therapies which more selective drugs may help overcome. Work with 
nAChR knockout mice has shown that the β2 nAChR is involved in nicotine reinforcement 
and tolerance however withdrawal symptoms are mediated by α7 nAChRs (Besson et al, 
2006; Grottick et al, 2000; Salas et al, 2007). Knowing which subtypes are most involved 
in addiction has helped to suggest α4β2* as a suitable target. Varenicline was developed 
from cytisine as a smoking cessation therapy due to its partial agonist activity at α4β2* 
nAChRs; however it is also a full agonist at α7 nAChRs (Coe et al, 2005; Mihalak et al, 
2006). Recent reports have shown that whilst effective in improving quit rates varenicline is 
associated with side effects such as nausea and suicidal ideation (Cahill et al, 2011). 
Varenicline has also been shown to be a full agonist at 5-HT3 receptors, a subtype known 
to be highly homologous to the α7 nAChR (Lummis et al, 2011), which may be responsible 
for some of the side effects of varenicline treatment such as nausea. Development of α4β2* 
selective partial agonists that avoid the α7 receptor may therefore give a drug with a better 
clinical profile. 
Depression is another condition for which nAChRs are a target. Many 
antidepressants such as monoamine oxidase inhibitors (MAOIs), selective serotonin 
reuptake inhibitors, and serotonin-noradrenaline reuptake inhibitors act to increase amine 
levels. Surprisingly both nAChR agonists and antagonists are effective in models of 
depression (reviewed in Philip et al, 2010), suggesting that their mechanism of action is not 
via increases in neurotransmitter levels, and that nAChR desensitisation may be involved in 
the agonist effects in relieving depression. The nAChR antagonist mecamylamine has 
recently been shown to have antidepressant-like effect in the mouse forced swim and tail 
suspension tests (Rabenstein et al, 2006) and several studies have shown positive effects of 
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mecamylamine or varenicline in preclinical and clinical trials (reviewed in Philip et al, 
2010). Mecamylamine exists in two enantiomers, which are not usually separated. Fedorov 
et al (2009) have shown that these have different affinities for the high and low sensitivity 
stoichiometries of α4β2 nAChRs. Lippiello et al (2008) have shown that TC-5214, the 
+ stereoisomer of mecamylamine, is effective in a range of preclinical models of 
antidepressant activity, and is well tolerated and has a good safety profile in a range of 
species. Initial clinical findings using TC-5214 as an adjunct therapy in combination with 
citalopram in the management of depression have been encouraging (Dunbar, 2010). Side 
effects were mild, suggesting that this treatment may be well tolerated. 
Acetylcholine has been shown to have important roles in attention (Klinkerberg et 
al, 2011). Both muscarinic and nicotinic acetylcholine receptors have roles but here the 
focus will be on the nAChR mediated mechanisms. It has been shown that nAChRs in the 
FC but not the HC are important for attentional functions (Hahn et al, 2003). Antagonism 
with α7 nAChR antagonists impaired performance in challenging tasks suggesting that FC 
nicotinic signalling is involved in effortful processing, rather than the psychostimulant 
effects of systemic nicotine being responsible for the changes (Granon et al, 1995). 
Performance on the radial arm maze is differentially affected by α4β2* and α7 nAChRs, 
with α7 antagonism in HC causing an increase in working memory errors, whereas DHβE, 
a β2* selective antagonist impaired both working and reference memory performance. An 
α7 knock out mouse learns the 5-CSRTT more slowly and has a higher rate of omissions 
than wild type with impaired attention central to the deficit (Young et al, 2004; 2007). 
Guillem et al (2011) showed that β2 subunits are also involved in attention in the FC. 
The role of nAChR agonists as possible ADHD treatments has been investigated 
for several drugs in recent years. Both α4β2 and α7 nAChRs are being investigated as 
potential targets. Although these drugs show positive effects in animal models of cognitive 
performance this does not always translate to clinical efficacy. ABT-418, an agonist at 
α4β2 nAChRs was shown to be effective in improving symptoms on several ADHD scales 
in adolescents, but that effects were not as great in more severe cases or in adult ADHD 
(Wilens et al, 1999; 2007). Various α7 nAChR agonists have been found to be effective at 
increasing attention in animal trials and are currently being investigated in clinical trials. 
Another avenue that could be explored in future is the use of positive allosteric modulators 
(PAMs) of nAChRs. These act to increase receptor signalling upon activation by slowing or 
reversing desensitisation of the receptor. These may be a useful tool to enhance cognition as 
they do not give a constant, non context related, stimulation of receptors, but rather act to 
increase the signal to noise ratio. As α7 nAChRs have not been shown to be greatly 
involved in the hedonic properties of nicotine consumption PAMs targeting this subtype 
should not increase abuse of nicotinic agonists. 
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Other conditions for which the cognitive enhancing properties of nAChR ligands 
may be useful are schizophrenia, where cognition is a major unmet treatment need, and 
Alzheimer’s disease. 
1.5. Summary of Aims 
The work undertaken in this thesis aims to elucidate the subtypes of nAChR 
involved in noradrenaline release in the frontal cortex in comparison to the hippocampus. 
This was done using an in vitro system, in order to define key aspects to examine in vivo. 
Modulation of NA release in vivo was then examined using microdialysis, and further 
comparisons made between frontal cortex and hippocampus. 
Some novel compounds were also examined for their effects in vitro. 
The catecholamine metabolite profile in response to nicotine was also assayed in a 
preliminary attempt to examine regional differences in catecholamine regulation. 
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Chapter Two 
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2. NAChR modulation of monoamine release in vitro 
2.1. Introduction 
2.1.1. AChR pharmacology of neurotransmitter release 
The release of neurotransmitters elicited by nicotine has been seen by many groups. 
Arqueros et al (1978) found efflux of catecholamines from preloaded slices in a superfusion 
system that was quantitatively and qualitatively different from that induced by KCl 
challenge. This study however used high concentrations of nicotine (>1 mM) and did not 
find that the responses were Ca2+ sensitive. Westfall (1974) had earlier shown that [3H]-DA 
release could be stimulated from striatal tissue but concentrations of nicotine were again in 
the mM range. Giorguieff-Chesselet et al (1979) were the first to show that µM 
concentrations of nicotine could induce [3H]-DA release from striatal slices. By 1988 it was 
shown that µM concentrations of nicotine were effective in releasing DA from striatal 
synaptosomes, with EC50 3.8 µM (Rapier et al, 1988). Sacaan et al (1995) showed nAChR 
stimulated release of [3H]-NA from HC slices was different to [3H]-DA release from striatal 
slices. There were different sensitivities to nicotine and cytisine, and unlike striatum HC 
was not sensitive to DHβE, a β2* selective antagonist. No inhibition of [3H]-NA release 
from HC slices with α7 antagonists methyllycaconitine (MLA) or α-Bgt was seen, 
suggesting little contribution of α7 nAChRs (Sacaan et al, 1995). Clarke and Reuben 
(1996) showed that in synaptosomes nAChR-induced release of hippocampal [3H]-NA 
differed from that of striatal [3H]-DA. The HC was less sensitive than striatum to nicotine, 
DHβE and MLA.  
Using a novel 96-well format for release assays (see 2.1.2 for comparison) 
Anderson et al (2000) showed that nicotine was more potent in releasing [3H]-NA from FC 
than HC, and that DHβE caused a small non-competitive inhibition of responses. This is in 
contrast to the competitive inhibition observed for [3H]-DA release from striatum reported 
in the same paper. These results agreed with previous findings from superfusion studies in 
both slices and synaptosomes. Using the 96-well plate assay Barik and Wonnacott (2006) 
found that the α7 nAChR may play an indirect role in NA release in HC, although several 
other papers (Sershen et al 1997; Clarke and Reuben, 1996; Sacaan 1995) have shown no 
reduction in [3H]-NA release in response to agonist stimulation in the presence of α7 
antagonists. 
Together these studies show a lack of β2* mediated responses in HC [3H]-NA 
release with questions over the involvement of α7 and suggest the involvement of α3β4* 
nAChRs. In FC NA release has been less studied, with the work done so far suggesting a 
higher sensitivity to nicotine and partial as opposed to full agonism of cytisine (Sacaan et 
al, 1995). DA release from the FC has been somewhat better studied, with responses 
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broadly similar to striatum with a major contribution of β2* nAChRs. There is no 
sensitivity to α-conotoxin MII, which is a selective antagonist for α6/α3β2* nAChRs and 
partially inhibits striatal [3H]-DA release (Livingstone et al, 2009). A role for α7 nAChRs 
in DA release in FC has also been shown, with release elicited by choline and compound A, 
potentiated by PNU-120596 and blocked with selective antagonists. 
2.1.2. 96 well release method vs. superfusion 
In this study use has been made of a relatively novel 96-well neurotransmitter 
release assay. This method was developed and reported to expand throughput in 
comparison with the better established superfusion technique (Anderson et al, 2000). 
Results have been shown to be largely comparable to superfusion where the two techniques 
have been compared (2.1.1). The assay is a static release assay with collections of filtrate 
for baseline and stimulated responses and so does not allow the assessment of 
desensitisation of receptors or time course of responses as is possible with superfusion. 
Superfusion often makes use of synaptosomes (isolated nerve terminals), which allows the 
separation of purely presynaptic effects. In contrast we have used 150 µm prisms of tissue, 
which maintain some synaptic connectivity giving a better picture of the in vivo regulation 
of neurotransmitter release via indirect as well as direct mechanisms. This is important as 
there is some evidence of interneuronal contributions to neurotransmitter release, for 
example a glutamatergic contribution to DA release (Kaiser and Wonnacott, 2000; Barik 
and Wonnacott, 2006) and a GABAergic effect on NA in HC (Leslie et al, 2002). 
The relatively high throughput of this assay, with multiple replicates possible for a 
number of conditions in parallel means that concentration response curves can be easily 
constructed. In vivo microdialysis studies have previously been designed to test the findings 
from 96-well in vitro release assays and have found nAChR subtypes and interactions to be 
largely translatable, although concentrations of drugs required vary between the techniques 
(Livingstone et al, 2009). We therefore feel this assay is reliable, translatable and a useful 
tool for this project. 
2.1.3. Upregulation and chronic functional changes 
It is well established that repeated or chronic systemic nicotine administration leads 
to upregulation in nAChR binding in animal models (Jacobs et al, 2002). Upregulation in 
cell lines/neuronal cultures exposed to nicotine is also seen (Bullock et al, 1994; Lomazzo 
et al, 2010). High affinity receptors are thought to be upregulated to a greater extent than 
low affinity, with evidence that α4β2 nAChRs are particularly sensitive (Flores et al, 1997). 
Different subtypes of nAChR are upregulated to different extents, and as these are often 
expressed in differing brain regions this can have differential effects. The α4β2α5 subtype 
is resistant to upregulation (Mao et al, 2008) and a larger proportion of the α4β2* nAChRs 
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in the HC are associated with α5 than in the striatum and cerebral cortex. After 14 days of 
nicotine treatment binding sites increased by 50 % in cortex and hippocampus, whereas 
striatum was unaffected, suggesting a shift in the proportion of the different subtypes 
(Sanderson et al, 1993). Nuutinen et al (2005) also found that there was no increase in [3H]-
Epi binding in striatum after chronic nicotine treatment, with increases in hippocampus and 
cortex. This paper also examined low-affinity MLA binding sites (α7 and α3/α6β2β3*), 
finding upregulation in striatum and cortex after 4 weeks and hippocampus after 7 weeks 
treatment (Nuutinen et al, 2005). As well as changes in the number of agonist binding sites, 
changes to the stoichiometry of receptors have also been suggested, with an increase in the 
proportion of high affinity receptors. 
The implications of this upregulation are difficult to ascertain as there is evidence 
that there is not always a concomitant change in functional responses to nicotinic 
stimulation. Animals in fact develop tolerance to repeated nicotine administration as with 
many other drugs of abuse (Vann et al, 2006; Collins et al, 1988); however behavioural 
sensitisation to nicotine has also been reported (Kita et al, 1992; Kirshenbaum et al, 2011).  
The causes of upregulation are thought to be desensitisation and internalisation of 
receptors (Fenster et al, 1999), especially entry into the slowly recovering deeply 
desensitised or inactivated state. The mechanism of upregulation is debated, with increased 
receptor subunit assembly and trafficking being postulated, changes in degradation of 
receptors could also be involved in increasing numbers. It has been shown that increases in 
nAChR binding after chronic nicotine treatment are due to post-translational mechanisms, 
as mRNA levels remain the same (Marks et al, 1992; Mugnaini et al, 2002) and inhibition 
of protein synthesis does not inhibit the increase in binding (Wang et al, 1998; Darsow et 
al, 2005). It has also been shown by correlation of radioligand binding and antibody 
labelling that the upregulation measured is due to an increase in protein levels, not simply 
the creation of additional binding sites from subunits already present (Marks et al, 2011), 
supporting a theory of reduced turnover. Work from the Lester lab (Lester et al, 2009) has 
suggested that nicotine itself can enter cells and act as a pharmacological chaperone, 
stabilising the assembly of subunits and enhancing their trafficking (see 2.6.5.3). 
2.1.4. Production of novel compounds and rationale for design 
Partial agonists as smoking cessation therapies are well established. They are 
preferred to full agonists as potential therapies as there is a lesser side effect profile 
meaning they are better tolerated and a lower abuse liability as well as a more effective 
mechanism of action. Partial agonists act to relieve cravings by low level stimulation of 
nAChRs, but they also block the rewarding effects of nicotine administration by receptor 
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occupancy. There still some side effects of these therapies due to their actions at other 
nAChR subtypes centrally and peripherally, as well as interactions with other receptors.  
2.1.4.1. Cytisine analogues 
Varenicline is an analog of cytisine, developed in an attempt to create drugs with a 
better side effect profile for smoking cessation. As more prescriptions have been issued side 
effects including nausea, commonly associated with nicotinic drugs, as well as more serious 
side effects such as depression and suicidal thoughts have emerged, leading to a ‘black box’ 
safety warning to be issued. These side effects may be due to off target effects on 5HT3 
receptors (Lummis et al, 2011). Due to this there is a need for additional, more selective, 
partial agonists to enter development.  
 
Figure 2-1 The structure of cytisine 
Cytisine has a bridged bicyclic framework. Substitutions can be made at several of the carbon atoms 
(C3, C4 and C5, labelled above). C3 and C5 substitutions have been reported previously to have 
effects on cytisine binding and function. 
Substitutions (often halogenations) have previously been reported at C3 and C5 of 
cytisine (Figure 2-1). C3-halogenation increases binding affinity at nAChRs and also 
increases the functional potency of these compounds in comparison with cytisine 
(Abin-Carriquiry et al, 2006), with no changes determined in subtype selectivity. In 
particular 3-Br-Cytisine has been shown to have increased binding affinity compared with 
cytisine, and to have good functional potency both in vitro and in vivo (Abin-Carriquiry et 
al, 2006, 2010a). C5 halogenation on the other hand is detrimental to binding and 
functional efficacy (Abin-Carriquiry et al, 2006). 
The development of an in silico docking model of the acetylcholine binding protein 
(AChBP), a soluble molluscan homologue of the nAChR, has allowed the interactions with 
cytisine analogs to be calculated (Abin-Carriquiry et al, 2010b). This model has been tested 
by comparing the structure of the AChBP co-crystallised with nicotine to the predicted 
docking, showing high accuracy of reproduction of the docking pose. The model gives a 
good correlation between docking energy and experimentally measured affinity for a 
number of cytisine analogs with various substitutions including the C3 and C5 
halogenations mentioned above. 
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Modelling by Tasso et al (2009) in rat and human (α4β2)2β2 homology models has 
suggested that in general substitution in the aromatic moiety weakens binding by interfering 
with hydrogen bonding to a conserved tryptophan in the receptor binding site. The amino 
acids involved in cytisinoid binding are highly conserved between the AChBP and 
mammalian receptors, with 7 conserved amino acids in the α subunit and one in the 
complementary face shown to be particularly important. Interactions with other amino acids 
in the more variable complementary face of the binding site are more difficult to model and 
may have some effect on selectivity, however the main interactions with these is through 
the backbone atoms and so mutations will have less effect on the interactions (1.3.3; 
Abin-Carriquiry et al, 2010b). 
2.1.5. Aims & hypotheses  
• To investigate the nicotinic stimulation of NA release in FC in comparison with HC as 
a better studied model. The hypothesis is that HC will be modulated by α3β4* nAChRs 
as previously shown, and that as this subtype is not highly expressed in cortical regions 
responses in FC may be regulated by other nAChRs notably α4β2*, as expression is 
high throughout the brain. 
• To investigate the responses in vitro after acute or chronic in vivo nicotine 
administration. Previously it has been shown that receptor upregulation after chronic 
nicotine treatment does not correlate with a functional change. The hypothesis is that 
there will not be significant changes in function after in vivo nicotine treatment. 
• To investigate novel compounds to assess binding and functional potency. These 
compounds are analogs of cytisine and so are hypothesised to cause displacement of 
[3H]-Epi binding, although the changes to the molecules are expected to alter the 
potency of this binding.  
2.2. Materials and Methods 
2.2.1. Chemicals and Reagents 
 [7,8-3H]-Noradrenaline ([3H]-NA; 34-50 Ci mmol-1), [3H]-dopamine ([3H]-DA; 
38-45 Ci/mmol) and [3H]-epibatidine (55.8 Ci/mmol) were purchased from GE Healthcare 
(Little Chalfont, Buckinghamshire, UK) or Perkin Elmer (N.V. /S.A., Zaventem, Belgium). 
(-)-Nicotine hydrogen tartrate, pargyline hydrochloride, choline tartrate, ascorbic acid, 
mecamylamine hydrochloride, morphine, DIOA, dihydro-beta-erythroidine (DHβE) and 
nomifensine maleate were obtained from Sigma-Aldrich Co. (Poole, Dorset, UK). 
Nisoxetine hydrochloride, CGP54626, 5-Iodo-[3-(2(s)-azetidinylmethoxy) pyridine] 
dihydrochloride (5-Iodo-A85380, 5IA), bicuculline, bumetanide and GBR12909 
dihydrochloride were purchased from Tocris Cookson (Avonmouth, UK). α-bungarotoxin 
(α-Bgt) was acquired from Molecular Probes (Pourt Gebaow, Netherlands). PNU-120596 
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was synthesised at, and provided by GlaxoSmithKline (Harlow, Essex, UK). Optiphase 
Supermix was obtained from Perkin Elmer (N.V. /S.A., Zaventem, Belgium) and Optiphase 
‘Safe’ acquired from Fisher Chemicals (Loughborough, Leicestershire, UK). Naloxone 
hydrochloride was purchased from Ascent Scientific (Weston-super-Mare, UK). 3-Br-Cyt 
and novel cytisine analogs were obtained from the laboratory of Dr Timothy Gallagher. 
Other standard chemicals of analytical grade were obtained from Sigma-Aldrich Co.  
2.2.2. Animals 
Male Sprague-Dawley rats were purchased from Charles River Laboratories 
(Margate, Kent, UK). They were housed in groups (4-6 per cage) with ad libitum access to 
food and water. Animals weighed 200-320g at time of experiments. All procedures were in 
accordance with the Animals (Scientific Procedures) Act of 1986. 
2.2.3. [3H]-oradrenaline Release 
A 96 well plate method was adapted from previous studies of neurotransmitter 
release (Anderson et al, 2000; Barik and Wonnacott, 2006). Krebs buffer (KB; 118 mM 
NaCl, 2.4 mM KCl, 2.4 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4.7H2O, 25 mM 
NaHCO3, 10 mM D-glucose and 1 mM ascorbic acid) was gassed for 1 h at 37 °C with a 
95% O2, 5% CO2 mix and pH adjusted to 7.4. Rats were killed by cervical dislocation, 
decapitated, brains removed and placed on an ice-cold platform. FC (the 2mm anterior to 
corpus callosum), striatum and/or hippocampus (as stated for each experiment) were 
rapidly dissected and immediately immersed in KB containing 10 µM pargyline (a 
monoamine oxidase B inhibitor, to prevent degradation of the catecholamine) at 4 °C. A 
monoamine oxidase A (MAOA) inhibitor such as tranylcypromine could also be used as 
MAOA is involved in the metabolism of NA. Tissue was sliced using a McIlwain tissue 
chopper three times with 60° rotations to produce 150 µm prisms and transferred to 5 ml 
KB at 37 °C and triturated to suspend. Tissue was washed twice in warm KB and then 
incubated with radiolabelled catecholamine (70 nM [3H]-NA, 50 nM [3H]-DA) in 5 ml KB 
containing 10 µM pargyline, for 30 min with regular agitation. Tissue was washed 4 times 
with 5 ml KB supplemented with 10 µM pargyline and 0.5 µM nomifensine (KBN) to 
inhibit catecholamine reuptake. The tissue was resuspended in 5 or 10 ml KBN (5 ml per 
half plate) then transferred (100 µl per well) to a 96 well filter plate (Millipore Corporation, 
Hertfordshire, UK) with a multichannel pipette ensuring even distribution. Tissue in each 
well was washed twice with 100 µl buffer before addition of 70 µl buffer (with or without 
antagonists) and incubation at 37 °C for 5 min (except for studies including α-Bgt which 
was included during all post catecholamine uptake washes to give an additional 20 min 
incubation). Wells were filtered and buffer collected into a 96 well Optiplate (Perkin Elmer 
N.V. /S.A., Zaventem, Belgium). Tissue was then exposed to 70 µl buffer containing 
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agonists and/or antagonists for a further 5 min at 37 °C. Following a second filtration into a 
separate collection plate, filters were dried in an incubator at 37 °C, removed from plate 
and frozen overnight in a 96 well Optiplate after addition of 70 µl water per well. Optiplates 
containing collected buffer and release fractions were agitated for 45 min with 170 µl 
Optiphase Supermix and radioactivity determined using a MicroBeta liquid scintillation 
counter (Wallac 1450 MicroBeta Trilux; Perkin Elmer Wallac, Turku, Finland) at 30% 
counting efficiency. Percent release was determined as a fraction of the [3H]-NA in the 
tissue at the start of the stimulation period (defined by the amount released + that remaining 
in the tissue). Every condition used was performed in 6 replicates and each assay was 
repeated a minimum of three times with tissue from different animals. Buffer or antagonist 
only incubations were carried out before stimulation to confirm they had no effect on basal 
release for each assay. 
2.2.4. [3H]-oradrenaline Uptake 
FC minces were prepared as for release assays (from one animal per experiment) 
and washed for 5 min with KB at 37 °C. Aliquots (100 µl) were pre-incubated for 10 min in 
0.5 ml Eppendorf tubes with buffer alone, nomifensine (0.5 or 5 µM), GBR12909 (50 nM 
or 0.5 µM), morphine (10, 30 or 100 µM) or nisoxetine (1 µM or 10 µM), at 37 °C or 4 °C. 
All tubes then received 100 µl 140 nM [3H]-NA (70 nM final concentration) and were 
incubated with intermittent shaking for 30 min. Tissue was collected by filtration through a 
pre-moistened 96 well filter plate (Millipore Corporation, Hertfordshire, UK) and washed 
three times with 100 µM ice-cold KB before transfer to liquid scintillation vials. Optiphase 
‘Safe’ (4 ml) was dispensed into each vial before counting for 1 min in a 1600 Tri-carb 
liquid scintillation counter with 46 % counting efficiency (Perkin Elmer Life and Analytical 
Sciences) to determine radioactivity. Each condition was examined in four replicates and 
each experiment was repeated at least 3 times. 
2.2.5. Radioligand binding  
2.2.5.1. Membrane preparation 
Rat brain P2 membranes were prepared by the method outlined in Davies et al, 
(1999). Rat brains (minus cerebellum) were homogenised in ice cold 0.32 M sucrose 
containing 1 mM EDTA, 0.1 mM PMSF and 0.01 % NaN3 (pH 7.4, 10 % w/v). The 
homogenate was centrifuged at 1000 g for 10 min and the supernatant retained on ice. The 
pellet was then resuspended in sucrose and the spin repeated. The supernatants were 
combined (S1) and centrifuged at 15 000 g for 30 min. This pellet (P2) was resuspended in 
5 ml/g original weight of 50 mM phosphate buffer (40 mM K2HPO4, 10 mM KH2PO4, 
1 mM EDTA, 1mM PMSF and 0.01 % NaN3, pH 7.4) and centrifuged at 15 000 g for 
30 min. The wash step was repeated and the final pellet resuspended in 2.5 ml/g original 
 - 36 - 
weight in ice cold 50 mM phosphate buffer and frozen until use. Protein concentration was 
estimated by use of a BCA protein assay microplate procedure (Pierce Biotechnology, IL 
USA), a colorimetric protein dye reagent. 
2.2.5.2. [3H]-Epibatidine competition binding assay 
[3H]-epibatidine ([3H]-Epi) binding was carried out with a final concentration of 
200 pM [3H]-Epi (Houghtling et al, 1995). Rat brain membranes were diluted 1 in 40 in 
50 mM phosphate buffer (2.2.5.1) to a final volume of 2 ml, with 20 µl of serial dilutions of 
drugs to be tested (10-4 to 10-10 M final concentration) added to each tube. Nonspecific 
binding was determined in the presence of 1 mM nicotine. Samples were incubated for 2 h 
at room temperature followed by 30 min at 4 °C. Samples were then filtered through glass 
fibre filters (FB59431) pre-soaked in 0.3 % polyethyleneimine (PEI). Filters were washed 
three times using ice cold PBS (150 mM NaCl, 8 mM K2HPO4, 10 mM KH2PO4, 0.01 % 
NaN3, pH 7.4), and counted for radioactivity using a Packard 1600 Tricarb scintillation 
counter (efficiency 45 %). Each assay was conducted in triplicate. 
2.2.6. In vivo nicotine administration 
2.2.6.1. icotine administration by injection 
Rats were handled and weighed at the same time daily for at least seven days, with 
saline (0.9 %, 1 ml/kg) injected subcutaneously for the final three days. Rats were then 
injected once daily s.c. with either 0.9 % saline or nicotine (0.4 mg/kg free base, adjusted to 
pH 7.4) for 14 days. Thirty minutes after the final injection rats were sacrificed by cervical 
dislocation and brains rapidly removed and dissected. To study withdrawal effects rats were 
killed 3 days after the final injection. An additional group of rats received a single injection 
of nicotine (0.4 mg/kg s.c.) or saline and were sacrificed 30 min later to study the effects of 
acute nicotine administration on in vitro neurotransmitter release. No effect of nicotine 
administration or withdrawal was observed on growth rates. 
2.2.6.2. Chronic nicotine administration by osmotic minipump 
Rats were anaesthetised with isoflurane (3% isoflurane to induce; 1.5-2% to 
maintain: 1L/min O2) and the area between the scapulae shaved and swabbed with a 
mixture of 70% ethanol and Hibicet (a skin antiseptic). A small incision (~1 cm) was made 
and a subcutaneous pocket opened by blunt dissection to fit the minipumps. Alzet® osmotic 
minipumps (model 2002) were swabbed with 70 % ethanol and saline and implanted 
subcutaneously with the outlet of the flow moderator away from the incision. Osmotic 
minipumps were filled with nicotine bitartrate, dissolved in 0.9 % saline and pH adjusted to 
7.4, to deliver nicotine (4 mg/kg/day freebase) at a rate of 0.5 µl/h for 14 days. Control 
animals received a ‘blank’ implant formed from inert PTFE of similar size and weight to 
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the minipump. The concentration of nicotine in the pumps was calculated by the following 
formula; 
Nicotine (mg/ml) = (X mg/kg/day) * (estimated animal weight (g) on day 7) 
   24 * (Pumping rate of minipump (µl/h)) 
Following the insertion of the pump, the incision was closed with two wound clips 
and checked daily throughout the course of the experiment. Fourteen days later animals 
were sacrificed by cervical dislocation and brains rapidly removed and dissected. Pumps 
were removed and inspected to ensure correct delivery of nicotine. To study withdrawal 
effects pumps were surgically removed under isoflurane anaesthesia after 14 days and 
animals killed 2 or 3 days after pump removal. Nicotine and saline animals were paired for 
each condition, with samples run in parallel.  
The brain tissue remaining after the removal of FC and HC for release assays was 
frozen until use in binding assays (see 2.2.8). No effect of nicotine administration or 
withdrawal was observed on the weight of animals. 
2.2.7. [3H]-oradrenaline release from nicotine treated animals 
Release experiments were carried out as previously described (2.2.3) with minor 
modifications. Release was assessed from tissue from each animal individually. The 
incubation with [3H]-NA was in a volume of 2.5 ml and the final resuspension in a volume 
of 5 ml with prisms distributed across one half of a 96 well plate. On each plate tissue taken 
from nicotine- and saline-treated animals was assessed in parallel. 
2.2.8. Radioligand binding after chronic treatment 
2.2.8.1. Membrane preparation 
Membrane preparation was carried out as above (2.2.5.1) with minor modifications. 
Membranes from individual brains (minus cerebellum, frontal cortex and hippocampus) 
were prepared. Protein concentration was estimated by use of a BCA protein assay 
microplate procedure (Pierce Biotechnology, IL USA), a colorimetric protein dye reagent. 
2.2.8.2. [3H]-Epibatidine binding 
[3H]-Epi binding was performed on 150 µg of brain membranes in a final volume 
of 1 ml in Tris-HEPES buffer (NaCl 118 mM, KCl 4.8 mM, CaCl2.2H2O 2.5 mM, HEPES 
20 mM, Tris 20 mM, PMSF 0.1 mM, NaN3 0.01 %; pH 7.4). The final concentration of 
[3H]-Epi was 500 pM. Non specific binding was determined in the presence of 1 mM 
nicotine. Samples were incubated for 1.5 h at room temperature, followed by 30 min at 
4 °C and filtered and counted as above (2.2.5.2). 
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2.2.9. Data analysis 
Data were plotted using SigmaPlot version 10 (Jandel Corp., San Rafael, USA). 
Points or bars typically represent mean + SEM of at least 3 separate samples, each being 
the mean of 6 replicates performed in parallel. 
Concentration response curves were fit to a non-linear regression by fitting to a 
single site Hill equation: 
  y = a / [ 1 + ( k / x ) n ]  
where ‘a’ is the asymptotic maximum, ‘k’ represents the EC50 or IC50 value, ‘n’ is 
the Hill number and ‘y’ is the amount of neurotransmitter released, or [3H]-epibatidine 
bound, in the presence of concentration ‘x ‘of drug. Data were analysed by Students t test, 
or one or two way ANOVA followed by an appropriate post-hoc test such as Holm-Sidak 
(with adjustment for multiple comparisons) for pairwise comparisons or Dunnett’s to 
compare each value to control as appropriate using SigmaPlot or GraphPad Prism v5. 
Competition binding curves were analysed by non-linear regression with extra sum of 
squares F test to compare pIC50 values. 
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2.3. Results – [3H]-Noradrenaline release in FC and HC 
2.3.1. eurotransmitter uptake  
2.3.1.1. [3H]-A uptake specificity 
Before performing experiments examining [3H]-NA release from rat brain prisms, 
it was important to ascertain that the uptake of [3H]-NA was specific to noradrenergic cells. 
The uptake of amines, especially dopamine, is not always mediated by the correct 
transporter alone (Carboni et al, 2001). To assess the specificity of NA uptake, FC prisms 
were incubated with [3H]-NA (70 nM) at 37 °C for 30 min (uptake period for release 
assays) with a variety of amine transporter inhibitors; nisoxetine to inhibit the noradrenaline 
transporter (NET), GBR-12909 to inhibit the dopamine transporter (DAT) and nomifensine, 
to inhibit both NET and DAT. Samples were also incubated at 4 °C, to prevent transporter 
mediated uptake and so serve as a control for non-specific NA interactions with the tissue. 
Uptake in the presence and absence of inhibitors was determined by filtration and 
scintillation counting (2.2.4).  
Rat FC prisms accumulated 9267 + 542.9 cpm [3H]-NA/mg wet weight 
(244.1 + 14.3 fmol/mg) over 30 minutes when incubated in Krebs buffer alone at 37 °C. At 
4 °C very little [3H]-NA was taken up (3.6 + 0.4 fmol/mg) and there was no difference in 
[3H]-NA taken up in buffer alone or with inhibitors. These values were not different from a 









































H]-A uptake in the presence of catecholamine uptake blockers.  
Rat FC tissue was dissected, chopped into 150 µm prisms and preincubated with Krebs buffer (KB) 
alone, or catecholamine uptake inhibitors, GBR-12909 (GBR: DAT; 50 nM), nomifensine (NOM: 
general; 0.5 µM) or nisoxetine (NIS: NET; 1 µM) for 10 min, then incubated for 30 min with 70 nM 
[3H]-NA for 30 min at 37 °C. Prisms were also incubated at 4 °C as a control. Prisms were washed 
by filtration with ice cold KB. [3H]NA uptake was assessed by scintillation counting with each 
condition examined in four replicates from each experiment. Bars represent mean + SEM from 4 
separate experiments.  *** p<0.001 significantly different from KB, one way ANOVA with post hoc 
Holm-Sidak test. F(4,15)=25.54, p<0.001 
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The selective DAT inhibitor, GBR-12909 (50 nM), did not reduce NA uptake 
(Figure 2-2). In contrast, the catecholamine uptake inhibitors nomifensine (NET and DAT; 
0.5 µM) and nisoxetine (NET; 1 µM) reduced uptake by 71 + 6.6 % and 85 + 3.6 % 
respectively (Figure 2-2). At higher concentrations (0.5 µM GBR-12909, 5 µM 
nomifensine or 10 µM nisoxetine) there were no further reductions in uptake in comparison 
with the lower concentration (data not shown) showing an optimal block of uptake with the 
lower concentrations. 
Together these results show that the [3H]-NA uptake under these conditions is 
highly specific to the NET and therefore to noradrenergic cells within the FC, and so no 
DA transporter inhibitor was included during [3H]-NA incubation steps during subsequent 
release assays. 
2.3.1.2. Effect of morphine on [3H]-A uptake 
Many drug addicts use multiple drugs, so the interactions of an opiate (morphine) 
and NA uptake in FC were also explored with the intention of investigations in other 
aspects of the project. To assess the effect of morphine on [3H]-NA uptake FC prisms were 
preincubated for 10 min with morphine (10-100 µM) prior to addition of [3H]-NA for 
30 min before determination of [3H]-NA uptake by filtration and scintillation counting. The 
opioid receptor antagonist naloxone (10 µM) was also used to determine if any responses 
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H]-A uptake in the presence of morphine 
Rat FC tissue was dissected, chopped into 150 µm prisms and preincubated with Krebs buffer (KB) 
alone or morphine (10 -100 µM; green) in the presence (hatched bars) or absence of naloxone 
(10 µM), before incubation with 70 nM [3H]-NA for 30 min at 37 °C. Prisms were then washed by 
filtration with ice cold KB. [3H]-NA uptake was assessed by scintillation counting with each 
condition examined in four replicates from each experiment. Bars represent the mean + SEM from 4 
separate experiments. Data analysed by One way ANOVA, Holm-Sidak post hoc test. 
F(5, 18)=1.645, p=0.199 
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Naloxone alone had no effect on [3H]-NA accumulation into FC prisms. No 
difference in [3H]-NA uptake was seen at 10 µM morphine and a small, non-significant 
difference at 30 µM morphine. At 100 µM morphine caused a noticeable but non-
significant reduction of NA uptake compared to KB alone, reducing uptake from 
182.4 + 17 to 128.2 + 10.7 fmol/mg (Figure 2-3) which was reversed with the mu opioid 
selective antagonist naloxone (10µM) to 182.1 + 23.4 fmol/mg, showing that the effect of 
morphine was mediated via opioid receptors, and not a direct effect on the NET itself.  
The effect of morphine on [3H]-NA release was also examined and there was no 
significant difference in basal, KCl or nicotine stimulated release (data not shown) in the 
presence or absence of morphine. This shows that the reduction in uptake is due to uptake 
changes not a concurrent release of [3H]-NA during the uptake period.   
2.3.2. [3H]-A release in naïve animals 
[3H]-NA release from rat brain prisms was assessed as described (2.2.3). Briefly, 
prisms were incubated with 70 nM [3H]-NA, distributed onto a 96 well filter plate and 
incubated with buffer/antagonist. Filtrate was collected (basal) and prisms then incubated 
with drug + antagonist. Filtrate was again collected into a separate plate (stimulated). Basal, 
stimulated and tissue plates were each counted for radioactivity and results calculated as a 
percentage of the radioactivity in the sample at the start of the collection period. Basal 
release of [3H]-NA in buffer alone were around 15-20 % fractional [3H]-NA content, and 
data are expressed as % basal for each experiment except as stated. 



































Figure 2-4 Antagonism of nicotine induced [
3
H]-A release 
Prisms (150 µm) from rat FC or HC were loaded with [3H]-NA (70 nM) and stimulated for 5 min 
with nicotine. FC (Red) and HC (Blue) prisms were incubated with 10 or 100 µM nicotine to 
stimulate [3H]-NA release + 10 µM mecamylamine (hatched bars), a non-selective nAChR 
antagonist. Bars represent the mean + SEM from 3 separate experiments as % basal. * p<0.05, ** 
p<0.01, *** p<0.005 compared to basal efflux. ## p<0.01, ### p<0.001 compared to agonist alone, 
one way ANOVA, Holm-Sidak post hoc test for each region. FC F(4,12)=22.57, p<0.001, 
HC F(4, 8)=23.16, p<0.001 
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2.3.2.1. icotine stimulated [3H]-A release 
To determine if nAChRs are involved in eliciting [3H]-NA release in the rat brain 
[3H]-NA release from rat FC or HC prisms was determined in response to nicotine (10 or 
100 µM), in the presence or absence of general nicotinic antagonist mecamylamine. Post 
hoc analysis revealed that both concentrations of nicotine tested induced significant [3H]-
NA release in both FC and HC (p<0.01; Figure 2-4). This nicotine induced [3H]-NA release 
in FC and HC was shown to be mediated by nAChRs by use of mecamylamine. 
Mecamylamine (10 µM) blocked the response to 10 and 100 µM nicotine in FC (p<0.001), 
and to 100 µM nicotine in HC (p<0.01; Figure 2-4); the block in HC was not complete 
(p<0.05 compared to basal). This may be due to the involvement of nAChR subtypes less 
sensitive to mecamylamine suggesting a difference between the two regions or a proportion 
of non-nAChR mediated release. To further investigate the specificity of nicotine mediated 
[3H]-NA release, [3H]-NA release from rat FC or HC prisms was examined in response to 
nicotine (0.1 µM – 1 mM), in the presence or absence of β2* selective competitive 
antagonist dihydro-β-erythroidine (DHβE; 10 µM). 
Nicotine concentration-dependently elicited [3H]-NA release from FC prisms 
(Figure 2-5A) with EC50 4.9 µM, reaching a maximum of 165 + 1.1 % basal at 300 µM 
(F(8,52)=31.1, p<0.001). This response was competitively inhibited with DHβE with a 
rightward shift of nicotine dose response curve (EC50 28.6 µM; F(1,52)=18.21; p<0.001) 
with post hoc Bonferroni test showing a significant difference at 1 and 10 µM nicotine. 
There was no interaction between nicotine dose and DHβE administration (F(8,52)=1.06 
p=0.4074). These results suggest that β2* nAChRs are involved in [3H]-NA release in FC 
prisms in this assay. 
In the HC nicotine also elicited significant release (F(3,24)=33.28, p<0.001) 
maximal release of [3H]-NA was higher (191.5 + 14.7 %) measured at 100 µM nicotine 
(Figure 2-5B). There was no shift of the curve with DHβE in HC (F(1, 24)=0.41, p=0.53) 
and no interaction between nicotine concentration and DHβE (F(1,24)=0.1, p=0.96) 
suggesting that β2* nAChRs are minimally involved in nicotine elicited [3H]-NA release 
under the conditions used in these experiments. 
2.3.2.2. Cytisine stimulated [3H]-A release 
The differences between FC and HC responses to nicotine are suggestive of 
differing nAChR subtypes in the two regions, which was investigated with agonists with 
greater selectivity. Cytisine is a full agonist at α7 and a partial agonist at β2* and β4* 
nAChRs (Luetje and Patrick, 1991; Papke and Heinemann, 1994) with higher efficacy at 
β4* combinations.  
 - 43 - 
 
[Nicotine] (log M)






















































Figure 2-5 Effect of nicotine on [
3
H]-A release in FC and HC 
Prisms (150 µm) from rat FC (A) or HC (B) were loaded with [3H]-NA (70 nM) and stimulated for 5 
min with nicotine (0.1 µM-1 mM). A) Nicotine evoked [3H]-NA release from FC prisms (Red; 
pEC50 -5.3 + 0.34; 4.9 µM), and this was competitively inhibited by DHβE (dark red; pEC50 -4.5 + 
0.16; 28.6 µM) with a rightward shift of nicotine dose response curve. Data analysed by two way 
ANOVA with post hoc Bonferroni (F(1,52)=18.21; p<0.001). B) Nicotine evoked [3H]-NA release 
from HC prisms (Blue) showed no significant rightward shift with DHβE (Dark blue; F(1, 24)=0.41; 
p=0.53) Data analysed by two way ANOVA. Points represent the mean + SEM from 4-6 separate 
experiments as % basal.  
Cytisine elicited significant release of [3H]-NA in both regions (F(6,28)=17.07, 
p<0.0001). In FC cytisine elicited release to a maximal of 133.9 + 3.8 % basal with EC50 
4.2 µM (Figure 2-6). In HC cytisine was less potent (EC50 25.5 µM) but reached a maximal 
of 140 + 8.8 % basal, comparable of that in FC. This difference in response between the 
regions was significant (F(1,28)=9.45; p=0.0047) but there was no interaction between 
region and cytisine concentration (F(6,28)=1.47, p=0.2237) and post hoc testing showed no 
individual concentrations with significantly different responses between the two regions. 
The maximal release elicited by cytisine was less than that elicited by nicotine in each 
region, possibly showing partial agonism, as previously seen for cytisine. 
A 
B 
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Figure 2-6 Effect of cytisine on [
3
H]-A release in FC and HC 
Prisms (150 µm) from rat FC or HC were loaded with [3H]-NA (70 nM) and stimulated for 5 min 
with cytisine. [3H]-NA release was stimulated with cytisine, a partial α4β2 and α3β4 agonist. 
Cytisine was equally efficacious in releasing [3H]-NA in FC (red) and HC (blue). In FC pEC50 -5.4 + 
0.44 (4.1 µM) and in HC pEC50 -4.6 + 0.26 (25.5 µM) and the curves are significantly different 
between the two regions Data analysed by two way ANOVA with Bonferroni post hoc test 
(F(1,28)=9.45;p0.0047). Points represent the mean + SEM from 4 separate experiments as % basal. 
2.3.2.3. 3-Bromo-Cytisine 
3-Bromo-Cytisine is a full agonist at α7 and partial agonist at α4β2* (with similar 
efficacy to cytisine), with slightly higher activity at α4β4* compared with 30 µM 
acetylcholine (Houlihan et al 2001). 3-Bromo-cytisine elicited significant release 
(F(4,50)=7.90, p<0.001). Post hoc tests showed that in FC concentration-dependent release 
of [3H]-NA was seen, which reached significance at 100 µM (128.7 + 10 % basal; Figure 
2-7). In the HC [3H]-NA release was higher, reaching a maximum of 162.1 + 13.1 % basal 
at 10 µM 3-Bromo-cytisine. Region had a significant effect on the responses 
(F(1,50)=9.635, p<0.01) but there was no interaction between region and treatment 
(F(4,50)=2.173, p=0.0855). Post hoc Bonferroni tests showed that the responses were 
significantly different at 10 µM 3-Bromo-cytisine. In HC EC50 was 0.6 µM, in FC the EC50 
could not be determined due to lack of significant responses and the linear nature of the 
response in the concentration range tested. The responses to 10 µM 3-Bromo-cytisine were 
fully inhibited with 10 µM mecamylamine in both regions. 
2.3.2.4. 5-Iodo-A-85380 stimulated [3H]-A release 
As covered earlier (2.1.1) NA release in HC is thought to be principally mediated 
by α3β4* nAChRs, with no sensitivity to β2* antagonists. The preceding results suggest 
differences between HC and FC in nAChR subtypes involved in [3H]-NA release, and a 
probable involvement of β2* nAChRs in FC, as shown by DHβE inhibition of nicotine-
mediated responses. 5-iodo-A-85380 (5IA), an agonist with a distinct profile for β2* versus 
β4* nAChRs was therefore utilised. 
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Figure 2-7 Effect of 3-Bromo-Cytisine on [
3
H]-A release in FC and HC 
Prisms (150 µm) from rat FC or HC were loaded with [3H]-NA (70 nM) and stimulated for 5 min 
with 3-Bromo-Cytisine. [3H]-NA release was stimulated from FC (red) or HC (blue) prisms with 
3-Bromo-Cytisine (10 nM-100 µM) in the presence (darker symbols) or absence of 10 µM 
mecamylamine. Points represent mean + SEM from 4 separate experiments as % basal. * p<0.05, 
** p<0.01 compared to basal F(4, 50)=7.90, p<0.0001. # p<0.05 between FC and HC F(1, 50)=9.63, 
p=0.0031. Analysed by two way ANOVA with Bonferroni post hoc multiple comparisons. 
5IA is a very potent selective β2* nAChR agonist with much lower affinity at β4* 
nAChRs (Mukhin et al, 2000). In FC 5IA elicited [3H]-NA release with EC50 1.6 nM 
reaching a maximum of 143.4 + 9.9 % at 30 nM (F(6,46)=5.732, p<0.001; Figure 2-8A). 
This release was sensitive to DHβE (F(1,46)=5.69; p=0.0213) although post hoc Bonferroni 
showed no individual concentrations were significantly different with or without DHβE. A 
change in the EC50 was seen (EC50 43.0 nM; F(1,54)=5.87; p=0.0188 by non-linear 
regression) confirming the involvement of β2* nAChRs. There was no interaction between 
5IA concentration and DHβE administration (F(6,46)=0.965, p=0.4593). 
HC was much less sensitive to 5IA and although release was elicited by higher 
concentrations this did not quite reach significance (F(5,24)=2.513, p=0.0577), [3H]-NA 
release reached a maximal of 131.6 + 12.6 % at 30 µM (EC50 5.9 µM) and the response was 
not sensitive to DHβE (F(1,24)=0.00, p=0.99; Figure 2-8B; EC50 6.9 µM). As DHβE did 
not account for any of the variance in the responses there was no interaction between 5IA 
concentration and DHβE (F(5,24)=0.05698, p=0.998). The large difference in EC50 between 
these two regions agrees with studies on the binding potency and functional responses of 
5IA at α4β2* and α3β4* nAChRs (Mukhin et al, 2000; Mogg et al, 2004) that have found 
comparable differences, suggesting these as possible nAChR types involved in FC and HC 
respectively. 
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Figure 2-8 Effect of 5-iodo-A-85380 on [
3
H]-A release in FC and HC 
Prisms (150 µm) from rat FC or HC were loaded with [3H]-NA (70 nM) and release was stimulated 
from FC (A) and HC (B) prisms with various concentrations of 5IA. 10 µM DHβE was used as 
antagonist. A) 5IA evoked [3H]-NA release in the FC (red; pEC50 -8.8+ 0.6; 1.6 nM), and this was 
competitively inhibited by DHβE (dark red; pEC50 -7.4+ 0.4; 43.0 nM; F(1,46)=5.69; p=0.0213). B) 
5IA evoked [3H]-NA release in HC (blue; pEC50 -5.23 + 0.76; 5.9 µM) showed no shift in EC50 with 
DHβE (dark blue; pEC50 -5.16 + 0.75; 6.9 µM F(1,24)=0.99; p>0.95) Points represent mean + SEM 
from 4-6 experiments as % basal. Note differing x axis scales. Analysed by two way ANOVA. 
2.3.2.5. Choline stimulated [3H]-A release 
A component of NA release mediated by α7 nAChR in the HC has previously been 
shown in several systems (Barik and Wonnacott, 2006; Fu et al 1999). To test this in FC, 
prisms were incubated with choline, a full agonist at α7 and a partial agonist at α3β4 
nAChRs. Choline elicited significant release of [3H]-NA at 3 and 5 mM in the HC 
(F(3,15)=6.806, p<0.01; 165.5 + 13.7 %; Figure 2-9A). Post hoc tests revealed that 
mecamylamine (30 µM) inhibited this response (p<0.05). In FC there was a small but non-
significant release over basal (F(3,18)=1.269, p=0.315), which was not reduced by 
mecamylamine showing this was not a nAChR mediated effect. Choline mediated release 
in HC was not inhibited by α-Bgt (data not shown) or MLA (Figure 2-9B) suggesting that 
α7 nAChRs are not a major component of the NA release under these conditions. 
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Figure 2-9 Effect of choline on [
3
H]-A release in FC and HC 
Prisms (150 µm) from rat FC or HC were loaded with [3H]-NA (70 nM) and stimulated for 5 min. 
A) Rat FC (Red) or HC (Blue) prisms were incubated with 3 or 5 mM choline in the presence 
(hatched bars) or absence of 30 µM mecamylamine. Bars represent mean + SEM from 4 experiments 
as % basal. * p<0.05 ** p<0.01 compared to basal # p<0.05 compared to agonist. Analysed by one 
way ANOVA for each region with Holm-Sidak post-hoc test FC F(3,18)=1.269, p=0.315 HC F(3, 
15)=6.806, p=0.004. B) Rat HC prisms were incubated with 3 or 5 mM choline in the presence or 
absence of 10 nM (light hatched) or 100 nM (close hatched) MLA and [3H]-NA release measured. 
Bars represent mean + SEM from 3 experiments as % basal. ** p<0.01, *** p<0.001 compared to 
basal, analysed by one way ANOVA, Holm-Sidak post-hoc test. F(5, 10)=13.288, p<0.001 
To further assess any role of α7 nAChRs in mediating [3H]-NA release in FC or 
HC the effect of ARR-17779 (α7 nAChR agonist; Levin et al, 1999) was tested (Figure 
2-10). ARR-17779 (with or without PNU-120596) does not elicit significant [3H]-NA 
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Figure 2-10 Effect of ARR-17779 on [
3
H]-A release in FC and HC  
Prisms (150 µm) from rat FC (red) or HC (blue) were loaded with [3H]-NA (70 nM) and release 
stimulated with ARR-17779 (10 or 30 µM) in the presence (hatched bars) or absence of 10 µM 
PNU120596. Bars represent mean + SEM from 3-4 experiments as % basal. Analysed by one way 
ANOVA for each region FC F(6,21)=0.680, p=0.668, HC F(6, 14)=0.385, p=0.876. 
A 
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2.3.2.6. GABA  
Previous work in this and other labs has suggested an involvement of GABAergic 
interneurons, and GABAA receptors in particular, in NA release (Leslie et al, 2002; Barik 
and Wonnacott, 2006). To test this, GABA (100 µM) was examined to see if it would 
stimulate [3H]-NA release, with choline (1 mM) and nicotine (100 µM) used as positive 
controls. This panel of drugs gave significant results in both regions (FC F(7,24)=10.87, 
p<0.001, HC F(7,21)=20.04, p<0.001).  
Post hoc Holm-Sidak multiple comparisons showed that GABA (100 µM) elicited 
significant release of [3H]-NA over basal in both FC (118.9 + 4.3 % basal) and HC (121.8 + 
6.2 % basal; Figure 2-11), and this release was partially inhibited by bicuculline (100 µM) 
reducing release to 111.8 + 6.2 and 108.5 + 6.8 % basal in FC and HC respectively. These 
reductions were not significant, but evoked release was no longer significantly different to 
basal release. Release elicited by nicotine was partially attenuated by bicuculline but not 
significantly. Release was reduced from 146.2 + 7.8 to 132.4 + 7.4 % basal and 136.9 + 8 
to 121.8 + 8.7 % basal in FC and HC respectively. Interestingly, release elicited by choline 
in HC was completely blocked by bicuculline (from 121.6 + 3.9 to 101.5 + 4.9 % basal) 


































Figure 2-11 Effect of GABA on [
3
H]-A release in FC and HC 
Prisms (150 µm) from rat FC (red) or HC (blue) were loaded with [3H]-NA (70 nM) and stimulated 
for 5 min with agonists. [3H]-NA release was stimulated from prisms by incubation with nicotine (10 
µM), choline (1 mM) or GABA (100 µM) in the presence (hatched bars) or absence of 100 µM 
bicuculline. Bars represent the mean + SEM from 4 separate experiments as % basal.  * p<0.05, ** 
p<0.01 compared to basal. # p<0.05 compared to agonist alone analysed by one way ANOVA, 
Holm-Sidak post-hoc tests for pairwise comparisons for each region. FC F(7,24)=10.87, p<0.001, 
HC F(7,21)=20.04, p<0.001 


































Figure 2-12 Effect of CGP54626 on GABA and nicotine induced [
3
H]-A release 
Prisms (150 µm) from rat FC (red) or HC (blue) were loaded with [3H]-NA (70 nM) and stimulated 
for 5 min with agonists. [3H]-NA release was stimulated with 100 µM GABA or nicotine in the 
presence (hatched bars) or absence of 1 µM CGP54626, a GABAB antagonist. Bars represent the 
mean + SEM from 4 separate experiments as % basal.  *p<0.05, ** p<0.01, *** p<0.001 compared 
with basal. Analysed by one way RM ANOVA, Holm-Sidak post-hoc tests for each region FC 
F(4,15)=16.466, p<0.001, HC F(4,15)=4.779, p=0.011 
To further investigate the role of GABA in [3H]-NA release the effect of 
CGP54626 (GABAB antagonist, 1 µM) on GABA- and nicotine-mediated release in FC and 
HC was investigated. CGP54626 had no effect on [3H]-NA release elicited by either agonist 
(Figure 2-12), although the response to GABA in FC became slightly larger (and therefore 
significant in comparison to basal). 
GABA is usually regarded as an inhibitory signal, and so the increased release of 
[3H]-NA in response to GABA is intriguing but could be due to inhibition of tonically 
active GABAergic interneurons, or an excitatory effect of GABA, usually thought to be a 
developmental process. In adult brain stimulation of GABAergic receptor is usually 
inhibitory due to the existence of a gradient that promotes the influx of Cl- upon receptor 
activation, causing a hyperpolarisation of the cell. Excitatory GABA, with an altered Cl- 
gradient has been postulated in adult born neurons and also in dendrites (Stein and Nicoll, 
2003; see 2.6.4). GABAA receptor mediated release of [3H]-NA from superfused 
synaptosomes has been seen (Fassio et al, 1999), consistent with a direct excitatory effect. 
To test which mechanism is involved in [3H]-NA release in this assay, inhibitors of the 
NKCC and KCC cotransporters were used.  
DIOA (a KCC2 inhibitor) provoked a large amount of [3H]-NA release at 100 µM 
(data not shown) indicative of a disruption of a gradient required for tonic inhibition. At 
lower concentrations which do not affect basal release (1 µM) no effect of DIOA on GABA 
or choline mediated release were seen. There is a possible potentiation of some responses 
but none of these are significant (Incubation F(4,30)=1.71, p=0.1745; Figure 2-13A). There 
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was no difference in the responses between the regions (F(1,30)=0.1438, p=0.7072) or 





























































Figure 2-13 Effect of DIOA and bumetanide on GABA and choline induced [
3
H]-A release 
Prisms (150 µm) from rat FC (red) or HC (blue) were loaded with [3H]-NA (70 nM) release was 
stimulated with GABA (100 µM) or choline (1 mM) in the presence (hatched bars) or absence of  A) 
1 µM DIOA or B) 100 µM bumetanide F(4,30)=1.71, p=0.1745 Analysed by two way ANOVA. 
Bars represent the mean + SEM from 4 separate experiments as % basal. # p<0.05 compared to 
agonist alone. Analysed by two way ANOVA with post hoc Bonferroni. Treatment F(4, 46)=8.17, 
p<0.0001, Region F(1,46)=5.98, p<0.05 
Bumetanide (100 µM), an NKCC1 cotransporter inhibitor, reduced release of 
[3H]-NA elicited by GABA in both FC and HC (F(4,46)=8.17, p<0.001), although post hoc 
tests showed that this was only significant in HC (p<0.05; Figure 2-13B). There was no 
effect of bumetanide on basal [3H]-NA release or on choline elicited release, in contrast 
with a bicuculline mediated reduction, suggesting different mechanisms of GABAA 
mediated release between GABA and choline stimulation. Lower concentrations of 
bumetanide did not reduce GABA elicited release in either region (data not shown). There 
was a significant effect of region (F(1,46)=5.98, p=0.0184) post hoc Bonferroni showed 
that only the choline plus bumetanide condition differed significantly between the regions 
but there was no interaction between region and treatment (F(4,46)=2.043, p=0.1039). 
A 
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2.4.  Results - [3H]-Noradrenaline release and [3H]-Epibatidine 
binding in nicotine treated animals 
After chronic nicotine treatment both in vivo and in vitro heteromeric nAChRs are 
known to be upregulated, although the functional consequences of this are less clear. For 
α7 nAChRs Barik and Wonnacott (2006) found no increase in 125I-αBgt binding, but a 
change in functional α7 activity when stimulated by choline during nicotine withdrawal. 
2.4.1.1. Single injection 
In order to be confident that when investigating chronic treatment differences seen 
in [3H]-NA release are due to chronic changes and not acute receptor occupancy or 
desensitisation [3H]-NA release was assessed after a single nicotine injection. The animals 
were given a single injection of either nicotine (0.4 mg/kg s.c.) or saline (see 2.2.6.1). The 
nicotine dose was chosen as it is a near optimal psychostimulant dose which gives reliable 
responses across rat strains (See Matta et al, 2007 for a review of nicotine dose selection). 
Animals were killed by cervical dislocation 30 min after injection, with nicotine and saline 
animals paired. FC was rapidly dissected and transferred to ice cold KB. Tissue from each 
animal was kept separate and loaded with [3H]-NA as previously described (2.2.7). Tissue 




































H]-A release after single nicotine injection 
Saline (grey) or nicotine (0.4 mg/kg, green) was administered s.c. 30 min before tissue collection. 
Tissue was incubated with 10 µM nicotine with or without PNU-120596 (10 µM; hatched bars) or 
PNU-120596 + α-Bgt (40 nM; cross hatched bars). Bars represent the mean + SEM from 7 
experiments as % basal * p<0.05 compared to basal analysed by two way ANOVA with Dunnett’s 
post hoc test for comparisonstocontrol. Incubation F(4,58)=4.56, p=0.0028 Injection F(1,58)=2.03, 
p=0.1592 Interaction F(4,58)=0.2928, p=0.8815 
A single nicotine injection 30 min prior to tissue collection did not alter basal 
[3H]-NA release from FC tissue (data not shown), or the response elicited by nicotine in 
comparison to saline treated animals (F(1,58)=2.03, p=0.1592; Figure 2-14). As previous 
studies (Barik and Wonnacott, 2006) have found functional differences in α7 nAChR 
mediated [3H]-NA release after chronic nicotine treatment, the responses to positive 
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allosteric modulation and antagonism of the α7 nAChR were investigated. No effect of 
PNU-120596 or α-Bgt (α7 selective antagonist) was seen on nicotine mediated [3H]-NA 
release in agreement with results for tissue from on naïve animals (2.3.2) and responses did 
not differ between saline and nicotine treated animals. As there were no changes caused in 
[3H]-NA release after acute nicotine treatment, any acute receptor occupancy or 
desensitisation is reversed during the wash stages in this type of experiment. 
2.4.1.2. 14 days injection 
Nicotine administration or withdrawal did not affect the weight gain of the animals 
over the time period studied, in comparison with saline treated animals (final weight 
339+20g in nicotine and 321+4.6g in saline treated animals and 331+4.4g in nicotine and 
341+13.6g in saline withdrawn animals). The basal release elicited by buffer alone was not 
different between the groups (13.6 + 1 and 12.7 + 0.8 % in nicotine and saline groups 








































































Figure 2-15 Effect of 14 days of nicotine injection on [
3
H]-A release in FC 
Animals were injected once daily for 14 days with 0.4 mg/kg nicotine, or 0.9 % saline. Animals were 
sacrificed 30 min or 3 days after final injection. Prisms (150 µm) of rat FC were loaded with 
[3H]-NA (70 nM) and release was stimulated by incubation for 5 min with agonists. Bars represent 
the mean + SEM from 4 experiments as % basal * p<0.05, ** p<0.01 compared to basal. ## p< 0.01 
compared to agonist alone. Analysed by two way ANOVA with ‘Injection’ and ‘Incubation’ as 
factors. Incubation F(5, 70)=6.44, p<0.0001, Injection F(3, 70)=2.68, p=0.0537 
The in vitro incubation conditions had significant effects (F(5,70)=6.44, p<0.0001). 
Post hoc Dunnett’s test showed that there was no response to 3 mM choline in FC (Figure 
2-15A), in agreement with results from naïve animals (Figure 2-9). The response to a 
maximally effective concentration of nicotine (100 µM) was no different between the four 
groups (Figure 2-15A). The response to 5IA at 10 nM was around 120 % of basal in all 
treatment groups, and this response was blocked with DHβE. In the FC the response to 5IA 
(10 µM) was around 140 % of the basal response (Figure 2-15B). These responses did not 
differ between the two treatments or during withdrawal, although responses were in general 
B A 
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slightly smaller (and therefore non-significant) in both nicotine and saline animals on 
withdrawal days. Overall the injection conditions had no significant effect on [3H]-NA 
release ((F3,70)=2.68, p=0.0537) and there was no interaction between injection and in 
vitro incubation conditions (F(15,70)=0.3725, p=0.982). 
Baseline release values of [3H]-NA in the HC were 16.6 + 0.5 and 16.1 +0.5 % in 
nicotine and saline animals and 16.0 + 1.9 and 14.5 + 1.4 % respectively during 
withdrawal. These values were not significantly different from one another. In the HC there 
was again no difference between nicotine and saline treated or withdrawn animals 
(F(3,70)=0.2645, p=0.85) however the profile of significant responses (F(5,70)=29.42, 
p<0.0001) is slightly different to the FC. Post hoc Dunnett’s reveals a response to 3 mM 
choline in the HC of around 130% baseline and nicotine (100 µM) elicits a response of 
around 160% of basal (Figure 2-16A). There is no response to the lower concentration of 
5IA (10 nM) in HC consistent with Figure 2-8 and the response to 10 µM 5IA is around 
130 % of basal in all treatment groups (Figure 2-16B), showing that chronic nicotine 
treatment by injection does not alter the sensitivity to 5IA. Again there was no interaction 








































































Figure 2-16 Effect of 14 days of nicotine injection on [
3
H]-A release in HC 
Animals were injected once daily for 14 days with 0.4 mg/kg nicotine, or 0.9 % saline. Animals were 
sacrificed 30 min or 3 days after final injection, nicotine and saline animals were paired. Prisms 
(150 µm) from rat HC were loaded with [3H]-NA (70 nM) and release was stimulated by incubation 
for 5 min with agonists. Bars represent the mean + SEM from 4 experiments as % basal * p<0.05, ** 
p<0.01, *** p<0.001 compared to basal. Analysed by two way ANOVA with ‘Injection’ and 
‘Incubation’ as factors. Injection F(3, 70)=0.26, p=0.8508, Incubation F(5, 70)=29.42, p<0.0001 
These profiles of [3H]-NA release after chronic treatment and withdrawal fit with 
the pharmacology already outlined for the two regions in naïve animals (2.3.2). The same 
patterns are observed at 14 days of nicotine treatment and after 3 days withdrawal, with no 
change in any of the responses; however the overall variability increases during withdrawal 
suggesting that subtle changes may have taken place in some animals. 
B A 
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2.4.1.3. 14 day minipumps  
Single daily injections give large peaks in plasma levels of nicotine, which are 
cleared from the bloodstream by the time of the next injection in rats. In contrast, smokers 
maintain a plasma concentration of nicotine, and each cigarette gives a smaller peak. To 
mirror sustained plasma levels of nicotine, rats were implanted with osmotic minipumps as 
described in methods (2.2.6.2). Briefly, rats were anaesthetised with isoflurane and Alzet® 
osmotic minipumps to deliver nicotine (4 mg/kg/day) implanted subcutaneously. Fourteen 
days after pump insertion animals were sacrificed by cervical dislocation and brains rapidly 
removed and dissected. To study withdrawal effects pumps were surgically removed after 
14 days in separate groups of animals and animals killed 2 or 3 days after pump removal. 




To ascertain if receptor binding was upregulated after chronic nicotine as expected 
(Wonnacott, 1990) brain tissue remaining after the removal of FC and HC for release 
experiments (2.4.1.3) was used to determine changes in [3H]-Epi binding (2.2.8). Chronic 
minipump treatment with nicotine (4 mg/kg/day) induced an increase in [3H]-Epi binding 
(F(1,37)=14.65, p<0.001) that Bonferroni post hoc tests showed was significant at the end 
of treatment and following two days of withdrawal (Figure 2-17). After three days of 
withdrawal the [3H]-Epi binding was no longer significantly different from control, 
although a numerical difference could be observed. 




































H]-Epibatidine binding in chronically treated and withdrawn animals 
Nicotine was administered at a rate of 4 mg/kg/day for 14 days via Alzet® osmotic minipump. After 
14 days animals were sacrificed (light green), or pumps removed and animals sacrificed 2 (dark 
pink) or 3 (dark green) days later. P2 membranes were prepared and 150 µg incubated with 500 pM 
[3H]-Epi in a final volume of 1 ml. [3H]-Epi bound was quantified by scintillation counting. Bars 
represent the mean + SEM from 4-6 animals as % basal * p<0.05 compared to paired control group 
(grey). Analysed by two way ANOVA with corrections for multiple comparisons in Bonferroni post 
tests. Injection F(1,37)=14.65, p=0.0005, Timepoint F(2,37)=0.0244, p=0.976 Interaction 
F(2,37)=0.0244, p=0.976 
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[
3
H]-&A release  
FC and HC prisms were taken for use in release assays. Basal fractional release is 
presented in Figure 2-18. In FC (panel A) no differences are found in fractional release 
after any of the treatments (F(3,34)=1.483, p=0.237). In HC (panel B) a difference in basal 
release is seen (F(3,32)=6.472, p<0.01) with post hoc Tukey tests revealing significantly 
higher basal release of [3H]-NA at 2 days of withdrawal, this returned to baseline levels by 






























































H]-A basal release after chronic nicotine treatment 
Nicotine was administered at 4 mg/kg/day for 14 days via Alzet® osmotic minipump. After 14 days 
animals were sacrificed, or pumps removed and animals sacrificed 2 or 3 days later. Responses from 
control animals did not differ in any treatment regimen and responses were pooled. A) Basal 
[3H]-NA release as % fractional from FC. Control (white), nicotine (red), 2 day WD (dark pink), and 
3 day WD (green). B) Basal [3H]-NA release as % fractional from HC. Control (white), nicotine 
(blue), 2 day WD (dark pink), and 3 day WD (green). Bars represent mean + SEM from 6-7 
experiments (18 for control) * p<0.05 compared to control. Analysed by one way ANOVA with 
Tukey post hoc test for pairwise comparisons. FC F(3,34)=1.483, p=0.237, HC F(3, 32)=6.472, 
p=0.002 
Tissue taken from animals treated chronically via minipump was incubated with the 
same drugs as used for injections. As previously seen in FC there was significant effect of 
in vitro incubation conditions (F(5,202)=9.133, p<0.0001). Post hoc Dunnett’s tests showed 
that as before choline had no effect on [3H]-NA release (Figure 2-19A). Nicotine induced 
release in each of the treatment groups. The response to 5IA and block by DHβE was also 
similar in magnitude between groups. In the frontal cortex chronic nicotine treatment or 
withdrawal did not have any significant effect on response to a variety of agonists 
(F(3,202)=0.1815, p=0.9089) and there was no interaction between in vivo and in vitro 
treatments (F(15,202)=0.08549, p=1).  
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Figure 2-19 Effect of chronic nicotine treatment on frontal cortex responses 
Nicotine was administered at a rate of 4 mg/kg/day for 14 days via Alzet® osmotic minipump. After 
14 days animals were sacrificed, or pumps removed and animals sacrificed 2 or 3 days later. 
[3H]-NA release was stimulated from FC with a variety of agonists. Responses from control animals 
did not differ in any treatment and responses were pooled. In both panels control (white), 14 day nic 
(red), 2 day WD (dark pink), 3 day WD (green) A) Response to choline or nicotine. B) Response to 
5IA and DHβE. Bars represent mean + SEM from 6-7 experiments (18 for basal) * p<0.05, ** 
p<0.01 compared to basal, # p<0.05 compared to agonist alone. Analysed by two way ANOVA with 
in vivo treatment and in vitro treatment as factors. In vivo F(3, 202)=0.18, p=0.9089, In vitro 
F(5,202)=9.13, p<0.0001 
Tissue taken from animals treated chronically via minipump was incubated with the 
same panel of drugs as used for chronic injections (F(5,192)=31.07, p<0.0001; Figure 
2-16). Post hoc Dunnett’s test showed that as previously seen (Figure 2-9) in HC choline 
had a significant effect on [3H]-NA release (Figure 2-20A). Nicotine induced release in 
each of the treatment groups; however this was only significant in control animals due to a 
smaller SEM. The responses to 5IA were also similar in magnitude and sensitivity to tissue 
from naive animals (Figure 2-8). Although there were differences in basal [3H]-NA efflux 
in the HC during withdrawal, chronic nicotine treatment or withdrawal did not have any 
significant effect on response to a variety of agonists expressed as % basal 
(F(3,192)=2.627, p=0.0516) and there was no interaction between in vivo and in vitro 
treatments (F(15,192)=0.4022, p=0.9773). 
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Figure 2-20 Effect of chronic nicotine treatment of hippocampal responses  
Nicotine was administered at 4 mg/kg/day for 14 days via Alzet® osmotic minipump. After 14 days 
animals were sacrificed, or pumps removed and animals sacrificed 2 or 3 days later. [3H]-NA release 
was stimulated from HC with a variety of agonists. Responses from control animals did not differ in 
any treatment regimen and so responses were pooled. In both panels control (white), 14 day nicotine 
(blue), 2 day nicotine withdrawal (dark pink), 3 day nicotine withdrawal (dark green) A) Responses 
to choline and nicotine B) Responses to 5IA. Bars represent the mean + SEM from 6-7 experiments 
* p<0.05, ** p<0.01 compared to basal, # P<0.05 compared to agonist alone. Analysed by two way 
ANOVA with in vivo treatment and in vitro treatment as factors. In vivo F(3, 192)=2.63, p=0.0516, 
In vitro F(5, 192)=31.07, p<0.0001. 
 
A B 
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2.5. Results - Novel compound binding and release assays 
2.5.1. PM and FA compounds 
 A number of novel compounds have been developed at the University of Bristol in 
the laboratory of Dr Tim Gallagher and are investigated here for ability to displace [3H]-Epi 
binding at heteromeric nAChRs and also their ability to elicit [3H]-NA or [3H]-DA release 
from rat brain prisms. The PM and FA compounds presented herein (Figure 2-21) have side 
group substitutions at the C4 position of cytisine (Figure 2-1). 
 
Figure 2-21 FA and PM compounds 
Analogs of cytisine with various side group substitutions at C4 were synthesised A) FA series of 
compounds B) PM series of compounds. 
2.5.1.1. [3H]-Epibatidine Binding 
P2 rat brain membrane homogenates were prepared by centrifugation and incubated 
with 200 pM [3H]-Epi for 120 min with various concentrations of drug to be tested (see 
2.2.5). Non-specific binding was determined in the presence of nicotine (1 mM).  
All of the compounds tested were able to compete for nAChR sites labelled with 
[3H]-Epi (Figure 2-22). Table 2-1 summarises the IC50 values for the FA and PM 
compounds as well as cytisine. From this it can be seen that all of the IC50 values for the FA 
series are higher than that of cytisine. This shows that substitutions at C4 reduce the ability 
of cytisine to compete with [3H]-Epi for nAChR binding sites. For the PM series the IC50 
values are again higher than for cytisine; however the most efficacious compounds exhibit 
similar binding to that of cytisine, suggesting that they may be of use as nicotinic ligands. 
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Figure 2-22 FA and PM series competition binding against [
3
H]-Epibatidine 
Rat brain P2 membranes were incubated with serial dilutions (10-4 to 10-10 M) of drug and 200 pM 
[3H]-epibatidine. Nonspecific binding was determined in the presence of 1 mM nicotine. A) FA 
series of compounds. B) PM series of compounds. The same cytisine data set is shown on each 
panel. 
Table 2-1 Summary of binding potencies of FA and PM compounds. 
Rat brain P2 membranes were incubated with serial dilutions (10-4 to 10-10 M) of drug and 200 pM 
[3H]-epibatidine. *** p< 0.001, n.s. not significant compared to cytisine. Analysed by non-linear 
regression with extra sum of squares F test to compare pIC50 values. 









Cytisine 8.0 0.11 0.008 / PM99 6.5 0.05 0.316 *** 
FA-10 6.4 0.19 0.040 *** PM103 7.6 0.17 0.025 n.s. 
FA-14 5.7 0.05 1.995 *** PM111 8.0 0.08 0.01 n.s. 
FA-18 6.9 0.16 0.398 *** PM125 7.9 0.05 0.013 n.s. 
FA-20 6.3 0.12 0.316 *** PM126 7.0 0.05 0.126 *** 
A 
B 
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2.5.1.2. Functional assays 
Using the results from the binding assays a number of the FA and PM series were 
selected for functional testing. The [3H]-NA release assay was used, to determine release 
from rat HC, in addition [3H]-DA release from striatum was assessed for FA compounds. 
The FA compounds elicited relatively low release of [3H]-NA from the HC (Figure 2-23A), 
with FA-18, FA-20 and PM111 eliciting significant release above basal at 100 µM. PM111 
elicited a similar amount of release to cytisine, and so is likely to be a partial agonist of 
similar efficacy as well as similar potency. When tested over a larger concentration range, 
PM111 was the only compound causing significant [3H]-NA release over basal at 
concentrations below 100 µM (Figure 2-23B EC50 12.6 µM). 


































































Figure 2-23 Effect of FA and PM compounds on [
3
H]-A release 
Rat HC prisms (150 µm) were loaded with [3H]-NA (70 nM) and release was stimulated by 
incubation for 5 min with selected compounds from the FA and PM series. A) FA and PM 
compounds (100 µM), with cytisine and nicotine to compare. Bars represent mean + SEM of 4 
experiments. * p<0.05, *** p<0.001 compared to basal. Analysed by one way ANOVA with Holm-
Sidak post hoc test for multiple comparisons to control F(7,27)=20.886, p<0.001 B) Compounds that 
elicited significant release at 100 µM were incubated with rat HC prisms at a range of concentrations 
and [3H]-NA release assessed. Points represent mean + SEM of 3-4 independent experiments. * 
p<0.05, ** p< 0.01, *** p<0.001 compared to basal. Analysed by one way ANOVA with Holm-
Sidak post hoc test for multiple comparisons to control for each compound. PM111 F(4,18)=12.557, 
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Figure 2-24 Effect of FA compounds on [
3
H]-DA release 
Rat striatum prisms (150 µm) were loaded with [3H]-DA (50 nM) and release was elicited by 
incubation for 5 min with compounds from the FA series. A) FA compounds (10 and 100 µM), with 
cytisine (100 µM) as comparator. Bars represent the mean + SEM of 6 replicates from one pilot 
experiment * p<0.05, *** p<0.001 compared to basal. Analysed by one way ANOVA with Holm-
Sidak post hoc test for multiple comparisons to control F(7,39)=19.957, p<0.001 B) Release elicited 
by FA-18 (0.1 – 100 µM). Points represent the mean + SEM of 3-5 independent experiments. 
* p<0.05, ** p< 0.01, *** p<0.001 from basal release. * p<0.05, ** p< 0.01, *** p<0.001 compared 
to basal. Analysed by one way ANOVA with Holm-Sidak post hoc test for multiple comparisons to 
control. F(7,23)=3.791, p=0.007 Experiments performed in our lab by Claire Thomas.  
[3H]-DA release from rat striatal prisms was also assessed for the FA compounds. 
In a pilot high concentrations (10 and 100 µM) of FA-10 and FA-14 failed to elicit any 
release of [3H]-DA (Figure 2-24A). FA-18 elicited significant release at both of these 
concentrations, and so a wider concentration range was tested. FA-18 elicited [3H]-DA 
release in a concentration dependent manner from striatal prisms reaching a maximal of 
124.5 + 6.8 % basal at 300 µM (EC50 1 µM; Figure 2-24).  
2.5.2. Cytisine analogues  
Aryl-cytisine, cyfusine and 4-F-cyfusine as well as a further C4 analogue of 
cytisine, 4-F-Cytisine are also reported (Figure 2-25). Cyfusine is formed when the bridged 
bicyclic framework of cytisine is fused into a tricyclic form, and 4-F-cyfusine is the 
subsequent halogenation at the C4 position. The addition of an aryl group, linked to the C3 
and C4 of cytisine forms aryl-cytisine. 
A 
B 
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Figure 2-25 Cytisine analogs 
Cyfusine and 4-F-Cyfusine have the bridged bicyclic structure of cytisine fused into a tricyclic 
structure, with a C4 substitution also in the case of 4-F-cyfusine. Aryl-cytisine is an arylation of the 
cytisine molecule linked to C3 and C4. 4-F-cytisine is a further C4 substitution of cytisine. 
2.5.2.1. [3H]-Epibatidine Binding 
P2 rat brain membrane homogenates were incubated with 200 pM [3H]-Epi for 120 
min with various concentrations of the drug to be tested (see 2.2.5). Non-specific binding 
was determined in the presence of nicotine (1 mM). Cyfusine gave extremely poor 
displacement of [3H]-Epi binding to rat brain membranes (Figure 2-26), and 4-F-Cyfusine 
did not displace binding within the concentration range tested suggesting that alterations to 
the ring structure of the molecule severely disrupts the ability to bind to nAChRs. 
4-F-Cytisine and Aryl-cytisine however show 3 and 10 fold lower binding potency than 
cytisine respectively. Changes at the C4 position of the molecule have been suggested to 
play a role in selectivity. While this cannot be determined in these binding assays it can be 
seen that 4-F-Cytisine and Aryl-cytisine bind to the nAChR with potencies similar to that of 
cytisine, and so may be active at the receptor. 
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Figure 2-26 Competition binding against [
3
H]-Epi for cytisine analogs 
Rat brain P2 membranes were incubated with serial dilutions (10-4 to 10-10 M) of drugs to be tested 
and 200 pM [3H]-epibatidine. Nonspecific binding was determined in the presence of 1 mM nicotine. 
Cytisine was also assayed as a comparison.  
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Table 2-2 IC50 values for cytisine analogs 
Rat brain P2 membranes were incubated with serial dilutions (10-4 to 10-10 M) of drug and 200 pM 
[3H]-epibatidine. *** p< 0.001. Analysed by non-linear regression with extra sum of squares F test 
to compare pIC50 values. 




Cytisine 8.2 0.08 0.006  
4-F-Cytisine 7.8 0.05 0.017 *** 
Aryl-Cytisine 7.1 0.04 0.085 *** 
Cyfusine 5.6 0.12 2.8 *** 
4-F-Cyfusine N.D.    
2.6. Discussion 
In this chapter the subtypes of nAChRs involved in modulating noradrenaline 
release in FC and HC were compared in vitro by use of a [3H]-NA release assay. The 
responses to a range of ligands varied between the two regions, suggesting the involvement 
of different nAChR subtypes. In particular there was much greater sensitivity to β2* 
nAChR selective compounds in FC than HC, which was found to be predominantly 
modulated by α3β4* nAChRs in agreement with previous reports. The interaction of 
GABA and cholinergic mechanisms on NA release was also investigated, showing that 
there is a potential GABAA mediated excitatory component to the nicotinic response. 
Several series of novel structural analogs of cytisine were also assessed for their ability to 
compete with [3H]-Epibatidine for binding to nAChRs in rat P2 membranes showing a 
range of affinities. Selected compounds from these series were also assessed for their 
ability to release [3H]-NA or DA and showed variable functional potency, with most 
behaving as partial agonists. 
2.6.1. 96-well method critique 
The 96-well method used in this study was first developed by Anderson et al 
(2000) to study catecholamine release from brain prisms. This assay has both advantages 
and disadvantages in comparison with other in vitro methods. The main advantage is the 
relatively high throughput of the technique, which allows 16 conditions to be assessed in 6 
replicates during each experiment. This means that concentration-response curves can 
easily be constructed within a single experiment, often from two regions or + antagonist, 
reducing animal usage and variability. In comparison superfusion systems usually have 12 
chambers, meaning that fewer replicates and conditions can be examined simultaneously. 
The main disadvantage in comparison to superfusion is that this is a static assay, with only 
one drug-stimulated sample collected. This means that the timecourse of drug response or 
desensitisation is not determined. It has previously been shown that Ca2+ levels have 
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returned to baseline after 5 min of stimulation with nicotine (Gueorguiev et al, 2000), 
supporting the use of a 5 min sampling period. 
The prism preparation also has advantages and disadvantages. Prisms have 
additional synaptic connectivity in comparison with synaptosomes, meaning that some 
interactions and indirect drug affects can be assessed. This is both an advantage and a 
limitation depending on the questions asked. In general synaptosomes are used when 
isolation of the presynaptic effects is required to determine, for example, the localisation of 
certain receptors. The results in section 2.3.2.6 show the importance of retaining some 
connectivity to examine the interactions between different neurotransmitter systems within 
brain tissue. A prism or slice preparation with an additional degree of complexity is a closer 
representation of in vivo tissue, although there will not be the full connectivity and intrinsic 
stimulations that would exist in vivo. As with any in vitro assay there will be unavoidable 
differences from the whole animal, but results from this assay have been found to be largely 
translatable (Livingstone et al, 2009). 
Fractional release is calculated for each well, i.e. the neurotransmitter released is 
calculated as a percentage of the neurotransmitter in the well at the start of the release 
period. This eliminates variability that is an artefact of tissue loading. Data has then been 
presented as a percentage of fractional release in buffer alone (except where stated). This 
allows data to be normalised between animals as basal efflux varies but relative responses 
are usually similar. 
2.6.2. Uptake specificity 
Previous work (Carboni et al, 2001; Moron et al 2002) has shown that monoamine 
uptake is somewhat promiscuous, for example DA uptake occurs in part via the NET. This 
has been shown to be especially relevant in the FC (Williams and Steketee, 2004) where 
uptake via NET modulates FC DA levels substantially. Moron et al (2002) showed that in 
wild type mice DA uptake in FC synaptosomes was inhibited by nisoxetine but not GBR-
12909, and that in NET knockout mice there was no effect of nisoxetine on DA uptake in 
FC synaptosomes. The importance of this difference in uptake will be further explored in 
section 3.7. In order to validate the [3H]-NA release assay used in these experiments it was 
essential to ensure that the uptake of [3H]-NA was specifically into noradrenergic cells via 
the NET. This is important in order to interpret the results accurately in a physiological 
context. Nomifensine and nisoxetine were both effective inhibitors of NA uptake (Figure 
2-2). The selective DAT inhibitor, GBR-12909 (Andersen, 1989), did not inhibit uptake of 
[3H]-NA, showing that uptake is specific to noradrenergic neurons. This result showed that 
there was no need to include a DAT inhibitor in [3H]-NA uptake steps in release assays. 
GBR-12909 has also been shown to be an antagonist of nAChRs (Szasz et al, 2007), and 
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although there is some evidence that nomifensine can reduce release in superfused brain 
slices, it has been shown that this reduction is in carrier mediated, and not exocytotic, 
release at the concentration used in the current study (Kiss et al, 1997). Carrier mediated 
release is likely to be a non-specific process that would not be triggered at the agonist 
concentrations used within these studies and so the action of nomifensine on this is not 
likely to affect results. The inclusion of nomifensine to block reuptake of stimulated release 
is important in a static assay, as the neurotransmitter released from the tissue is not 
immediately moved away as is the case with superfusion. Nomifensine increases recovery 
and reduces variability (own work, data not shown). 
2.6.2.1. Interaction with opiates 
Many drug users abuse multiple drugs with around three times as many smokers in 
substance abuse populations as normal subjects (Stark and Campbell, 1993). To determine 
if there is a direct interaction between nicotine and morphine’s actions in the brain the 
effect of morphine on [3H]-NA uptake was assessed. The reversal by naloxone of the partial 
inhibition of [3H]-NA uptake by morphine shows that this effect was mediated by opioid 
receptors, not by a direct interaction of morphine with the NET. When morphine was tested 
in release assays there was no change in [3H]-NA release in buffer alone in the presence of 
nomifensine, showing that the reduction in [3H]-NA accumulation is due to a change in 
uptake, not a concurrent weak releasing action. Responses to nicotine (10 or 100 µM), or 
KCl (15 mM) were also unchanged in the presence of morphine suggesting minimal direct 
interaction between the opiate and nicotinic systems in these conditions. In vivo it has been 
shown that NA reduces in response to acute morphine administration in naïve animals 
(Rossetti et al, 1993), in morphine pretreated animals tolerance to this developed, however 
naloxone caused an increase in NA levels that was not seen in naïve animals. The reduction 
in [3H]-NA uptake seen here would be expected to translate to an increase in NA measured 
in vivo, so the reduction seen suggests that wider compensatory mechanisms are active in 
vivo. As there were no significant interactions with nicotinic responses in release assays 
opiates were examined no further. 
2.6.3. Pharmacology in naïve animals 
2.6.3.1. icotinic pharmacology 
As nicotine is known to elicit [3H]-NA release it was decided to further investigate 
these responses and the subtypes involved by the use of a range of selective nAChR 
agonists in both FC and HC. The responses are summarised in Table 2-3. [3H]-NA release 
in response to many nicotinic drugs differed between the two brain regions. 
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Table 2-3 Responses in FC and HC to a range of nAChR ligands 
 FC HC 
Agonist EC50 (µM) Antagonist EC50 (µM) Antagonist 
icotine 0.8 DHβE shift Mec block 12.6 
No DHβE shift 
Mec block 
Cytisine 3.9  21.4  
3-Br-Cyt n.d.    
5IA 2.6 nM DHβE shift to 33.9 nM 4.5 
No DHβE shift 
5.1 
Choline No response Significant responses 
Mec block 
No MLA block 
Other α7 No response No response 
 
HC responds as previously shown, with a significant release elicited by choline and 
no significant β2* nAChR component in responses elicited by nicotine. In contrast FC 
showed no significant choline response and a strong β2* nAChR mediated component to 
[3H]-NA release. HC NA release has previously been shown to be modulated in large part 
by α3β4* nAChRs, with a contribution of α7 found in some studies but not in others (See 
2.1.1). As there is no antagonism with MLA of choline mediated responses and no [3H]-NA 
release elicited by the more selective α7 agonist ARR-17779 it is likely that the response 
seen here to choline is due to actions at α3β4* nAChRs. No α7 nAChR responses were seen 
in FC, which contrasts with the indirect effect of α7 nAChRs seen in FC for [3H]-DA 
release (Livingstone et al, 2009). The presence of the α7 nAChR positive allosteric 
modulator PNU-120596 made no difference to responses with a range of agonists in either 
brain region, further confirming that α7 nAChRs are not involved in modulating [3H]-NA 
release under the current conditions (data not shown). There is little or no response to 
choline in FC, suggesting a lack of α3β4* involvement in this region which is in contrast 
with the HC.  
Dopaminergic responses in FC have previously been shown to be predominantly 
mediated by β2* nAChRs with a contribution from α7 (Livingstone et al, 2009) and so, 
given the lack of α3β4* or α7 responses, the role of β2* nAChRs in [3H]-NA release in this 
region was investigated. In agreement with previous results (Sacaan et al, 1995) DHβE, a 
selective β2* nAChR antagonist, did not affect the response to nicotine in HC but was here 
found to have a significant effect on FC [3H]-NA release, a further indication that the 
nAChR subtypes differ in FC from HC. Unlike Anderson et al (2000) DHβE was seen to 
give a rightwards shift of the concentration-response curve in FC, consistent with a 
competitive antagonism as seen for striatal DA responses. 
5-Iodo-A85380 (5IA) was originally developed as a radioiodinated PET ligand 
derived from A-85380, but assays showed that its selectivity profile differed. 5IA has 
similar binding potency to epibatidine at α4β2*, however it has much lower binding 
potency at α3β4* sites. The binding is around 5,000 fold less potent at α3β4* than α4β2*, 
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and potency at α7 and muscle type nAChRs is even lower. The functional potencies follow 
a similar pattern with much greater potency at α4β2* than α3β4* nAChRs (Mogg et al, 
2004). These large differences in potency of binding to the different nAChR subtypes 
allows 5IA to be used as a selective agonist for β2* nAChRs. FC had much more sensitive 
responses than HC to 5IA and these responses were competitively antagonised with DHβE 
(Table 2-3). The difference in potency in the two regions is nearly 2000-fold, suggesting 
that the subtypes involved are likely to be α3β4* in HC, as previously postulated, and a β2* 
containing subtype in FC. Although 5IA is highly selective for β2* nAChRs no further 
information about the subunit combination can be elucidated, although it is likely β2 is the 
sole beta subunit (2.6.3.2). 
Responses to the other agonists tested here are consistent with the results already 
discussed giving strong evidence for differences in the subtypes involved in the two brain 
regions. If these differences are also found in vivo it may be possible to exploit them in 
order to target NA responses in selected brain regions. 
2.6.3.2. Regional differences in nAChRs 
The differences in nAChR subtypes involved in [3H]-NA release between the two 
regions of the brain studied in these experiments may be due to differences in the 
expression of nAChRs. The noradrenergic neurons mainly arise from the locus coeruleus 
(LC) and there is evidence of two distinct populations as defined by mRNA expression 
levels (Lena et al, 1999). One population contain predominantly α3 and β4 (and also α6, 
β3, α5 and α4) mRNAs and the other α6 and β3 (and sometimes also α4 and α7) mRNAs. 
All cells tested contained β2 mRNA.  
Although both of these neuronal populations contain β2 nAChR mRNA it may be 
that the subcellular distribution of receptors varies between the different cell populations. 
The β2* nAChRs on projections to HC arising from the LC may be somatic, and so not 
contribute to terminal field responses. This could lead to β2* responses in the terminal field 
(the responses measured by this assay) in FC but not HC.  
High and low affinity subtypes of heteromeric receptors have been found, with the 
differing accessory subunit altering the functional profile (Nelson et al, 2003). The 
(α4β2)2α4 stoichiometry has previously been shown to have lower agonist sensitivity but a 
higher efficacy than (α4β2)2β2. Although the channel of the nAChR is permeable to K+, 
Ca2+ and Na+ the differences in CA2+ permeability are the most important distinction. The 
high affinity receptor has a smaller total Ca2+ flux, and so a large proportion of cellular 
responses are mediated by the low affinity stoichiometries. It has recently been 
demonstrated that a homomeric receptor will open with just one binding site occupied, but 
that this opening is brief (1.3.4). If two binding sites are occupied (as for heteromeric 
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receptors) channel opening is stabilised. Occupation of 3 non-consecutive binding sites is 
required to give maximal channel open time (Andersen et al, 2011). Extrapolating this to 
heteromeric receptors suggests that the accessory subunit may contribute to function, and 
indeed an α4-α4 interface has been shown to contribute to channel function (Mazzaferro et 
al, 2011). The knowledge of an agonist binding site at the α4-α4 interface explains the 
ability of the receptor to display different responses with the two α-β interfaces remaining 
identical which is not well explained with a model of two agonist binding sites. The 
increased conductance found with α5 as the accessory subunit (1.3.4) would indicate that 
this subunit may also contribute to a third binding site, and so stabilise the open 
conformation of the receptor allowing increased Ca2+ influx. The necessity for two (or 
three) binding sites to be occupied to stabilise channel opening suggests that the perceived 
affinity to agonist of a channel is dependent on the lowest affinity binding site. In terms of 
the data presented in this chapter this suggests the possibility that the receptor subtype in 
HC could be complex, containing α3β4β2* combinations, but supports FC nAChRs 
involved in [3H]-NA release containing β2 as the sole beta subunit. This would explain the 
lower affinity to 5IA in HC while not dismissing the fact that β2 nAChR mRNA has been 
detected in all cells tested in the LC, the source of the NAdrenergic stimulation of HC and 
FC. The lack of antagonism in HC by DHβE may suggest the lack of β2* expressed 
terminally on HC NAdrenergic neurons, however as DHβE is a competitive antagonist the 
inhibition of the putative β2* interface may be overcome by concentrations of agonist 
sufficient to activate the non-β2* interface and so the presence of complex receptor 
subtypes cannot be ruled out. 
Overall FC NA release appears to be more similar to FC DA release than to HC 
NA release with β2* nAChRs involved in FC and α3β4* in HC. The roles of these different 
brain regions could therefore be targeted independently by use of selective agonists. 
2.6.3.3. Importance of regional differences 
As examined in the introduction the roles of the FC and HC are different, with FC 
involved in executive tasks, and HC in spatial tasks (see 1.1.1 and 1.1.2). Hahn et al (2003) 
found attention enhancing effects of nicotine that were mediated via PFC and not HC. This 
means that drugs that could selectively target one or other of these regions could have 
specific cognitive benefits. As many of the side effects of nicotinic drugs that have been 
trialled are thought to be regulated by the α3-containing nAChRs, this leaves β2* or α7 as 
suitable targets, suggesting FC tasks may be improved most by nicotinic stimulation. In fact 
several studies targeting these subtypes have found enhancement in FC regulated tasks. 
Both subtypes seem to improve performance on certain cognitive tasks, although the 
improvements are in different cognitive domains. β2* nAChRs improve attentional 
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performance (Guillem et al, 2011) whilst α7 is involved in procedural learning (Young et 
al, 2011). Mice with either the β2 or the α7 nAChR knocked out show cognitive deficits 
(see 1.4). It is not known if the cognitive effects of nAChRs are mediated by NA or by DA, 
or whether the modulation of both of these systems is important. There is evidence that NA 
is required for the attribution of salience to rewarding or aversive stimuli (Ventura et al, 
2008). In the context of the work presented in this thesis this suggests that targeting β2* 
nAChRs may therefore be of benefit to enhance attentional processing.  
Many cognitive deficits in humans are complex and it can be difficult to define a 
single aspect that is impaired. Both β2* and α7 nAChRs are useful potential targets. ABT-
089 is a drug with an interesting selectivity profile. It is a partial agonist at α4β2* and α7, 
and weak partial agonist with low potency at α3β4* nAChRs, giving a substantially 
reduced side effect profile compared to nicotine (Rueter et al, 2004). In a trial in adults 
ABT-089 (40 mg once or twice daily) was effective in reducing ADHD deficits with 
minimal adverse effects (Apostol et al, 2011), however a trial in a paediatric population (6-
12 years) showed no efficacy of ABT-089 at doses of up to 1.4 mg/kg (Wilens et al, 2011). 
No adverse effects of this dose were reported and so it may be that the metabolism of ABT-
089 is faster in the paediatric population, leading to the lack of effect. ABT-418, another 
selective partial agonist for α4β2* nAChRs has also been trialled for ADHD (1.4). 
Some cognitive enhancement has been found with drugs that selectively target the 
α7 nAChR. The development of selective agonists has been hampered by the high degree of 
homology between α7 and the 5-HT3R, meaning that many α7 agonists have 5-HT3 activity. 
Many α7 selective compounds have been tested in a wide range of cognitive tasks in 
several species with positive results on episodic and working memory and sensory gating, 
but mixed results for attention with improvement found in impaired (e.g. by ketamine or 
PCP) but not normal animals (reviewed in Wallace and Porter, 2011). The interaction 
between α7 ligands and 5HT3 receptors can cause side effects. Many α7 agonists act to 
inhibit 5HT3 receptors. 5HT3 antagonists act as antiemetics, but can also slow colonic 
transit, causing constipation (Stables et al, 1987, Talley et al, 1990). Interestingly 
varenicline has been shown to be an agonist at 5HT3, explaining some of the 
gastrointestinal side effects seen (Lummis et al, 2011). The effects at 5HT3, whether 
agonist or antagonist activity, make the development of effective and selective α7 ligands 
difficult. Positive allosteric modulators (PAMs) of α7 nAChRs have been developed, 
including PNU-120596. These molecules bind at a site distinct to the acetylcholine binding 
site and so could represent a novel line of investigation. PNU-120596 slows desensitisation 
of the α7 nAChR, thus increasing functional responses, and this effect is lost in a 5HT3/α7 
nAChR chimera, suggesting that there would be no 5HT3 mediated side effects (Bertrand et 
al, 2008). As they do not cause direct receptor activation PAMs could be used to increase 
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signal to noise ratio upon endogenous cholinergic signalling, which would help to maintain 
efficacy of treatments which sometimes fail due to the development of tolerance. Overall 
these results suggest that the responses to α7 are in different domains than the β2* mediated 
effects and so combined treatments may be useful for some patient populations where 
cognitive deficits are across multiple domains. A risk factor for the use of PAMs is that by 
increasing the signal to noise ratio they may increase the response to nicotine. As the α7 
nAChR is not involved in mediating the hedonic properties of nicotine (Grottick et al, 
2000) a selective α7 PAM may not greatly raise the risk of increased nicotine use. 
2.6.4. GABA 
As previously determined (2.3.2.5) choline induces release of [3H]-NA via α3β4 
nAChRs, this release is partially sensitive to the GABAA antagonist bicuculline (2.3.2.6). 
Nicotine mediated release in FC and HC is also partially attenuated by bicuculline 
application. GABA release from mouse synaptosomes from a variety of brain regions can 
be elicited by α4β2 or α4β2α5 nAChRs (McClure-Begley et al, 2009). T-type Ca2+ channels 
can be activated by α3β4 nAChRs on synaptic regions of GABAergic interneurons, leading 
to the release of GABA (Tang et al, 2011). This suggests that a portion of the release of 
[3H]-NA in the two brain regions is mediated indirectly by GABA. The administration of 
GABA elicited the release of [3H]-NA from both FC and HC prisms and this was inhibited 
by bicuculline. The GABAB antagonist CGP54626 caused no reduction in GABA mediated 
[3H]-NA release. The involvement of GABAA in neurotransmitter release has been 
observed before (Barik and Wonnacott, 2006; Leslie et al, 2002). As GABA is traditionally 
thought of as an inhibitory neurotransmitter, there arises the question of whether these 
responses are due to the inhibition of tonically active inhibitory interneurons, or due to a 
direct excitatory effect of GABA stimulation.  
 
Figure 2-27 Developmental Regulation of Chloride Homeostasis in eurons 
The regulation of Cl- gradients in A) immature and B) mature neurons. Dorsal root ganglion (DRG) 
cells have the gradient defined in A) The size of the lettering for the transporters depicts their 
relative importance, and the relative size for Cl− depicts the gradient across the membrane. 
Reproduced from Stein and Nicoll, 2003 with permission. 
A B 
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During brain development there is a switch of chloride (Cl-) cotransporter in 
neurons from the NKCC1, to the KCC2 (Plotkin et al, 1997; Stein and Nicoll, 2003). In 
development NKCC1 predominates to give high intracellular Cl-, which means that upon 
GABAA activation Cl- exits the cell, leading to depolarisation (Figure 2-27A). In mature 
neurons the KCC2 predominates to give low intracellular Cl-, so receptor activation leads to 
influx of Cl- and which supports hyperpolarisation upon receptor activation (Figure 2-27B).  
NKCC1 has been observed in adult-born neurons suggesting that this difference in 
response is present until the individual neurons have matured. This means that adult-born 
neurons have an ‘immature’ excitatory phenotype. NKCC1 has also been shown to be 
important in the migration of neuroblasts during post-natal neurogenesis; however this may 
not be directly linked to its role in GABAergic signalling (Mejia-Gervacio et al, 2011). 
NKCC1 has also been shown in dendrites (but not somatic regions) in mature neurons, 
further suggesting a possible excitatory action of GABA (Romo-Parra et al, 2008, Khirug 
et al, 2008).  
In order to test this theory, inhibitors of the NKCC1 and KCC2 Cl- cotransporters 
were used (Figure 2-13). The NKCC1 inhibitor, bumetanide, reduced GABA mediated 
[3H]-NA release showing a role for the developmental transporter form and supporting the 
excitatory GABA theory. Further work in other systems would be required to ascertain if 
this was due to dendritic NKCC1 or adult-born neurons (See 2.6.7). 
The baseline effect of DIOA to elicit [3H]-NA release in the absence of other 
stimulation (2.3.2.6) may suggest perturbation of the maintenance of the mature 
hyperpolarising gradient. This suggests that this is also an important component in the 
prism preparation. Together these results suggest that both excitatory and inhibitory 
GABAergic responses are occurring within the prisms from both FC and HC, consistent 
with a mixture of immature and mature cells, or dendritic vs. somatic actions of GABA. 
This fits with a review from Marty and Llano (2005) which discusses the complexity of the 
GABAergic system in terms balance between inhibition and excitation. The role of adult-
born neurons in memory formation has been reviewed by Koehl and Abrous (2011). 
Selectively enhancing the function of these neurons may help enhance encoding of 
memories in neurodegenerative disorders. Inhibition of the reconsolidation of fear 
memories has been shown with a variety of neurotransmitter systems, including GABAA 
(Diergaarde et al, 2008) and may be a useful therapy in post traumatic stress disorder; 
however the exact mechanisms involved have yet to be elucidated. The GABAA mediated 
effects on [3H]-NA release do not seem to differ between FC and HC, although responses 
and inhibition are slightly clearer in HC. It might be expected that the immature component 
of the GABA response would be larger in HC, as there is substantial neurogenesis in this 
region (Gross, 2000). The lack of distinction between these brain regions suggests that 
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dendritic GABA may be responsible for the excitatory component. The coexistence of 
excitatory and inhibitory GABA, with an overall inhibitory phenotype in vivo means that 
selective pharmacological targeting is difficult. 
Another explanation for the effect of bumetanide is a direct inhibitory effect at 
GABAA receptors, as discussed by Russell (2000). As no effect was seen at concentrations 
below 100 µM this may be a possibility as only concentrations below 10 µM can be 
reliably determined to be selective for NKCC. This has led to the development of the 
NKCC cotransporter knockout mouse by Delpire et al (1999) however this mouse has a 
variety of developmental problems and so the relevance of information gained on 
neurotransmission by electrophysiology is limited. To the authors knowledge there is no 
conditional knockout for this gene. This lack of distinction between brain regions, when 
only the HC would be expected to contain developing neurons again suggests that 
bumetanide as used in these experiments may be acting more as a GABAA antagonist than 
NKCC inhibitor. 
2.6.5. In vivo nicotine treatment 
2.6.5.1. Single injection 
The dose of nicotine administered within these assays (0.4 mg/kg) was high enough 
to induce locomotor depression, although this was not quantified. The time of tissue 
collection (30 min post injection) was such that nicotine in the brain should be near peak 
(peak is at 15 min, Turner, 1975). Singer et al (2004) show that brain nicotine levels are at 
88 % of maximum at this time. There were no significant differences in the responses to 
any of the agonists tested between saline and nicotine treated animals. This suggests that 
acute receptor occupancy or desensitisation does not affect in vitro responses. The washing 
of the tissue may to some extent explain the lack of a significant difference in response to 
nicotine in the two groups as nicotine may have been washed out. Bullock et al (1994) 
show a development of tolerance to chronic nicotine treatment (7 days pretreatment in 
vitro), however the changes in nicotine response were quickly eliminated (~1 hour), 
suggesting that receptors can recover from desensitised states quickly, especially when 
undergoing washes. The lack of effect of a single nicotine treatment is useful information as 
it shows that acute desensitisation or receptor occupancy is washed out over the course of 
the assay, and unlikely to affect results, so any differences after chronic treatment are not 
due to these factors and so are due to changes in receptor expression or subunit 
stoichiometry. 
2.6.5.2. Multiple injections 
Nicotine (0.4 mg/kg) was administered to the animals once daily by s.c. injection 
for 14 days and tissue was collected 30 min after the final injection to produce maximal 
 - 73 - 
brain concentrations as before. In this experiment there was no significant difference in the 
responses of tissue from nicotine and saline treated animals. The dose of nicotine 
administered was high enough to induce locomotor depression on initial days, although 
tolerance to this effect developed within 3-4 days suggesting chronic changes. Differences 
after repeated nicotine injection in response to a nicotine challenge on both locomotor 
activity and DA changes measured by microdialysis from PFC have been seen (Nisell et al, 
1996). DA release in the mesoaccumbens, involved in locomotor stimulation and 
reinforcement of self-administration, is sensitised after repeated nicotine administration 
(Reviewed in Balfour et al, 1998). There are strain differences in sensitisation to repeated 
nicotine treatment, with evidence that Sprague-Dawley rats show a greater sensitisation 
than Lister hooded rats (Iyaniwura et al, 2001). After repeated nicotine administration as 
well as tolerance to the locomotor depression caused by acute nicotine a locomotor 
stimulant effect is seen (Stolerman et al, 1973) although Iyaniwura et al (2001) showed a 
disconnect between sensitisation of mesoaccumbens dopamine release and locomotor 
responses. An increase in operant responding for an audiovisual cue has been shown to be 
dependent on repeated nicotine exposure (Barrett and Odum, 2011), however it is unclear if 
this is a reward enhancement or due to the locomotor sensitisation caused by repeated 
nicotine administration. The sensitisation outlined above is centred on the dopaminergic 
system, with no evidence of sensitisation in NA release seen, although Barik and 
Wonnacott (2006) saw changes in NA release after nicotine administration, although this is 
during withdrawal from sustained rather than intermittent treatment. 
There are no significant differences in [3H]-NA release in response to nAChR 
stimulation between treated and untreated animals in either brain region. There are also no 
differences in responses to the range of nAChR ligands after 3 days of withdrawal in either 
brain region. It can be concluded that any changes caused by repeated nicotine injection are 
masked in this assay. The time period required for loading of [3H]-NA, and the extensive 
washing required to ensure an accurate result may have meant that any differences caused 
by the repeated nicotine administration in vivo could not be observed in this in vitro assay.  
The three day withdrawal time point was chosen on the basis of results from Barik 
and Wonnacott (2006) which show that changes in α7 nAChR function can be measured 
after 3 days of withdrawal, but without a concurrent change in receptor binding levels. The 
previous study used osmotic minipumps in order to deliver a constant dose of nicotine. The 
difference in results in the current study could therefore reflect differences between 
continuous and intermittent nicotine administration, as the whole of one dose is 
metabolised before the next administration, allowing desensitised receptors to revert to the 
resting state.  
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Constant infusion of nicotine (1 mg/kg/hour tartrate salt) has been shown to 
increase [3H]-Epi binding to a greater extent than twice daily 2 mg/kg (tartrate) s.c. 
injection (Ulrich et al, 1997). Due to the differing total doses between injection and 
infusion studies it is often difficult to ascertain if differences in the responses are due to 
constant elevated plasma nicotine, or the total dose of nicotine being larger. Smokers 
maintain a steady state plasma level, as well as administering nicotine intermittently so both 
models of administrations have some experimental validity, but both also have 
shortcomings as they are simplified models. The minipump model has been used here to 
investigate if sustained elevated plasma nicotine concentrations in vivo are required to 
produce changes in response to nAChR agonists in vitro. 
2.6.5.3. Minipumps 
In this experiment nicotine (4 mg/kg/day) was administered via osmotic minipump. 
No differences were observed in agonist responses after chronic nicotine treatment or 
withdrawal (2 or 3 days). The profile of responses in the two brain regions was the same in 
control as treated animals, and these profiles did not differ from naïve animals. There was 
however an increase in basal [3H]-NA efflux in HC after 2 days of withdrawal, basal 
responses did not differ at any other time or in the FC. Different methods of presenting 
results may have led to an apparent increase in NA release in response to agonist at this 
time across different treatments, hence percentage of buffer stimulated efflux is a good 
measure to use to normalise responses. An increase in NA in mice withdrawn from nicotine 
in drinking water was seen by Gaddnas et al, (2000) in post-mortem brain tissue 
homogenates. The difference in baseline efflux may be important as it could correlate to an 
increased HC NA level during nicotine withdrawal, something that may be linked to some 
of the signs of withdrawal such as anxiety. Somatic signs of withdrawal from nicotine 
infusion can be observed at 16 hours after withdrawal, but have largely subsided by 40 
hours (Malin et al, 1992). This suggests that at the 48 hour timepoint used here, when a 
baseline change in NA efflux was seen, somatic signs will be minimal. Affective signs of 
withdrawal such as anxiety have been shown after spontaneous withdrawal. Intracranial self 
stimulation thresholds are elevated from 4 hours after spontaneous withdrawal, and this 
elevation remains significant for at least 4 days (Epping-Jordan et al, 1998). 
There were significant changes in [3H]-Epi binding after chronic treatment, which 
were maintained at 2 days of withdrawal, showing upregulation of nAChRs. An elevated 
nAChR binding was still seen at 3 days withdrawal; however this was no longer significant. 
A disparity between receptor binding and functional changes has been observed previously 
(Barik and Wonnacott, 2006; Jacobs et al, 2002). Recent work has suggested a role for 
nicotine as a pharmacological chaperone to increase the assembly and trafficking of 
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nAChRs to the cell surface (Lester et al, 2009; Srinivasan et al, 2011). It has already been 
shown that there is a change in stoichiometry after chronic nicotine treatment (Srinivasan et 
al, 2011). The high affinity (α4β2)2β2 stoichiometry is preferentially upregulated (Son et al, 
2009), potentially leading to higher levels of binding but lower ion flux across the 
membrane (1.3.4), therefore explaining the ability of nAChRs to upregulate without 
increased functional responses. 
[3H]-Epi binding takes place on P2 brain membranes, and so represents both 
internal and external receptor pools. It is possible that receptor numbers are increased after 
chronic nicotine treatment, but that the number available at the cell surface does not 
change, hence the unchanged functional responses. Internalisation of receptors in this 
manner could be tested by labelling of the surface population and western blotting. 
Desensitisation of receptors whilst maintaining them at the cell surface could also occur; 
this would lead to a reduced pool of available receptors for functional actions but with 
increased surface binding.  
2.6.6. ovel compounds and binding models 
A series of cytisine analogs were synthesised in the lab of Dr Tim Gallagher. 
Previous cytisine analogs with halogenations at C3 and C5 have been reported with C3 
halogenation tending to lead to greater binding affinity (Abin-Carriquiry et al, 2006; 
2010a). C5 halogenations on the other hand tended to reduce the binding affinity.  
The compounds reported here are a series of C4 substituted cytisine analogs, as 
well compounds formed by the fusing of the bridged bicyclic framework of cytisine 
(cyfusine) or the addition of an aryl group (aryl-cytisine). The binding data presented in 2.5 
shows that many of the substitutions at C4 decrease the ability of cytisine compounds to 
displace [3H]-Epi binding. [3H]-Epi binding gives an indication of binding at heteromeric 
nAChRs; however the rat P2 membranes contain a mixed population so subtype selectivity 
cannot be ascertained.  
Using the docking model outlined above (2.1.4.1) C4 of cytisine was not identified 
as a critical region for the interaction between ligand and receptor, and accordingly most of 
the changes in binding affinity are relatively small. N-methylation of cytisine has 
previously been shown to be detrimental to nAChR binding due to the disruption of a 
hydrogen bond between ligand and receptor (Tasso et al, 2009). The fusion of the bridged 
bicyclic structure of cytisine was developed as a possible way to retain the structural 
rigidity of cytisine and orient the key elements in the same manner, whilst allowing a 
simpler synthesis. As previously reported cyfusine has lower binding affinity to the nAChR 
(Yohannes et al, 2008) and this was shown also in the current study. A C4 substitution of 
cyfusine (4-F-cyfusine) was shown to have little or no ability to displace [3H]-Epi binding 
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to the receptor. Arylation of cytisine reduced binding affinity approximately 10-fold, 
suggesting that there is some disruption to the interactions between C3 and the receptor 
molecule. 
Several of these cytisine analogs bind well in the mixed heteromeric population 
present. Testing these compounds for the ability to displace radioligand binding in 
homogenates from specific brain regions or cell lines expressing known subunit 
composition would allow assessment of the selectivity. Many of the known cytisine 
derivatives are selective for α4β2* over α3β4* nAChRs, an important distinction thought to 
improve the side effect profile of nicotinic drugs. Improving this selectivity ratio could 
allow further use of these compounds as pharmaceuticals.  
2.6.6.1. Functional assays 
The [3H]-NA release assay data presented (Figure 2-23) shows that only PM111 
elicits a comparable amount of release to cytisine. Several of the other compounds 
exhibited similar binding profiles to PM111 and so the inability of these to elicit release 
may indicate an extremely weak partial agonist or an antagonist effect. [3H]-DA release 
was elicited by FA-18, but minimally with FA-10 and FA-14 (Figure 2-24). Again this 
assay does not give a precise indication of subtype selectivity; however the differences 
between striatal DA and HC NA suggest that PM111 may activate α3β4* nAChRs and 
FA18 may be more selective for β2*.  
Cytisine and related compounds have previously been shown to act as partial 
agonists and so it is likely that the compounds tested here will behave in a similar manner. 
The release elicited by these compounds is indeed smaller than for nicotine; however this 
may be due to lower potency as full concentration response curves have not been examined. 
For those compounds with no significant activity on [3H]-catecholamine release which do 
however show [3H]-Epi displacement it is likely that their action is as a weak partial 
agonist/competitive inhibitor. The coincubation of the compounds with a range of nicotine 
concentrations would allow assessment of the degree of antagonism. In addition to smoking 
cessation another area of possible use of partial nAChR agonists is for treatment of ADHD 
and depression (1.4). If any of the compounds here has additional selectivity for α4β2* 
nAChRs over α3β4*, or could separate effects at α7 nAChRs from those at 5-HT3, then 
they could represent a better tolerated pharmacological agent. This system is not ideal for 
such comparisons and expression of nAChR subunit combinations in oocytes and testing of 
the drugs for function would be a more accurate and reliable way of assessing this.  
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2.6.7. Further work 
2.6.7.1. nAChR pharmacology in FC and HC 
Investigations into the pharmacology of the responses in the two regions could be 
expanded with the use of selective antagonists e.g. α-conotoxins to determine if more 
complex subtypes of nAChR are involved.  
Confocal microscopy on slices colabelled with antibodies for specific nAChR 
subunits and dopamine-β-hydroxylase could show the subtypes of nAChR expressed in 
noradrenergic terminals. This may be difficult as some nAChR subunit antibodies, 
especially for α7, show cross-reactivity with other subunits; however this can be overcome 
thanks to the development of a gold-conjugated α-Bgt (Jones and Wonnacott, 2004). 
Colabelling of nAChR subunit antibodies or labelled α-Bgt with markers for dopaminergic, 
serotonergic and glutamatergic neurons has already been shown (1.3.2).  
2.6.7.2. GABA 
Electrophysiology in acute slices could be used to confirm the excitatory 
mechanism of action. Romo-Parra et al (2008) showed a shift from depolarising to 
hyperpolarising responses to GABA during neuronal development was slower in apical 
dendrites than in somatic regions and basal dendrites. Repeating these experiments in tissue 
from older animals would allow the assessment of the spatial restriction of depolarising 
GABA responses at later timepoints although responses to GABA stimulation were seen to 
reduce through early postnatal stages, suggesting that fewer neurons are responding in an 
excitatory manner. 
2.6.7.3. Treated 
After chronic nicotine treatment withdrawal could be precipitated by injection of 
mecamylamine. This gives a stronger withdrawal syndrome and a shorter withdrawal 
timecourse than simply removing the osmotic pumps and so changes in basal [3H]-NA 
release could be assessed. We would expect this to cause a larger change than spontaneous 
withdrawal and there may be a correlation between this elevated NA baseline and 
withdrawal symptoms such as anxiety (as measured by reduced open arm time on the 
elevated plus maze for example) if these are modulated by the HC. It may also be the case 
that a shortened withdrawal timecourse allows changes to be seen in basal NA in the FC. 
This may reveal differences in nAChR modulation of [3H]-NA within the preparations. 
The observation that basal HC NA release is elevated in vitro during nicotine 
withdrawal would be interesting to test in vivo by the use of microdialysis. The changes are 
small, and so this would only be feasible to test if mecamylamine increases the size of this 
response and shortens the timecourse.  
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2.6.7.4. ovel compounds 
The novel compounds reported here could be tested for the ability to displace the 
binding of α-Bgt to ascertain binding at α7 nAChRs. This has been done for the FA series 
of compounds, with all of the compounds showing binding in the µM range (53-84 µM) as 
opposed to the nM range for heteromeric receptors. This suggests similar selectivity for 
heteromeric over homomeric receptors as cytisine, and is likely to be the case for the other 
cytisine compounds presented here. 
To further test the functional profile of these novel compounds their actions as 
partial agonists or competitive antagonists could be assessed by coincubation with a 
maximally effective concentration of nicotine. Effects on both HC NA and striatal DA 
would be tested as the responses may differ depending on the subtype selectivity of the 
compounds.  
To further test the selectivity of the compounds that show activity the 
electrophysiological responses caused in oocytes expressing different subunit combinations 
could be examined. Changes in the selectivity of the compounds in comparison to cytisine 
may correlate with the changes made to the molecules and so may help inform future drug 
development in combination with docking models. 
2.6.8. Conclusions 
Overall the results presented in this chapter indicate that the subtypes of nAChR 
involved in the release of [3H]-NA are different between FC and HC.  An increase in [3H]-
Epi binding was seen after chronic nicotine treatment which was not accompanied by a 
change in functional responses either in magnitude nor sensitivity to a range of selective 
agonists. Acute nicotine treatment also had no effect on in vitro responses, suggesting a 
rapid recovery from any receptor desensitisation. This suggests that in vivo models may be 
better suited for testing the effects of chronic nicotine administration. 
There is also the suggestion in the data presented that a proportion of the nAChR 
mediated [3H]-NA release is via excitatory GABAA receptor stimulation, although this 
needs to be further elucidated in other systems. 
Selective stimulation of certain regions of the brain with selective agonists is a real 
possibility, so docking models that allow more accurate prediction of the binding and 
functional potency may allow the design of better drugs. The docking model shown here is 
to a certain extent validated by the binding work presented, however the functional assays 
need to be extended to allow assessment of the predictive ability of the model, especially in 
terms of subtype selectivity.  
The differences in nAChR subtypes involved in [3H]-NA release between FC and 
HC are important as the function of these regions differs and so it may open a route for 
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pharmacologically selective treatments for cognitive conditions. In vitro work, however, 
does not always translate into the clinical setting and so ascertaining if the subtypes of 
nAChR involved also differ between brain regions in vivo is an important next step in the 
development of this work.  
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Chapter Three 
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3. NAChR modulation of monoamine release in vivo 
3.1. Introduction - Microdialysis 
The results outlined above (Chapter 2) show that there are differences in vitro in 
the nAChR subtypes involved in [3H]-noradrenaline release between frontal cortex (FC) 
and hippocampus  (HC). In vitro results however may not be translatable to in vivo 
situations due to the dissociation of tissues and isolation of brain regions from modulatory 
inputs. To measure changes in neurotransmitters in response to drug administration in vivo, 
microdialysis can be used. 
3.1.1. Intracerebral microdialysis 
In this section the limitations and advantages of in vivo microdialysis coupled to 
high performance liquid chromatography with electrochemical detection (HPLC-ECD) for 
sampling and detection of monoamines will be examined. In vivo microdialysis coupled to 
HPLC is a well established technique to measure extracellular neurotransmitter 
concentrations in the rodent brain, having been used to measure responses to nicotine as 
early as the 1980s (Damsma et al, 1988) as well as use in many studies over the years into a 
variety of systems. Simply, a concentric microdialysis probe (Figure 3-1) is implanted into 
the brain region of interest and continuously perfused with artificial cerebrospinal fluid 
(aCSF). Neurotransmitters diffuse across the semipermeable membrane portion of the 
probe and are collected in the aCSF flow and HPLC-ECD is used to analyse samples. This 
is a highly sensitive method that can detect small amounts of electro-active compounds by 
oxidisation on a glassy carbon electrode. The amount of compound in the sample is 
proportional to the area of peak on a chromatogram (see Appendix 3 for examples).  
The advantages of this technique are that the sampling takes place continuously 
across the timecourse of a response from a conscious, freely moving animal with minimal 
manipulation during the sampling period. The effect of modulatory pathways from 
elsewhere in the brain can be examined and clearance and production of neurotransmitters 
(NTs) will be occurring, unlike in dissociated tissue in vitro. The main limitations are 
temporal resolution, sample recovery and detection sensitivity. These are interlinked, as a 
faster flow rate (better temporal resolution) will lead to poorer sample recovery and so the 
need for more sensitive detection techniques. These factors will be discussed in more detail 
below. 
3.1.2. Development of microdialysis 
Hernandez et al (1983) is the earliest report of the development of intracerebral 
dialysis in rats, showing increases in DA after amphetamine administration. This method 
was an improvement on earlier push-pull techniques as it minimised brain distension, 
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however the probe was somewhat larger than those used for push-pull extraction as the in 
and out flows were in parallel tubes in a U-shape formation. Horizontal probes were also 
developed, which consist of a length of dialysis tubing implanted horizontally through the 
region of interest (e.g. Benveniste and Diemer, 1987). The development of concentric 
probes (Hernandez et al 1986) meant that minimal tissue disruption was caused upon 
implantation, while also allowing more precise targeting than side-by-side or horizontal 
probes. A diagram of a concentric probe as used in the present study is shown (Figure 3-1). 
The microdialysis probe can be very accurately placed within selected structures of the 
brain by the use of stereotaxic coordinates; however there is still some limit on the spatial 





Figure 3-1 Cross section of concentric microdialysis probe 
The microdialysis probes used in this study consist of a rigid Y shaped structure, with a concentric 
central arm with a diameter of 0.6 mm. The base of the probe is comprised of a semipermeable 
membrane with a molecular weight cut off of 14 KDa, across which neurotransmitters can diffuse. 
This allows sampling of neurotransmitter levels without alteration of the cerebrospinal fluid (CSF) 
volume. Artificial CSF flows into the probe, past the semipermeable membrane and is then pushed 
back up the probe to the outlet where it can be collected. 
3.1.3. Timing of microdialysis sampling 
Microdialysis can be undertaken in anaesthetised or awake animals. While the 
anaesthetised animals can be used immediately a study by Westphalen et al (2009) shows 
that isoflurane, even at subanaesthetic concentrations, has an effect on nicotine induced 
hippocampal NA release (from isolated synaptosomes). Anaesthetics bind to a site within 
the plasma membrane domain of many pentameric ligand-gated ion channels, including the 
nAChR where they are inhibitory (Nury et al, 2011). As well as direct effects of 
anaesthetics on nAChRs there are likely to be global changes in the anaesthetised vs. awake 
brain. Therefore the use of unanaethesised animal is important to give an accurate picture of 
the changes happening in response to drug administration. This also allows the technique to 
be combined with behavioural measurements, a successful correlation of locomotor activity 
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and DA increases after amphetamine administration has recently been demonstrated 
(Jackson et al, 2009). Attempts have also been made to correlate behavioural task 
performance with dialysate changes (e.g. Ostlund et al, 2011); however the temporal 
resolution limits the conclusions that can be drawn (3.1.5). 
Another major consideration is that the probe is a foreign body which causes 
damage to the surrounding tissue upon insertion which may lead to neurochemical 
perturbations. Benveniste and Diemer (1987a) used histological techniques to assess 
reactions at varying timepoints to a microdialysis fibre implantation. At 1-2 days post 
implantation minimal changes were observed in the tissue with a heterogeneous distribution 
of small areas of oedema and some minor haemorrhage. On later days haemorrhage and 
oedema decreased, however phagocytic cells and increased glial fibrilary acidic protein 
were observed. Another paper from the same group (Benveniste et al, 1987b) showed that 
local cerebral glucose metabolism and blood flow are disturbed during the two hours 
following surgery, and these disturbances have normalised by around 24 hours after 
surgery. Combining these factors suggests that around 24 hours after surgery is the best 
time to perform microdialysis experiments and so in these studies microdialysis was 
performed the day following surgery (3.3.2). Animals were placed into the microdialysis 
chambers and connected to the perfusate flow immediately after surgery and allowed to 
recover and acclimatise overnight. 
3.1.4. Sampling methodology 
Due to the continuous flow of perfusate the level of neurotransmitter will never 
equalise to that in the surrounding tissue. The amount that can be assessed is known as the 
recovery of the probe. Factors affecting the recovery include the dimensions of the active 
membrane area, molecular weight cut-off of the membrane, the diffusion of NTs through 
the extracellular space, the flow rate of the perfusate and the charges associated with 
molecules (Stenken, 1999). Recovery can vary between probes of identical design and 
manufacture, this is more common with probes made ‘in house’ than with commercially 
available probes and so although there is a large cost difference the decision was made to 
purchase probes for these studies to minimise variability.  
In vitro compared to in vivo recoveries are postulated to be different due to the 
influence of composition of tissue in vivo on the creation of diffusion gradients (Cano-
Cebrian et al, 2005). The volume from which sampling takes place in vivo is smaller than in 
vitro as it is only from the extracellular volume. The presence of cells also means that the 
diffusion path is extended. The diffusion is difficult to quantify as the tissue composition 
and drug metabolism may be important factors. Keeping to the same probe type minimises 
the variation in recovery caused by membrane area and composition. The factors outlined 
 - 84 - 
above also affect the delivery of drug across the probe. Although quantifying absolute 
recovery is difficult, the relative changes in neurotransmitter levels can be determined 
removing the need to quantify recovery in vivo. The issue of recovery is further discussed 
below (3.6.1.3). 
3.1.5. Sample analysis 
The collection of small, dilute samples means that sensitive detection techniques 
are needed. HPLC-ECD has been used for many years for the determination of monoamine 
NT levels in samples. The main issues are chromatogram separation, sensitivity of peak 
detection and sample throughput. 
To increase sample throughput faster flow rates through the HPLC system can be 
used, however this impacts negatively on peak separation. Separation of peaks is also 
affected by the buffer composition and temperature. The usual factors altered to optimise 
peak separation are pH and the amount of ion-pairing agent (in these studies OSA). The 
solvent (methanol) content of the buffer can also be altered. Changing the methanol or OSA 
content tends affect all peak times, with those that are retained longer being changed by a 
larger amount than those early in the separation. The effect of changing pH is dependent on 
the molecule; there is a much bigger effect on acids or bases of pH manipulation than on 
neutral molecules which allows peaks to be moved in relation to one another not just spread 
further over time.  
Good peak separation improves the ability to detect small amounts of the 
compound of interest however the limit of detection of ECD is still an issue in analysing the 
samples derived from microdialysis. The development of more sensitive detection methods 
has been useful in alleviating this limitation. The use of mass spectrometry in the analysis 
of microdialysates is becoming more common as it analyses the molecular weight of 
compounds and so removes the barrier of interfering peaks, although ECD is still the 
preferred method due to much wider availability. Mass spectrometry will not be further 
covered here, see Zhang and Beyer (2006) for a review.  
3.1.5.1. Alternatives to microdialysis 
The main in vivo alternative to microdialysis allowing better temporal resolution is 
cyclic voltammetry. In this technique carbon fibre electrodes are inserted into the selected 
brain sites and oxidisation occurs on the surface of the electrode. This technique has better 
spatial (fibres measure 5-30 µM diameter) and temporal (second scale) resolution than 
microdialysis, but is less sensitive and is limited to electroactive molecules. A review of 
this technique is found in Robinson et al (2003). 
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3.1.6. icotine in microdialysis studies 
Nicotine has been used in a number of microdialysis studies, mostly looking at the 
effect on DA levels in dopaminergic areas such as striatum and nucleus accumbens (Mifsud 
et al 1989; Benwell and Balfour, 1992; Nisell et al 1994; Wonnacott et al 2000). There are 
fewer studies on the effect of nicotine on NA; many of these have focussed on the HC 
although other regions have also been examined.  
Systemic nicotine 
In HC acute nicotine has been shown to increase NA when administered 
systemically by i.p. or s.c. injection (Singer et al 2004; Brazell et al, 1991; Mitchell, 1993). 
Singer et al (2004) used fluoxetine or desipramine in the perfusion buffer to decrease 
neurotransmitter reuptake in some experiments in order to increase detection. This may in 
itself have caused increases in neurotransmitter levels, but uptake inhibitors were included 
in the perfusion buffer for 2 hours before sampling to allow baseline stabilisation and 
remained throughout the experiment. The inclusion of reuptake inhibitors in the perfusion 
fluid is now considered to be scientifically invalid, as it compromises neuronal function 
(discussed in Borland et al, 2005). 
When administered systemically nicotine increased NA in FC (Liang et al, 2008; 
Rossi et al 2005; Singer et al 2004; Summers and Giacobini 1995) although the increase 
was in general smaller than that of DA. Summers and Giacobini (1995) found the greatest 
increases in NA at 1.2 mg/kg nicotine; this high dose induced seizures and so is untenable. 
However, significant changes in NA, DA, ACh and 5HT were found at 0.2 mg/kg in the 
same study. Studies using antagonist (typically mecamylamine) have confirmed that the 
responses after nicotine in both FC and HC are nAChR mediated. 
Local administration 
Drug can also be administered locally via the microdialysis probe (referred to as 
reverse dialysis). This method will be used in this study to mirror the in vitro experiments. 
When administered locally nicotine (1 µM via the probe) gave an increase in NA in both 
FC and HC, however the same administration gives a rise in DA in FC and a decrease in 
the HC (Shearman et al 2005). Marshall et al (1997) showed that nicotine administered 
locally to FC, striatum and nucleus accumbens (1-10 mM) elicited DA release with the FC 
being less sensitive. Possible reasons for the requirement of much higher concentration of 
nicotine in the probe than in Shearman et al (2005) are discussed below (3.6.1.3).  
Other studies 
A few studies have failed to find changes in NA levels in HC or FC e.g. Rossi et al 
(2005) with 0.3 mg/kg systemic nicotine. Kawahara et al (1999) infused nicotine into LC 
and found no change in PFC NA. Toth et al (1992) administered nicotine locally to 
striatum, substantia nigra, cerebellum, hippocampus, cortex (frontal, cingulate), and pontine 
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nucleus, and found no change in FC, HC, cerebellum or striatum but saw rises in NA in 
substantia nigra, cingulate cortex, and pontine nucleus.  
Subtype selectivity 
Relatively few studies have investigated the effect of selective nAChR agonists or 
antagonists on NA release. Those that have seem to suggest a role of both homomeric (α7) 
and heteromeric receptors in mediating the responses in HC (Fu et al, 1999a; 1999b).  
3.1.7. Study design 
The studies outlined above have confirmed a role for nAChRs in modulation of HC 
and FC NA levels in vivo, however nicotine is a non-selective agonist that is does not 
discriminate markedly between nAChR subtypes (Figure 2-5). In view of the large 
differences in sensitivity in vitro to 5IA between FC and HC it was decided that this was a 
good candidate with which to study the nicotinic responses operating locally in vivo and 
determine if differences are apparent. Previously 5IA has been used in one microdialysis 
study from this laboratory (Livingstone et al, 2009), showing robust increases in DA in the 
PFC at the concentrations tested (100 µM and 1 mM).  
3.1.8. Aims and Hypotheses 
The microdialysis experiments contained in this study aim to elucidate differences 
in the nAChR subtypes involved in NA release between FC and dorsal HC in vivo upon 
local stimulation. This will be done through local administration of the β2* nAChR 
selective agonist 5IA with the hypothesis that FC will be more sensitive to 5IA but that 
maximal responses will not differ between the regions, in line with the results from in vitro 
work.  
These experiments also aim to confirm that the 96-well plate in vitro release assay 
gives translatable responses to aid in defining questions to study by microdialysis in vivo. 
3.2. Introduction - Neurochemical fingerprinting 
Increased neurotransmitter levels can be produced by several mechanisms in the 
brain such as increased release, reduced reuptake or reduced breakdown. The profile of 
metabolites (the ‘fingerprint’) differs for drugs that target these different mechanisms of 
action, although changes in NA or DA levels may appear the same when measured by 
microdialysis (Heal et al, 2009). For example, a monoamine oxidase inhibitor will reduce 
the breakdown of DA to DOPAC and 3MT to HVA thereby increasing the level of 3MT. A 
drug that prevents uptake of dopamine will increase synaptic DA levels, impede 
intraneuronal catabolism of DA to DOPAC, but have no effect on the extraneuronal 
catabolism of this monoamine, reflected by no change in HVA. The different mechanisms 
 - 87 - 
of action may affect the abuse liability of a drug. The major metabolic pathways for DA, 
NA and 5HT are shown in Figure 3-2. 
 
Figure 3-2 Major metabolites of oradrenaline, Dopamine and Serotonin 
The major metabolic pathways in the breakdown of A) Dopamine B) Noradrenaline and C) 
Serotonin within the CNS. MAO Monoamine oxidase; ADR, Aldehyde reductase; ADH, Aldehyde 
dehydrogenase; COMT, Catechol-O-methyl transferase 
For this method animals are injected with drug and killed after a set period of time 
(Tani et al, 1997; Heal et al, 2009). The selected brain regions are rapidly dissected and 
frozen to prevent post-mortem changes and then homogenised and centrifuged. Samples of 
supernatant are analysed by HPLC-ECD with reference to an internal standard contained in 
the homogenising solution to correct for sample degradation. 
3.2.1. Advantages and limitations 
Neurochemical fingerprinting allows the assessment of a range of neurotransmitters 
and their metabolites at a single timepoint after drug administration. The analysis of a wider 
range of compounds than from microdialysates is made possible due to the higher levels 
found in homogenates. The analysis of multiple compounds is an advantage over 
microdialysis as it gives a picture of the metabolic changes occurring as well as the simple 
changes in e.g. NA. The limitation to a single timepoint means that the timecourse of a 
response to drug is more difficult to assess. A timecourse can be examined by conducting 
analyses at different timepoints in separate groups of animals. The measurement of the 
compounds is from homogenised tissue, which means that it is the entire content not just 
extracellular or intracellular, and a whole brain region is used so the spatial localisation is 
not as good as with microdialysis. Administering the drug in vivo means that metabolic 
pathways are intact, whereas in vitro with dissociated tissue this may not be the case. 
A B 
C 
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3.2.2. Previous work  
A previous study (Tani et al, 1997) used similar methodology to assess the effect of 
nicotine on a range of monoamines and metabolites. They found that administration of 
1 mg/kg nicotine increased 5-HT, MHPG and DOPAC, but had little effect on NA or DA in 
homogenates of whole mouse brain. There was a small but non-significant decrease in 
5HIAA levels. These changes were reversed with mecamylamine but not hexamethonium, a 
peripherally acting antagonist. The lack of response in total NA and DA levels with a rise 
in their metabolites suggests increased turnover, with production matching the level of 
breakdown. Chronic nicotine decreased NA and 5-HT in FC with no significant effect on 
5HIAA, DA or HVA (Kirch et al, 1987). DOPAC was decreased in striatum but no other 
changes were seen in this region. This suggests that after chronic nicotine treatment there is 
desensitisation to the releasing effects, and so reduced monoamine turnover. Administration 
of a monoamine oxidase inhibitor (MOAI) has been used as a positive control. Previously 
MOAIs have been shown to increase dopamine and decrease DOPAC, HVA and 5HIAA in 
striatum (Iurlo et al, 2001). As well as decreases in DOPAC and HVA, Heal et al (2009) 
show that MAOI administration increases 3MT in striatum. 
3.2.3. Study design 
The effect of nicotine on DA and 5-HT metabolism and NA levels has been 
investigated here. The range of metabolites investigated differs from Tani et al (1997) who 
observed NA, MHPG, DA, DOPAC, 5-HT and 5HIAA. In the present study NA, DA, 
DOPAC, HVA, 3-MT, 5HIAA and 5-HT were assessed. This gives a more detailed picture 
of DA metabolism. A refinement to Tani et al (1997) is the dissection of striatum and 
frontal cortex selected. These regions were chosen as they are expected to differ in their 
monoamine content and release monoamine in response to nAChR stimulation. The half 
life of nicotine is known to be very short in mice (~6.9 min Petersen et al, 1984) however 
the timecourse of response seen by Tani et al (1997) showed significant responses up to an 
hour after nicotine treatment. Therefore, a pilot study to determine the optimal timepoint 
was conducted. Mice are less sensitive to the acute effects of nicotine than rats (see Matta et 
al, 2007) although whether this is purely a pharmokinetic effect is unknown. Doses of 0.3, 
1 and 3 mg/kg were chosen based on the 0.04-5 mg/kg range in Tani et al (1997), and 
suggestions of dosing in Matta et al (2007).  
3.2.4. Aims and hypothesis 
These experiments aim to investigate nAChR mediated changes in catecholamine 
metabolism in vivo as measured from brain homogenates. The hypothesis is that nicotine 
will increase the metabolism of DA and NA by increasing release in both regions, with a 
larger effect detectable in striatum for DA due to the higher DA content of this region. 
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3.3. Materials and methods 
3.3.1. Chemicals and Reagents 
5-Iodo-A85380 (5IA) was purchased from Tocris Cookson (Avonmouth, UK). 
Tranylcypromine HCl, noradrenaline (NA), 3,4-dihyroxyphenylacetic acid (DOPAC), 
3,4-dihydroxybenzylamine HBr (DHBA), 3-methoxytyramine HCl (3-MT), 
5-hydroxyindoleacetic acid (5-HIAA), serotonin creatinine sulphate (5-HT), (-)-nicotine 
hydrogen tartrate, dopamine HCl (DA), homovanillic acid (HVA) and all other standard 
chemicals of analytical grade were obtained from Sigma-Aldrich Co. 
3.3.2. Microdialysis  
3.3.2.1. Animals 
Male Sprague-Dawley rats were purchased from Charles River Laboratories 
(Margate, Kent, UK). They were group housed (4-6 per cage) with ad libitum access to 
food and water until the time of surgery. Animals weighed 280-320g at time of 
experiments. Lights were on a 12 hour cycle, with lights on at 8 am. All procedures were in 
accordance with the Animals (Scientific Procedures) Act of 1986.  
3.3.2.2. Probe implantation 
Animals were anaesthetised with isoflurane (5 % for induction; 2.5 % maintenance; 
O2 1 L/min) and the head shaved and disinfected. They were then placed into a Kopf 
stereotaxic frame with the incisor bar set at -3.3 mm from the interaural line. An incision 
was made to reveal bregma from which coordinates were taken. Holes were then drilled for 
the placement of two anchor screws and a concentric microdialysis probe with 2mm 
membrane into FC or dorsal HC (MAB9.14.2, Microbiotech; coordinates of placement FC 
AP +3.2, ML +2.5, DV -4.0 mm.; dorsal HC AP -5.1, ML +4.8, DV -5.1 mm). Using dental 
cement the probe, anchor screws and a copper wire tether were secured in place and the 
wound was then sutured. Following surgery rats were housed in individual circular 
chambers with the microdialysis probe connected to a liquid swivel and a counterbalanced 
arm to allow free movement (see appendix 2 for diagram of setup). To aid recovery from 
anaesthesia animals were given an injection of saline (1 ml/kg) and a heated blanket was 
placed underneath the chamber to maintain body temperature. The probes were 
continuously perfused with artificial cerebrospinal fluid (aCSF; 140 mM NaCl, 3 mM KCl, 
0.27 mM Na2HPO4.H2O, 1 mM MgCl2, 1.2 mM CaCl2.2H2O, 7.2 mM Glucose, pH7) at a 
rate of 1.6 µl/min and rats were allowed a recovery period of at least 16 hours with food 
and water available ad libitum.  
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3.3.2.3. Sample collection and drug administration 
Samples of dialysis flow from freely-moving animals were collected at 15 minute 
intervals into 0.3 ml polypropylene sample vials containing 5 µl of a solution of 0.1 M 
perchloric acid (PCA) and 400 µM sodium metabisulphite to prevent oxidation of sample. 
Samples were collected for an hour for chromatogram optimisation, allowing baselines to 
settle after lights on. Samples were then collected for baseline and treatment conditions (see 
Figure 3-3 and Figure 3-5). Samples were placed onto dry ice immediately after collection, 
and stored at -80 °C for up to 14 days prior to analysis. Drugs were administered via the 
probe by inclusion in the infusion fluid. Syringes were primed and loaded onto syringe 
pump to ensure flow before switching between aCSF and drug. Syringes were switched in 
the same manner (between two separate aCSF syringes) for control animals. 
At the end of the collection period animals were euthanized by the i.p. 
administration of 0.4 ml pentobarbitone (Euthatal), and brains removed and stored in 4 % 
formalin before probe placement verification. Coronal sections 50 µM thick were made 
using a vibratome, mounted on Superfrost Plus slides and stained with cresyl violet. The 
location of the probes was verified by reference to the atlas of Paxinos and Watson (1986).  
3.3.2.4. Sample analysis 
Detection and quantification of DA and NA in the samples used reverse-phase, ion 
pair HPLC-ECD. A reverse-phase column packed with 5 µM C18 silica based octadecyl 
silane material was used and mobile phase (16 % MeOH, 10.48 mM Na acetate, 8-30 mM 
OSA, 0.27 mM EDTA and 0.18 % glacial acetic acid, pH 4-4.5) circulated at a rate of 0.2 
ml/min.  
For the detection of NA alone the mobile phase contained 3.5 % MeOH, 0.15 M 
NaH2PO4, 20 mM octanesulphonic acid and 1 mM EDTA, adjusted to pH 4 with 
orthophosphoric acid. In each case the mobile phase was filtered through a 0.22 µm filter 
and degassed by sonication prior to use. Samples (20 µl) were injected onto the column by 
a Triathlon autosampler refrigerated to 4 °C. HPLC systems were calibrated to the average 
of two 40 fmol/20 µl (2 nM) standard samples daily. Standards of NA and DA (1 mM) 
were prepared weekly in a 1:1 mixture of deionised water and PCA (0.1 M) stored at 4 °C 
and diluted in aCSF daily to give 40 fmol/20 µl. Antec-Intro electrochemical detector was 
used in conjunction with an Antec wall-jet design cell (VT-03). The cell employs a high 
density glassy carbon working electrode combined with an Ag/AgCl reference electrode. 
The electrode signal was integrated using PowerChrom data acquisition system. 
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3.3.2.5. Data analysis 
Data were plotted and analysed using SigmaPlot (version 11) for one way ANOVA 
and GraphPad Prism for 2 way ANOVA. Adjustments were made for multiple comparisons 
in all post tests. 
3.3.3. eurochemical fingerprinting 
3.3.3.1. Animals 
Experiments were carried out in conjunction with RenaSci, in male C57/BL6 JAX 
mice (20-25 g body weight; Charles River, UK). Animals were housed in groups of 4 on a 
12 h/12 h light/dark cycle (lights on at 07.00 h), at an ambient temperature of 21 ± 2 °C and 
55 ± 20 % humidity. Food and water were available ad libitum. Animals were allowed to 
acclimatise to these conditions for at least 5 days prior to the study. These studies took 
place at the Biomedical Services Unit of the University of Nottingham. All experiments 
were in accordance with the Animals (Scientific Procedures) Act (1986). 
3.3.3.2. Pilot study to determine time course of response 
Drug (or 0.9 % saline) was administered by intraperitoneal injection in a volume of 
10 ml/kg body weight. The drugs were made up fresh and pH adjusted (pH 5-7) within 
1-2 h of dosing. Saline-treated mice (n=3) were dosed and sacrificed by cervical dislocation 
at 15 minutes post-dose. Mice treated with nicotine (3 mg/kg) were dosed and sequentially 
sacrificed, (n=3 at 10, 15 and 30 minutes post-dose). All drug doses are expressed as the 
free base using the appropriate conversion factor of salt: free base. 
3.3.3.3.  Dose response study 
Mice treated with saline, nicotine (0.3, 1 or 3 mg/kg) or tranylcypromine (5 mg/kg) 
i.p. were sacrificed by cervical dislocation, (n=8 at 15 min post-dose, determined by pilot 
study). Tranylcypromine is a MAOI which is used as a positive control for 3-MT analysis. 
3.3.3.4. Sample collection  
All brains were removed onto ice and the striata and prefrontal cortices rapidly 
dissected and snap frozen in liquid nitrogen. This procedure took less than 120 seconds to 
counter the effects of rapid post-mortem changes in monoamines and their metabolites. The 
frozen tissues were stored in individual plastic microcentrifuge tubes on dry ice and frozen 
at -80 °C until analysis.  
The dissected tissues were weighed and homogenised in 5 (cortex) or 10 (striata) 
volumes of homogenising solution (0.1 M perchloric acid and 400 µM sodium 
metabisulphite containing 0.1 ng/µl DHBA as the internal standard). Homogenates were 
then microcentrifuged prior to determination of the following monoamine and metabolites 
from supernatant by HPLC-ECD: HPLC system 1: NA, DA, 5-HT, 5-HIAA, DOPAC and 
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HVA; HPLC system 2: 3-MT. Concentrations of monoamines and metabolites were 
calculated by reference to an internal standard, DHBA.  
The monoamine system mobile phase contained 0.1M NaH2PO4, 1 mM EDTA, 
14% MeOH, 1.2 mM OSA adjusted to pH 3.40. Flow rate 1.0 ml/min with a Spherisil C18 
ODS2 5 µm 250 x 4.6 mm column (with Aquapore RP300 7 µm 30 x 4.6 mm guard 
column), ECD cell set at +0.70V, Range 0.5 nA/V (striatum) or 0.2 nA/V (PFC). 
The 3-MT system mobile phase contained 0.01 M NaH2PO4, 8% MeOH, 0.6 mM 
OSA, 5.9 mM di-n-butylamine, adjusted to pH 3.80. The flow rate was 1 ml/min and the 
samples were separated on a Hypersil C18 ODS 5 µM 250 x 4.6 mm column (with 
Aquapore RP300 7 µM 30 x 4.6 mm guard column) electrode 1 set at +0.20V, range 100 
µA and electrode 2 (monitoring) set at +0.45V, range 20 nA.  
Each day HPLC systems were calibrated to two 5 µl replicates of a standard 
solution containing 0.04 ng/µl of 3-MT, 0.1 ng/µl of NA, DHBA, DOPAC, DA, 5-HIAA 
and 5-HT and 0.2 ng/µl of HVA. Sample supernatant (5 µl) was injected onto the HPLC 
and chromatograms obtained. DHBA, the internal standard was used to calibrate sample 
recovery. The limits of detection for the system are 3-5 ng/g brain tissue weight for each 
amine or metabolite.  
3.3.3.5. Data analysis 
In striatum DA levels are high, and so the chromatogram peaks go positively off 
scale. The area under the curve must be converted into ng/g tissue by the following method;  
1. The peak area for the 0.5 ng (on column) DA standard is multiplied by 2, correcting to 1 ng. 
2. The DA peak area for the sample is divided by the calculated area for 1 ng DA standard giving 
ng of DA in sample on column (in an injection volume of 5 µl). 
3. The value from point 2 is multiplied by 200 to convert to ng DA/ml i.e. 1000/5 (µl). 
4. The value from point 3 is multiplied by 10 to convert from ng DA/ml to ng DA/g tissue wet 
weight. This takes into account the 10-fold dilution of the sample with homogenising solution. 
5. The overall effect of points 3 and 4 is to convert ng DA injected to ng DA/g tissue wet weight 
(multiply by 200 and then 10, therefore a factor of 2000 is applied). 
6. The % recovery of the internal standard (X) for each sample is calculated by comparing the 
peak area of the internal standard in the sample to the mean area in the calibration standard. 
7. The internal standard recovery is then applied (100/X) to each sample ng DA/g tissue to 
correct the value for losses during the homogenisation process. 
In PFC NA was greater than DA and some NA responses were off scale. A similar 
calculation as to convert off scale striatal DA responses was performed however the 
dilution of PFC tissue is 5 fold, so the final conversion factor is 1000.  
Analysis of pilot study data was by one way ANOVA on log transformed data to 
normalise variance. Comparison to vehicle was by multiple t-test. Analysis of main study 
data was by robust regression with treatment and study as factors, followed by Williams’ 
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test to compare nicotine to vehicle, and multiple t-test to compare tranylcypromine to 
vehicle. Means are back-transformed and adjusted for differences between studies. SEMs 
are calculated from the residuals of the statistical model. These analyses were performed 
with the assistance of Richard Brammer at RenaSci. 
3.4. Results - Microdialysis 
3.4.1. Response of FC to nomifensine administration 
In order to establish that local administration of drug via the perfusion fluid into the 
frontal cortex is a valid model, a known DA and NA uptake inhibitor, nomifensine (100 
µM) was used. Rats were anaesthetised and a microdialysis probe was stereotaxically 
implanted into the FC (3.3.2). The probe was continuously perfused with aCSF and 
sampling took place the day after surgery. This study was performed at RenaSci 
Consultancy (Nottingham) and used a flow rate of 1.2 µl/min and a collection period of 20 
min per sample. After 80 min baseline collection period nomifensine was included in the 
perfusion buffer for the remainder of the experiment to increase NA and DA levels by 
inhibiting reuptake. Levels of DA and NA measured from the dialysates. Both 
catecholamines were monitored in the same samples by HPLC with ECD. 
 
Figure 3-3 omifensine administration timeline 
The probe was perfused with aCSF at a rate of 1.2 µl/min. After equilibration four basal samples 
were collected. Nomifensine (100 µM) was then administered via the probe for the remainder of the 
sampling period by switching syringes. 
The mean + S.E.M. basal levels of NA were 11.1 + 1.1 fmol/20 µl (n=4), and for 
DA 2.3 + 0.2 fmol/20 µl. Some basal samples (6 of 16) did not contain high enough levels 
of DA to detect, for statistical purposes these have been substituted with 2 fmol. All 
samples contained measurable NA. Figure 3-4 shows NA and DA as percentage of the 
baseline levels. DA increased from 2.3 + 0.2 fmol/20 µl to a peak of 28.0 + 5.9 fmol/20 µl 
(F(13,42)=5.937, p<0.001). This equates to 1190 + 298 % of baseline levels (Figure 3-4A). 
Levels of NA increased from 11.1 + 1.1 fmol/20 µl to 66.5 + 11.2 fmol/20 µl by 40 min 
after the start of nomifensine administration (F(13,42)=36.44, p<0.001), this equates to 608 
+ 62 % of basal levels (Figure 3-4B). Post hoc Holm-Sidak comparing each point to 
baseline (average of first four timepoints) showed that 100 µM nomifensine gives a 
significant increase in both DA (Figure 3-4A) and NA (Figure 3-4B) levels by 40 min after 
the start of drug infusion, which is stable across the remainder of the infusion period. 
Overall it can be seen that the administration of a drug (in this case a reuptake 
inhibitor) via the microdialysis probe is an effective way to alter neurotransmitter levels 
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detected in a reliable manner. As a consequence 5IA was administered by the same route to 
examine effects on neurotransmitter levels in FC (Figure 3-7) and dorsal HC (Figure 3-9). 
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Figure 3-4 Catecholamine changes in the rat FC after nomifensine administration. 
Rats were anaesthetised and a microdialysis probe with membrane length 2 mm was implanted 
stereotaxically into the FC (AP +3.2, ML +2.5, and DV -4.0 mm) and constantly perfused with aCSF 
at a rate of 1.2 µl/min. The following day sampling commenced; samples (24 µl) were collected into 
tubes containing 5 µl 0.1 M PCA and 400 µM Na metabisulphite. 4 basal samples were collected and 
nomifensine (100 µM) was then administered locally by inclusion in the perfusion fluid. A) DA 
levels as percentage baseline. F(13, 42)=36.444, p<0.001 B) NA levels as percentage baseline. Each 
point represents the mean + SEM of 4 animals. Data analysed with a one way repeated measure 
ANOVA with Holm-Sidak multiple comparisons to control. Where samples contained levels of DA 
below the detection limit 2 fmol/20 µl sample was substituted.  ** p<0.01 ***p<0.001 F(13, 
42)=5.937, p<0.001 
3.4.2. Administration of 5-I-A85380 to frontal cortex 
A previous study reported from this lab (Livingstone et al, 2009) looked at the 
effect of 5-iodo-A85380 (5IA) in the FC, locally administered by reverse dialysis. Increases 
in DA levels were found after 5IA administration at two concentrations, 100 µM and 1 
mM, and these responses were not different from one another, suggesting they were at the 
top of the dose-response curve. With this in mind lower concentrations of 5IA were 
assessed in FC. Two infusions at different concentrations were given to each animal, 
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separated by 90 min aCSF. This allows more data to be gathered from each animal whilst 
allowing transmitter levels to return to baseline between infusions and minimising 
desensitisation. 
Probes were implanted as before (3.3.2) and perfused with aCSF. Local 
administration of 5IA took place via the microdialysis probe from time 0-30 and a second 
infusion at 120-150 min (Figure 3-5). The first administration was 1 or 10 µM; the second 
administration was 100 µM in each case. Control animals received aCSF throughout, with 
syringe changes at the same timepoints as treated animals to control for any effects of 
manipulation when switching between syringes. No behavioural responses were noted in 
the animals upon administration or washout of drug (although this was not formally 
scored). 
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Figure 3-5 5-Iodo-A85380 administration timeline 
The probe was infused with aCSF throughout the experiment for control animals. Local 
administration of 5IA took place via the microdialysis probe from time 0-30 and 120-150 min by 
switching syringes.  Syringes were also switched for aCSF animals to control for effects of 
manipulation. 
Probe placements for both control and treated animals were visually verified (3.3.2) 
and an example placement is shown below (Figure 3-6A) with the probe tract clearly 
visible in the left side, and the unimplanted right side as comparison. Figure 3-6B shows 
compiled probe placements in FC, all probes had the active membrane portion within 
frontal cortex.  
 
Figure 3-6 Probe placement in the frontal cortex. 
Brains were removed, fixed in 4 % PFA to fix, and sectioned. Slices (50 µm) were mounted onto 
Superfrost slides and stained with cresyl violet. A) An example FC probe placement (left 
hemisphere) with unimplanted right hemisphere for comparison. B) Compiled probe placements for 
FC n=14. Adapted from Paxinos and Watson, 1986  
Initially samples were analysed for levels of both NA and DA, however this posed 
many problems in achieving viable chromatography and baselines were often variable. For 
A B 
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DA in particular there was a very low baseline in many subjects, which fell below the limit 
of detection of the HPLC (as seen above 3.4.1). As attempting to measure both amines 
necessitated a compromise in the peak resolution it was decided to measure NA only, 
which gave more reliable results (see Appendix 3 for example chromatograms). 
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Figure 3-7 Effect of 5-I-A-85380 on noradrenaline levels in rat frontal cortex 
Rats were anaesthetised and a microdialysis probe with membrane length 2 mm inserted 
stereotaxically into the frontal cortex (AP +3.2; ML +2.5; DV -4.0). The probe was continuously 
perfused with aCSF at 1.6 µl/min. The following day 15 min samples (24 µl) were collected into 
tubes containing 5 µl 0.1 M PCA and 400 µM Na metabisulphite. Four baseline samples were 
collected then syringes were changed so that 5-I-A-85380 (5IA; 1 or 10 µM) was infused from 0-30 
min (shaded area). Animals were returned to aCSF for 90 min and a second infusion with 100 µM 
5IA then took place (120-150 min; 2nd shaded area). Control animals received aCSF throughout the 
infusion period. Data are presented as % of the 4 baseline samples for each animal. Each point 
represents the mean + SEM of 4-5 animals. * Significantly different from aCSF by 2 way ANOVA 
followed by pairwise Multiple Comparison Procedures (Holm-Sidak method). Infusion 
F(2,211)=8.65, p=0.0002, Time F(19,211)=4.635, p<0.0001, Interaction F(38,211)=1.329, p=0.109 
In FC the basal quantity of NA was quite variable between animals (ranging from 
12-60 fmol/20 µl); however baseline samples were very consistent within each animal 
(typical SEM + 5 %). In the FC 5IA elicited significant increase in NA above baseline and 
aCSF at 1, 10 and 100 µM, with equal efficacy at all drug concentrations (F(2,211)=8.65, 
p=0.0002; Figure 3-7). The responses reached a maximum by the second sample after the 
start of drug infusion, and returned to baseline within 30 min of the removal of drug with a 
sharply defined peak shape. Treatment groups were larger than for nomifensine pilot due to 
the smaller responses expected to 5IA than to nomifensine. 
At 1 µM 5IA NA levels reach a maximum of 230.6 + 45.4 % of baseline in the 
second sample after the commencement of 5IA administration (Figure 3-7). At 10 µM 5IA, 
NA levels reached a maximum of 171.7 + 29.2 % baseline in the first sample after the start 
of drug infusion which was not significantly different from control allowing for 
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adjustments for multiple comparisons (Holm-Sidak method). The response in the second 
sample after drug administration was slightly attenuated in comparison with 1 µM 5IA to 
163 + 32.6 % baseline.  
At 100 µM both treatment groups achieved a peak response in the second sample 
after the start of drug administration of 228.6 + 44.7 % and 206.0 + 9.4 % (Figure 3-7) 
respectively for 1 µM and 10 µM initial dose groups. In the group that had previously 
received 1 µM this response remained significant at the following sample, the first after 
drug removal. There was no difference in the magnitude of the response to 100 µM 5IA 
between the two initial treatments. 
3.4.3. Administration of 5-I-A-85380 into the hippocampus  
In dorsal HC 5IA was administered at 1 and 100 µM following the same procedure 
as in FC (Figure 3-5). These concentrations were chosen on the basis that in the in vitro 
assay HC was less sensitive to 5IA than FC (Figure 2-8), and that FC had large responses to 
these concentrations in vivo. An example probe placement is shown below (Figure 3-8A) 
with the probe tract clearly visible in the left side, and the unimplanted right side as 
comparison. Figure 3-8B shows a compilation of the probe placements in the dorsal HC, 
although there is some variation in placement in the ML axis the active membrane portion 
of all probes was within the hippocampal formation. 
 
Figure 3-8 Probe placements in hippocampus 
Brains were removed, fixed in 4 % PFA to fix, and sliced. Slices (50 µm) were mounted onto 
Superfrost slides and stained with cresyl violet. A) An example HC probe placement (left 
hemisphere) with unimplanted right hemisphere for comparison. B) Compiled probe placements for 
HC n=16 Adapted from Paxinos and Watson, 1986 
In HC baseline was again variable between animals (ranging from 10-60 fmol/20 
µl); however baseline samples were very consistent within each animal (the typical SEM 
was + 5 %). Upon changing syringes an increase in NA in aCSF animals was observed 
(to 129 + 18 % baseline). Although this effect was not significant above the basal time 
period, it may have masked changes in the drug treated group.  
Levels of NA in the HC reached maxima of 160 + 23.1 % and 173.6 + 22.9 % of 
baseline in the second sample after administration of 1 µM and 100 µM 5IA respectively 
A B 
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(Figure 3-9). Using a two way ANOVA and post hoc comparisons (Holm-Sidak method) it 
is shown that although the curves as a whole differ there are no significant differences 
between treated and aCSF animals at any single timepoint (Treatment F(1,260)=9.726, 
p=0.002). As treatment had an effect overall it was decided to look at the area under the 
curve for each hour to see if the NA levels are different over longer time periods however 
no significant differences were observed (data not shown).  
Time (min)
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Figure 3-9 Effect of 5-I-A-85380 on noradrenaline levels in rat hippocampus 
Rats were anaesthetised and a microdialysis probe with membrane length 2 mm inserted 
stereotaxically into the hippocampus (AP +5.2; ML +4.8; DV -5.1). The probe was continuously 
perfused with aCSF at 1.6 µl/min. The following day 15 min samples (24 µl) were collected into 
tubes containing 5 µl 0.1 M PCA and 400 µM Na Metabisulphite. Four baseline samples were 
collected then syringes were changed so that 5-I-A-85380 (5IA; 1 µM) was infused from 0-30 min 
(shaded area). Animals were returned to aCSF for 90 min and a second infusion with 100 µM 5IA 
then took place (120-150 min; 2nd shaded area). Control animals received aCSF throughout the 
infusion period. Data are presented as % of the 4 baseline samples for each animal. Each point 
represents the mean + SEM of 8 animals. Analysed by 2 way ANOVA followed by pairwise 
Multiple Comparison Procedures (Holm-Sidak method) Treatment F(1, 260)=9.73, p<0.002, Time 
F(19,260)=2.249, p=0.0025, Interaction F(19,260)=0.6151, p=0.8939. 
Although the responses are not significant there does appear to be an increase in 
NA levels after 5IA administration (Figure 3-9). The responses in the HC are smaller than 
those in the FC (173.6 + 22.9 % vs. 228.6 + 44.7 % after 100 µM 5IA respectively) and 
have a less sharp, defined peak shape. The significant NA levels in the FC and non-
significant changes in HC even with a larger n (8) per condition to reduce variation indicate 
regional differences in the response to 5IA as seen in vitro.  
Overall it can be seen that there is a significant response in NA levels to the 
administration of 5IA at 1, 10 and 100 µM in FC. In the HC this response is blunted and 
confounded by a more responsive baseline that leads to changes being statistically 
insignificant. The reasons for the different responses will be discussed below (3.6). 
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3.5. Results - Neurochemical fingerprinting 
Local administration of drug, as in the microdialysis study presented above, allows 
the assessment of the involvement of terminal fields in neurotransmitter release; however 
this is not the full picture in vivo. Samples of tissue can be taken after drug administration 
to assess the action of systemic nicotine on a range of neurotransmitters and metabolites, 
giving the ‘neurochemical fingerprint’ of the response. It is not usually possible to assess 
this range of transmitters from microdialysates due to low levels of recovery and so tissue 
homogenates are used, limiting the technique to a single timepoint for each animal. 
3.5.1. Standard curves 
To ensure that the relationship between quantity of metabolite and area under curve 
(AUC) on chromatogram followed a linear relationship (and so could be calculated for 
unknowns) a standard curve was analysed. Calibration standard containing 0.08 ng/µl 3-
MT, 0.2 ng/µl NA, DHBA, DOPAC, DA, 5-HIAA and 5-HT, and 0.4 ng/µl HVA in 0.1 M 
PCA and 400 µM sodium metabisulphite (200% daily standard) was made. Neat and ½, ¼ 
and 1/20 serial dilution (to give 200%, 100%, 50% and 10% standards) of this calibration 
standard were injected onto each system and chromatograms obtained.  
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Figure 3-10 Standard curves for calibration of HPLC systems. 
Two replicates of a solution (200% standard) and containing 0.08 ng/µl 3-MT, 0.2 ng/µl NA, DHBA, 
DOPAC, DA, 5-HIAA and 5-HT and 0.4 ng/µl HVA in 0.1 M PCA serial dilutions (100, 50 and 
10%) was run through each system, and the AUC of peaks calculated from the resulting 
chromatograms.  
Table 3-1 Coefficients of determination for standard curves 
Rsq and p values were calculated from the data presented above (Figure 3-10) 
 NA DHBA DOPAC DA 5HIAA HVA 5HT 3MT 
Rsq 0.999 0.999 0.999 1.000 0.997 1.000 0.987 1.000 
p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
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The relationship between concentration and AUC for each standard is shown 
(Figure 3-10). The relationship between the standard concentration and the AUC is linear. 
For each amine and metabolite a linear relationship was shown with all Rsq values above 
0.987 (Table 3-1). 
3.5.2. Pilot study 
The time course of the response to nicotine was investigated in a pilot study (for 
detailed methods see 3.3.3). Briefly, 3 mg/kg nicotine was administered intraperitoneally to 
C57/BL6 mice and animals were sacrificed at 10, 15 and 30 min post-dose. Saline controls 
were sacrificed at 15 min post injection. Striata and PFC were rapidly dissected and tissues 
were prepared prior to determination of the monoamines and metabolites by HPLC-ECD 
(3.3.3). Locomotor depression was seen after injection in nicotine-treated animals, with 
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Figure 3-11 eurochemical fingerprinting pilot - Striatum 
Mice were treated with nicotine (3 mg/kg i.p.) and sequentially sacrificed by cervical dislocation, 
(n=3 at 10, 15 and 30 minutes post-dose). Saline-treated mice (n=3) were dosed and sacrificed at 
15 minutes post-dose. Striata were removed and homogenised and levels of DA, NA, DOPAC, 
5HIAA, HVA, 3MT and 5HT were determined by HPLC. Results are presented as ng/g wet weight 
(A) and as % change from saline control (B). Bars represent mean + SEM from 3 animals for each 
condition.  Data analysed by one way ANOVA on log transformed data for each compound. See 
Appendix 4 for output. 
A 
B 
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In the striatum high levels of DA were found (~7800 ng/g tissue weight) reflecting 
the major dopaminergic innervations (Figure 3-11A). The levels of dopamine were 
calculated from the area under the curve on chromatograms using the procedure outlined 
above (3.3.3.5). NA, DOPAC, 5-HIAA, 5-HT and 3MT are each found at lower 
concentrations of 250-650 ng/g tissue and HVA at 1400 ng/g tissue. As the levels of 
different amines and metabolites varied in comparison to one another data have been 
presented as percentage change from saline treated control (Figure 3-11B). 
No significant changes were observed in striatum at any timepoint (Figure 3-11) 
however some of the non-significant results showed a trend towards significance (P<0.1) at 
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Figure 3-12 eurochemical fingerprinting pilot - PFC 
Mice were treated with nicotine (3 mg/kg i.p.) and sacrificed by cervical dislocation, (n=3 at 10, 15 
and 30 minutes post-dose). Saline-treated mice (n=3) were dosed and sacrificed at 15 minutes post-
dose. PFC was removed and homogenised and levels of DA, NA, DOPAC, 5HIAA, HVA and 5HT 
were determined by HPLC. Results are shown as ng/g (A) and as % change from saline control (B). 
Bars represent mean + SEM from 3 animals for each condition *p<0.05, ** p<0.01. Data analysed 
by one way ANOVA on log transformed data for each compound. See Appendix 4 for output. 
In the PFC the more diffuse dopaminergic innervation is reflected in the lower level 
of DA and its metabolites, with less than 100 ng/g tissue DA, HVA and DOPAC (Figure 
3-14A). 5-HT is the most abundant component in the PFC with levels of ~550 ng/g. NA 
levels are slightly higher in PFC than striatum (340 vs. 291 ng/g).  
A 
B 
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Significant decreases were seen in NA and 5HIAA at all timepoints in the PFC 
(Figure 3-12B). No other significant changes were observed again due to the small number 
of animals studied for this pilot but there was a trend towards significance in HVA at 10 
and 15 min (Table 3-2). 3-MT is not reliably detectable in PFC (only above limit of 
detection in 5 of 12 samples; data not shown), and so was not assayed in this region for the 
main study. On the basis of these data and those for the striatum the 15 min time point was 
chosen for the main study.  
Table 3-2 Mean (ng/g), SEM and p values for each treatment 
Mice were injected with 3 mg/kg nicotine and Striata and frontal cortices dissected and frozen at the 








Striatal DA  Frontal cortex DA 
Vehicle 7722 585   Vehicle 32.2 13.5  
Nicotine 10 min 7824 135 0.82  Nicotine 10 min 29.7 0.5 0.799 
Nicotine 15 min 8731 73 0.06  Nicotine 15 min 41.1 5.5 0.46 
Nicotine 30 min 8549 114 0.11  Nicotine 30 min 54.1 2.7 0.137 
Striatal A  Frontal cortex A 
Vehicle 278 52   Vehicle 369 27  
Nicotine 10 min 217 10 0.13  Nicotine 10 min 277 23 0.019* 
Nicotine 15 min 245 8 0.41  Nicotine 15 min 269 18 0.012* 
Nicotine 30 min 208 11 0.08  Nicotine 30 min 256 12 0.006** 
Striatal DOPAC  Frontal cortex DOPAC 
Vehicle 713 125   Vehicle 43.4 7.3  
Nicotine 10 min 813 31 0.36  Nicotine 10 min 39.2 3.1 0.489 
Nicotine 15 min 964 63 0.06  Nicotine 15 min 44.9 1.6 0.812 
Nicotine 30 min 785 23 0.5  Nicotine 30 min 43.6 2.6 0.971 
Striatal 5HIAA  Frontal cortex 5HIAA 
Vehicle 331 42   Vehicle 112 9.7  
Nicotine 10 min 271 6 0.09  Nicotine 10 min 78.9 1.5 0.005** 
Nicotine 15 min 261 7 0.05  Nicotine 15 min 80.7 4.7 0.008** 
Nicotine 30 min 278 18 0.14  Nicotine 30 min 76.2 5.8 0.003** 
Striatal HVA  Frontal cortex HVA 
Vehicle 1626 242   Vehicle 121.6 5.8  
Nicotine 10 min 1521 20 0.55  Nicotine 10 min 83.6 10.1 0.053 
Nicotine 15 min 1682 28 0.76  Nicotine 15 min 83.7 12.7 0.053 
Nicotine 30 min 1570 44 0.76  Nicotine 30 min 93.1 11.3 0.145 
Striatal 5HT  Frontal cortex 5HT 
Vehicle 633 64   Vehicle 837 42  
Nicotine 10 min 583 21 0.37  Nicotine 10 min 765 79 0.449 
Nicotine 15 min 634 11 0.99  Nicotine 15 min 813 24 0.8 
Nicotine 30 min 623 34 0.86  Nicotine 30 min 816 87 0.825 
Striatal 3MT      
Vehicle 370 111       
Nicotine 10 min 321 95 0.74      
Nicotine 15 min 313 88 0.7      
Nicotine 30 min 294 86 0.59      
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3.5.3. Main study 
Forty C57/BL6 mice were used for this portion of the work. They were allocated 
into 5 groups, saline, tranylcypromine (5 mg/kg; positive control), and 0.3 mg/kg, 1 mg/kg 
and 3 mg/kg nicotine. Doses were based on Tani et al (1997) and Matta et al (2007). All 
nicotine doses are expressed as free base. Animals were sacrificed 15 min after i.p. 
injection and striata and PFC rapidly dissected and frozen before preparation of 
homogenates as before (3.3.3). 
Two animals (both 3 mg/kg nicotine group) died during the course of treatment, 
probably due to respiratory depression. No abnormalities were found at postmortem. Tissue 
was not collected for analysis from these animals. Samples from the corresponding time 
point in the pilot study (and saline controls) were included in the analysis to increase the n 
in the 3 mg/kg group with adjustments made to the statistical analyses to ensure there were 
no group differences between ‘pilot’ and ‘main study’ data. A dose of 3 mg/kg nicotine is 
quite high, and is likely to have caused toxicity. The effect of this on the results will be 
further discussed in section 3.7. 
3.5.3.1. Striatum 
The monoamine oxidase inhibitor tranylcypromine was used in this study as a 
positive control as it has a well characterized profile of effects (Heal et al 2009). Through 
inhibition of monoamine oxidase, tranylcypromine prevents the metabolism of DA to 
DOPAC and so increases the extracellular metabolism of DA to 3-MT. The increase in 
3-MT is further emphasized because it is not then broken down into HVA, therefore giving 
a reduction in HVA levels.  
It can be seen that the levels of DA are far in excess of the level of any other 
compound measured within the striatum (Figure 3-13A). For this reason data is also 
presented as a percentage change from control, so changes in the other compounds can be 
more clearly seen (Figure 3-13B). 
In this study tranylcypromine increased DA by 7.4 % (p=0.014), reduced DOPAC 
to 47.8% of control (p<0.001), decreased HVA to 84.2 % control (p=0.023) and increased 
3-MT to 189.3 % control. There was also a reduction in 5-HIAA to 83.7 % control 
(p=0.029). There was no significant change in NA or 5-HT, although there was a trend 
toward an increase in 5HT (112 % control; p=0.074). The only significant response in the 
striatum with nicotine was an increase in DOPAC at the 3 mg/kg dose to 110.9 % control 
(p=0.048). Increases in DOPAC were also seen at 0.3 and 1 mg/kg, although these were not 
significant. A decrease in 5HIAA (mirroring that produced by tranylcypromine) was seen at 
1 mg/kg nicotine, again this was non-significant. 
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Figure 3-13 eurochemical fingerprint of striatum after nicotine administration 
Nicotine (0.3, 1 or 3 mg/kg), tranylcypromine (5 mg/kg) or saline was administered to mice 
intraperitoneally. 15 min later mice were sacrificed by cervical dislocation and striata rapidly 
dissected on ice. Tissue was homogenised and levels of amines and metabolites quantified by HPLC 
with reference to an internal standard (DHBA) A) Amine and metabolite levels in the striatum. DA 
levels are high in this region. B) Amines and metabolites in striatum as % change from saline 
control. Bars represent mean + SEM from 8-11 animals for each condition *p<0.05, ** p<0.01, *** 
p<0.001. Data was analysed by robust regression with treatment and study as factors, followed by 
William’s test to compare nicotine to control and multiple t-tests to compare tranylcypromine to 
control. See Appendix 4 for output. 
3.5.3.2. Frontal cortex 
In FC levels of DA are much lower than in striatum, however levels of 5-HT and 
NA are higher than those of the other compounds (Figure 3-14A). Figure 3-14B shows the 
responses in the frontal cortex as a percentage change from saline control for each amine 
and metabolite in order that the changes can be more clearly observed. Tranylcypromine 
induced a significant increase in DA levels (210 % of control; p<0.001) and decreased NA 
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Figure 3-14 eurochemical fingerprint of the PFC after nicotine administration 
Nicotine (0.3, 1 or 3 mg/kg), tranylcypromine (5 mg/kg) or saline was administered to mice 
intraperitoneally. 15 min later mice were sacrificed by cervical dislocation and PFC rapidly dissected 
on ice. Tissue was homogenised and levels of amines and metabolites quantified by HPLC with 
reference to an internal standard (DHBA) A) Amine and metabolite levels in the PFC. B) Amines 
and metabolites as % change from saline control. Bars represent mean + SEM from 8-11 animals for 
each condition *p<0.05, ** p<0.01, *** p<0.001. Data was analysed by robust regression with 
treatment and study as factors, followed by William’s test to compare nicotine to control and 
multiple t-tests to compare tranylcypromine to control. See Appendix 4 for output. 
Nicotine induced an increase in DA at both 1 mg/kg (132.8 % control; p=0.039) 
and 3 mg/kg (147.1 %; p=0.003; Figure 3-14). DOPAC is also increased at 3 mg/kg 
nicotine (171 % control, p=0.003). There are significant decreases in NA (3 mg/kg 86.7 %; 
p=0.006) and 5HIAA (1 mg/kg, 85.1 %, p=0.043; 3 mg/kg, 85.8 %, p=0.031). Nicotine 
induced no significant changes in HVA or 5-HT levels.  
All of the responses to nicotine are smaller than those to tranylcypromine in both 
regions, although not all responses are in the same direction. In particular DOPAC is 
increased after nicotine treatment and reduced after tranylcypromine. Overall it can be seen 
that the responses to nicotine are larger in the PFC than the striatum, in particular the 
increases in DA and DOPAC. There are also larger reductions in NA and 5HIAA in PFC 
than striatum. There are no significant differences in HVA or 5-HT in either region. These 
differences between the drugs and the brain regions will be discussed below. 
A 
B 
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3.5.3.3. Ratios 
The ratio of amines to their metabolites can also give insights into turnover so the 
ratios of several combinations of the amines were calculated. This may allow changes that 
are not significant for a particular amine or metabolite to be more clearly seen, indicative of 
changes in monoamine turnover.  
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Figure 3-15 Striatal and PFC neurochemical ratios 
Nicotine (0.3, 1 or 3 mg/kg), tranylcypromine (5 mg/kg) or saline (0.9 %) was administered to mice 
i.p. 15 min later mice were sacrificed by cervical dislocation and PFC and striata rapidly dissected 
on ice. Tissue was homogenised and levels of amines and metabolites quantified by HPLC with 
reference to an internal standard (DHBA). The ratios of amines and metabolites in A) striatum and 
B) PFC were calculated and are expressed as % change from control. Bars represent mean + SEM 
from 8-11 animals for each condition *p<0.05, ** p<0.01, *** p<0.001. Data was analysed by 
robust regression with treatment and study as factors, followed by William’s test to compare nicotine 
to control and multiple t-tests to compare tranylcypromine to control. See Appendix 4 for output. 
Here the ratios are shown as % changes from control ratio. In striatum 
tranylcypromine decreases the ratio of DOPAC to DA (p<0.001; Figure 3-15A). The 
5HIAA/5HT ratio was increased after tranylcypromine treatment (p=<0.001; Figure 3-15A) 
with a trend towards an increase in the 3 mg/kg nicotine dose (p=0.078). These changes are 
indicative of decreased DA turnover. Nicotine increases the ratio of DOPAC to DA (1 
mg/kg p=0.024; 3 mg/kg p=0.016), as well as the DOPAC/HVA (1 and 3 mg/kg; p< 0.001) 
A 
B 
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ratio with no significant effect on HVA/DA ratio. An increased DOPAC/DA ratio is 
indicative of increased turnover, supporting nAChR mediated DA release as an important 
mechanism in this region. 
The ratios of the data from FC were also calculated and are presented as percentage 
changes from control (Figure 3-15B). Tranylcypromine decreased the DOPAC/DA, 
HVA/DA, and DOPAC/HVA ratios in the PFC in comparison with saline (to 33 %, 
p<0.001, 46.2 %, p<0.001 and 70.2 %, p=0.013 respectively; Figure 3-15B) and increased 
the 5HIAA/5HT ratio to 165.8 % control (p<0.001; Figure 3-15B). This suggests again that 
tranylcypromine reduces dopaminergic neuronal firing. Nicotine decreased the HVA/DA 
ratio to 69.9 % control (p<0.016) and increased the DOPAC/HVA ratio to 185 % control 
(p<0.001). The 5HIAA/5HT ratio is also increased by nicotine (122.3 %, p=0.024 and 
125 %, p=0.008 at 1 and 3 mg/kg respectively). Unlike striatum there is no significant 
effect on the DOPAC/DA ratio, suggesting that this metabolic route is less affected by 
nicotine in FC than striatum. In contrast the changes in HVA/DA are larger in FC than 
striatum. 
In summary, there are differences in the profile of changes in ratios of amine and 
metabolites between tranylcypromine and nicotine. In particular the change in ratio of 
DOPAC to DA is reversed in striatum. In FC there is no difference in DOPAC/DA ratio in 
nicotine treated animals, whereas there are significant differences in striatum. Possible 
reasons behind these differences are discussed below (3.7.7). 
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3.6. Discussion - Microdialysis 
To verify that local administration of drug via the microdialysis probe can induce 
increases in NA levels in our hands, nomifensine administration was used as a positive 
control. Nomifensine (100 µM) elicited significant increases in both NA and DA in the FC 
as expected. Due to the large in vitro differences in the potency of 5IA in eliciting [3H]-NA 
release the responses in vivo elicited by local administration were measured by 
microdialysis.  
In the FC the β2* nAChR selective agonist 5IA elicited significant release above 
aCSF of NA at 1 and 100 µM, with equal efficacy of both drug concentrations. The 
responses reached a maximum by the second sample after the start of drug infusion, and 
returned to baseline within 30 min to an hour of the removal of drug. The response to 10 
µM 5IA was not significant, although it was not significantly different to the responses 
elicited by the other concentrations of drug. 
In HC there appeared to be small responses to 5IA administration (1 and 100 µM), 
although these were not significantly different to aCSF control. The responses at the two 
drug concentrations were not different from one another, although a sustained increase in 
NA was seen after the second (100 µM) administration. 
3.6.1. Critique of the microdialysis technique 
3.6.1.1. Spatial resolution 
For most brain regions in the rat (FC, HC etc) the probe is easily placed within the 
boundaries of the structure, indeed all of the probe placements in the current study were 
within the areas of interest (Figure 3-6 and Figure 3-8). Some fine detail (e.g. the NAcc 
shell) may be more difficult to target, especially taking into account the diffusion gradients 
established within the area surrounding the probe. Finer probes are being developed 
(primarily for use in mice) to help target these smaller structures more precisely. These 
finer probes also help reduce tissue damage around the probe tip. One technical drawback 
of the use of finer probes is the increase in back pressure produced if the flow rate is not 
reduced (Chen, 2008).  
Slow flow rates can affect recovery and delivery across the probe. A slow flow rate 
will allow more complete recovery, but generate smaller sample volumes and samples take 
longer to reach the collection tubes. This leads to greater degradation of neurotransmitters 
and also effects temporal resolution for collected samples. This can be overcome by the 
addition of a carrier flow after sample collection (See Figure 3-16 Cremers et al, 2009). 
Although this lessens the lag-time between brain and collection tube and increases the 
sample volume, there is also significant dilution of the sample. This leads to the next major 
consideration in microdialysis studies, the sensitivity of sample analysis. 
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Figure 3-16 A MetaQuant probe 
For ultraslow flow microdialysis a different probe type can be used in which the slow dialysis flow is 
supplemented by a carrier flow to aid faster sample collection. An artificial cerebrospinal fluid is 
typically delivered at 0.1 µl/min through the middle (yellow) inlet. The carrier flow (typically ultra-
purified water) is delivered through the left (blue) inlet at 0.9 µl/min. The right outlet thus yields a 
combined outflow of 1 µl/min, consisting of 0.10 µl/min dialysate and 0.9 µl/min water. Reproduced 
from Cremers et al 2009 with permission. 
3.6.1.2. Sample analysis 
One of the main technical limitations of microdialysis is in the analysis of the 
samples by HPLC-ECD. Although this technique is sensitive (measuring fmol amounts per 
sample) the resolution of chromatograms and the presence of interfering peaks from other 
compounds often means that in practice the limit of detection is higher in samples than 
from standards. Alterations of the buffer can go some way to moving interfering peaks 
away from the peak of interest, however when wishing to analyse multiple components 
(e.g. both NA and DA) compromises must often be made to retain peak resolution. Within 
this study it was decided to assess NA alone as attempts to analyse both NA and DA gave 
variable baselines and poor detection of DA. The assessment of NA alone was much more 
successful as it allows the optimal separation of early running peaks (such as NA) on the 
chromatogram. An alternative to HPLC-ECD is the use of capillary electrophoresis and 
laser-induced fluorescence detection (Parrot et al, 2004). This method uses microdialysis to 
collect samples but require much smaller sample volumes for analysis, allows better 
temporal resolution (around 20 sec) than other detection methods. As with mass 
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spectrometry the equipment for this technique is expensive and was unavailable for the 
present study. 
3.6.1.3. Drug delivery 
Nomifensine (100 µM) was effective in increasing NA and DA levels in FC (3.4.1). 
In vitro it was seen that nomifensine (0.5 µM) was effective in inhibiting NA uptake into 
FC prisms (2.3.1). This large difference in drug concentration is in part due to efficiency of 
delivery of drug across the probe membrane. Several studies have sought to address the 
question of drug concentration in tissue after local delivery via the probe, with differing 
results. Marshall et al (1997) showed that over a 15-min period 0.5% of the nicotine 
delivered was found in the brain, leading to a calculation that the perfusion of 3 mM 
nicotine for 15 min at 4 µl/min gave approximately µM concentrations in the tissue. 
Shearman et al (2005) used longer infusion periods and a slower flow rate (30 min at 1 
µl/min) and found that with 1 µM nicotine, levels in the brain were 10- 20% of that in the 
probe, with this increasing with longer perfusion periods. These estimates are quite 
different, as are the in vitro recoveries of neurotransmitter (6.9% in Marshall et al vs. 
around 20 % in Shearman et al) meaning that the estimation of drug concentrations 
delivered via a microdialysis probe is very difficult. These large differences between labs 
further emphasise the importance of consistency in probe types used. Drug diffusion over 
the probe membrane will depend on the molecular weight and the charges associated with 
the molecule as well as the active membrane area (Stenken, 1999) and so cannot be 
assumed to be the same from one drug to another, or the same as recovery of 
neurotransmitter. Diffusion away from the probe also gives a concentration gradient within 
the tissue. Although radioiodinated forms of 5IA exist due to its development as a PET 
ligand, they are not generally available so a drug diffusion study was not possible to 
quantify the exact concentrations within the brain tissue. 
3.6.1.4. Synaptic overflow 
Microdialysis does not measure levels of neurotransmitter at the synapse directly 
due to the size of the probe. Overflow of neurotransmitter around the synapse can be 
detected, and is influenced by release, diffusion and reuptake of the transmitter. For 
dopamine and noradrenaline sufficient diffusion away from the synapse occurs to give 
consistent recovery. This overflow has been shown to be action potential mediated by 
reduction by TTX and Ca2+ sensitivity (Westerink, 2000, di Chiara, 1990). For glutamate, 
synaptic transmission is much more tightly regulated; with a smaller amount of synaptic 
overflow occurring. The synaptic density of a region will affect the extrasynaptic 
monoamine content and so establishment of a stable baseline for comparison is important 
(Plock and Kloft, 2005). The increase in NA and DA seen in the current study (3.4.1) in 
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response to an infusion of nomifensine (100 µM) confirms the role of transporter mediated 
reuptake in modulating the levels of neurotransmitter. This is as expected as nomifensine is 
a monoamine transporter inhibitor, which inhibits both NET and DAT (Tuomisto, 1977). 
The differential regulation of glutamate and the monoamines has led to the theory 
of ‘wired transmission’, mainly the GABA/glutamate system, and ‘volume transmission’ 
with the monoamines as a modulatory system (Fuxe et al, 2010). The ‘volume’ referred to 
is the extracellular space, the very place accessed by microdialysis techniques. This 
hypothesis was formed based on observations of extraneuronal DA fluorescence after 
amphetamine treatment (Fuxe and Ungerstedt, 1970). These observations were supported 
by the high incidence of non-synapse forming varicosities demonstrated by Descarries et al 
(1975). It has been seen that a single noradrenergic neuron arising from the LC has as many 
as 170,000 varicosities within the HC of which only around 15 % form synaptic 
connections (Umbriaco et al 1995). This evidence suggests that the measurement of 
extrasynaptic overflow of NA is therefore valid as a marker of physiological changes. The 
TTX sensitivity of NA release from varicosities is thought to be due to the propagation of 
action potentials after the opening of preterminal nAChRs (Vizi et al 1995; Sershen et al, 
1997).  
As neurotransmitters and other substances are removed by microdialysis there is 
the possibility that this will affect the extrasynaptic levels of DA or NA. Sam and Justice 
(1996) investigated this possibility by using a range of flow rates for sample collection. 
They did not find any significant effect of flow rate on DA estimation using a zero net flux 
method. This suggests that microdialysis will cause minimal neurotransmitter depletion, 
and have little effect on transmission once a concentration gradient has been established. 
3.6.2. Study design 
Local administration of drug via the microdialysis probe was chosen for this study 
to reflect the terminal field stimulation that takes place in the in vitro assay. Livingstone et 
al (2009) administered 5IA locally via the probe into FC and found increases in DA. In the 
current study two infusions of drug at different concentrations were given to animals, 
separated by 90 min aCSF. This allowed more data to be gathered from each animal whilst 
allowing transmitter levels to return to baseline between infusions and minimising 
desensitisation. The timing of the second infusion was based on data from Livingstone et al 
(2009), showing that the DA level has returned to baseline by 90 min after 100 µM or 1 
mM 5IA infusion. In the present study the response to the second (higher concentration) 
drug infusion did not differ between the two groups with differing initial drug 
administration in FC, suggesting that desensitisation is minimal by the time of the second 
administration.  
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3.6.3. Response to 5IA in frontal cortex 
The level of DA in several of the basal samples was below the limit of detection of 
the system. This meant that the calculation of percentage basal for the DA responses was 
less accurate than for NA, leading to greater variability. As DA was not consistently 
detected it was decided to assess NA alone for this portion of the study. This also allowed 
better separation of the NA peak as discussed above (3.1.5), so responses were clearer.  
NA levels increased comparably in FC with the infusion of 1, 10 or 100 µM 5IA 
although the responses were much smaller than with nomifensine. Finding increases in NA 
levels that are comparable with a range of concentrations suggests that maximal responses 
at the top of the dose-response curve are being assessed. Taking into account the large 
differences between the findings of Marshall et al (1997) and Shearman et al (2005) a 
reasonable estimate of drug delivery across the probe may be around 5 %. This would give 
an estimate of drug concentrations in the nM range in the region of interest, depending on 
diffusion away from the probe. This shows that the potency of 5IA is extremely high as 
seen in vitro. Further experiments with a lower concentration range may be warranted and 
would be required to find a local EC50. Other than Livingstone et al (2009) there is no 
published work on the effects of 5IA on microdialysates to the author’s knowledge.  
The responses to 5IA were smaller than those to nomifensine, which may be a good 
thing as increases in catecholamines that are too high cause dysregulation of FC and 
possibly HC function (1.2). The increases are similar to responses seen with nicotine 
previously and so any cognitive benefits may be of a similar size, although the relative 
magnitude of the responses after systemic injections would be a better measure in terms of 
a clinically relevant administration protocol. 
The responses have fast kinetics, with rises in the first sample after start of drug 
infusion, which reach a maximum at the second sample after the start of administration. 
With 10 µM 5IA, the response does not reach the same peak and is slightly lower in the 
second than the first sample after the start of drug administration. Although this could be 
due to receptor desensitisation the same attenuated peak NA response is not seen with 100 
µM 5IA treatments and so desensitisation may not be the cause of this effect. 
The NA levels return to baseline swiftly upon the removal of drug with little or no 
residual effect. This shows a fast clearance of 5IA from the FC either by washout or 
metabolism or a desensitisation of the nAChRs to 5IA. Saji et al (2002) examined the 
metabolism of [125I]-5IA after systemic injection. Around 90 % of radioactivity in brain 
homogenates could be extracted, and formed a single peak on HPLC indicating that no 
metabolised 5IA was present within the brain in samples taken at various times up to one 
hour after injection. In blood, the contribution of unchanged 5IA to the overall radioactivity 
fell quickly over time, with two additional metabolite peaks on HPLC. By 15 min after 
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injection only 18 % of the radioactivity could be attributed to unchanged 5IA. These results 
indicate that either brain metabolism is minimal or that any 5IA metabolised within the 
brain is quickly cleared. The much faster decline in 5IA levels in blood than brain suggests 
that the former of these explanations is the case, and so after administration via a 
microdialysis probe directly to the brain, as in the present study, minimal metabolism of 
5IA will take place. This suggests that the fast return to baseline in NA responses after the 
removal of 5IA from the perfusion flow is due to washout or to receptor desensitisation. 
3.6.4. Response to 5IA in hippocampus 
As the HC was shown to have lower sensitivity of 5IA in vitro (Figure 2-8) it was 
decided on the basis of the results from FC to test at 1 and 100 µM 5IA. In HC responses to 
5IA were markedly less than in FC and NA release did not reach significance above control 
at 1 µM or 100 µM. No significance was found for single timepoints, although when 
analysed by two-way ANOVA the aCSF and drug treated curves did differ. This is 
suggestive of subtle effects that were not significant at any timepoint in post hoc analyses.  
The baseline response to manipulation seen in this study may have masked any 
significant drug effects. There was an increase in NA that correlated with the syringe 
changes in aCSF treated animals. This did not lead to significant differences from baseline; 
however this may have masked drug responses. The larger response to syringe 
manipulation in HC than FC is possibly due to the different function of the two brain 
regions as described in the introduction and further discussed below. Another explanation is 
that small pressure changes upon tubing switches may perturb the local environment, 
although as the perfusate flow is separated from the brain by the membrane this should be 
minimal. Changes to the aCSF in the ‘old’ vs. ‘new’ syringes (containing aCSF from the 
same batch) may occur whilst the syringe is flowing (and so not refrigerated) overnight, but 
this is unlikely to affect HC whilst leaving FC unaffected so should not be a significant 
factor. The HC is more involved in stress responses and spatial tasks, so it is probable that 
this larger response in aCSF animals is due to reaching over the animals to switch syringes 
although no overt stress responses were observed. This seems the most likely reason as the 
other explanations should affect FC and HC equally and such changes in aCSF NA levels 
were not seen in FC. 
3.6.5. Regional differences 
In HC a larger n (8) was used than in FC (4-5) to attempt to reduce variation, and 
overall it is no different to that from the FC data. The lack of significant response in HC is 
therefore likely to be due to differences in the magnitude of the response or the more 
responsive baseline than to a lack of numbers. Comparing the curve to those obtained from 
FC suggests that any response is of smaller magnitude with a less well defined peak shape. 
 - 114 - 
Differences in the peak response to locally administered nicotine were found by Shearman 
et al (2005), with the FC showing a slightly larger peak response than the HC but with 
more variability over the administration period.  
Although the responses were not significant in HC there seemed to be a slower 
return to baseline in HC than FC after drug administration. Local feedback via NA α2-
adrenoceptor autoreceptors may inhibit further NA release in the FC, leading to a faster 
termination of response to drug although α2-adrenoceptors have been shown to be active in 
HC both in vitro (Allgaier et al, 1993; Milusheva et al, 1994) and in vivo (Abercrombie et 
al, 1988; Thomas and Holman, 1991). This suggests that autoreceptor modulation is similar 
between the two regions and so not responsible for the differences in NA peak shape. 
Extrapolating from in vitro results, that are suggestive of α3β4* in HC as opposed 
to β2* nAChRs in FC, it may be possible that the slower return to baseline is due to nAChR 
subtype differences between these two regions. Differences in desensitisation of α3β4 and 
β2* have been demonstrated using electrophysiology in oocytes expressing known subunit 
combinations, with α3β4 nAChRs having a slower desensitisation and recovery in 
comparison with β2 containing nAChRs (Fenster et al 1997; Wu et al 2006). The subtypes 
involved could also be more complex, as discussed in section 2.6.3.2. 
Overall the data presented here support differences in the subtype of nAChR 
involved in modulating NA release, with higher sensitivity to β2* selective agonist in FC 
than HC. 
3.6.6. Further experiments 
Further work on the actions of 5IA in inducing NA release is required. There is a 
need to test lower concentrations of 5IA administered through the probe in order to find a 
dose response relationship due to the extremely high potency observed so far. This would 
be important in order to compare EC50 values between FC and HC.  
Antagonism of the response of FC DA to 5IA has already been shown with DHβE 
(Livingstone et al, 2009), and is likely to be the same for FC NA as inhibition has been 
seen in vitro (Figure 2-8). Antagonism with systemic mecamylamine of the HC responses 
may allow confirmation of a specific nicotinic effect causing the non-significant increase 
above aCSF. The use of a selective antagonist such as DHβE given locally would allow 
further confirmation of the subtypes of nAChR involved in FC and HC for comparison with 
in vitro data. As DHβE is a competitive antagonist, achieving an appropriate concentration 
to inhibit responses is critical as the inhibition may be overcome by high concentrations of 
agonist which may lead to the assumption that there is no β2* mediated component when in 
actuality it is just responding maximally. 
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To test the theory of differential sensitivity to desensitisation between FC and HC 
two possible protocols could be tested; either a longer infusion period of drug, with 
assessment to see whether responses decline over time, to separate washout from 
desensitisation, or repeated administration of the same concentration of 5IA to see if the 
magnitude of the responses stays the same. In order to optimise conditions and for 
comparison with Fu et al (1999), the interval between infusions could also be altered to 
investigate the timecourse of desensitisation and recovery of nAChRs. 
Testing the effects on NA and DA of systemic administration of 5IA in various 
brain regions may give an indication of the functional profile of these responses. Systemic 
administration would be interesting to show if there are regional differences in responses. 
This may differ from local administration due to cell body vs. terminal field effects. 5IA 
readily penetrates the blood brain barrier (as it was designed to do so) meaning that it is a 
good candidate for systemic administration. Most studies with 5IA have so far focussed on 
its role as a PET ligand, and so use tracer doses to show β2* receptor availability (Saji et al, 
2002). Systemic administration of 5IA has been recently shown to be effective in a number 
of behavioural tasks, in both cognitive enhancement and drug discrimination to nicotine 
(Smith et al 2007). Some studies have now been done with 5IA at behaviourally active 
doses, studying the effects on cognitive and learning tasks. In particular the responses in 
5CSRTT and the odour span task have been assessed and 5IA has been show to be active at 
doses of 6 µg/kg compared with nicotine at 0.025-0.1 mg/kg (Shaoib et al, personal 
communication). 
The tasks used are frontal cortex based, no reports of HC tasks are available to the 
author’s knowledge, and so it may be that these doses are selectively targeting β2* 
nAChRs. NA may not be the main mediators of the behavioural responses as β2* nAChRs 
are the most common nAChR subtype, and so likely to have effects on many transmitter 
systems including DA. Systemically mediated behavioural effects may involve the 
interaction of multiple brain regions and neurotransmitters. Now that some studies have 
been done with systemic 5IA, behaviourally active doses are known and so work would 
focus on observing the changes in NA seen with these doses, and whether the responses in 
HC as well as FC. We would expect DA changes in the striatum as this region is known to 
contain β2* nAChRs and DA levels are higher than in FC and so more easily detectable. 
There may be responses in HC NA levels if β2* nAChRs are on cell bodies rather than 
terminal fields, or if there are network effects. The fact that all the noradrenergic neurons 
assessed from the LC contained β2* nAChR mRNA (Lena et al, 1999) suggests that β2* 
nAChR mediated effects may be important in modulating NA responses more widely than 
is found by terminal field stimulation. 
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3.7. Discussion - Fingerprinting 
3.7.1. eurochemical fingerprinting 
The technique of neurochemical fingerprinting involves the assessment of a range 
of neurotransmitters and metabolites in tissue homogenates after drug administration. The 
restriction of this technique to a single timepoint for each animal limits the ability to create 
a timecourse. As with microdialysis the ability to create dose-response curves is limited in 
comparison with in vitro assays. The main advantage over microdialysis is the analysis of 
multiple compounds in a manner not possible for dialysates due to the larger quantities 
contained in homogenates. The use of homogenates means that assessment of compounds is 
in terms of total tissue content, not extracellular release. Whilst this allows the examination 
of changes in metabolism, it does not necessarily equate to changes in transmission. As 
entire brain regions are used for this technique it is less spatially defined than microdialysis 
and variation in dissection my affect results. Neurochemical fingerprinting is a much higher 
throughput technique than microdialysis, with a single injection of drug and collection of 
brain tissue at the appropriate time as opposed to surgery, a recovery period and lengthy 
sample collection periods. This means that although only a single timepoint or drug dose 
can be assessed for each animal it is possible to create dose response or time profiles 
relatively quickly although consideration must be given to minimising animal usage.  
3.7.2. Study design 
In this study it was chosen to assess the response to nicotine in the frontal cortex 
and in the striatum. These regions were chosen as they are expected to differ in their 
monoamine content, have accepted monoamine release in response to nAChR stimulation 
and are easy to dissect quickly, a prime concern to prevent post-mortem metabolism 
occurring. The range of metabolites observed differed from Tani et al (1997) who observed 
NA, MHPG, DA, DOPAC, 5HT and 5HIAA. In the present study NA, DA, DOPAC, HVA, 
3MT, 5HIAA and 5HT were assessed. This gives a more detailed picture of DA 
metabolism, likely to be the main aspect to vary between these regions. 
In order to determine the optimal timepoint at which to assess the effect of nicotine 
injection on monoamine metabolism a pilot study was undertaken. The times investigated 
were based on knowledge of the fast metabolism of nicotine in the mouse (t½ ~6.9 min) and 
a similar previous study (Tani et al, 1997) that found maximal effects in most parameters at 
15-30 min after nicotine administration. Tani et al (1997) also influenced the dose 
selection, as did Matta et al (2007). Two mice in the highest dose group (3 mg/kg) died of 
respiratory failure during the main experiment. Other papers had previously used this and 
higher doses and all the animals in the pilot study received this dose, so this problem was 
unexpected. The ED50 for induction of clonic seizures (a known side effect of high dose 
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nicotine) is >5 mg/kg in most strains (Matta et al, 2007). Data from the appropriate 
timepoint in the pilot study were included in the analysis of the main study data.   
As 3 mg/kg nicotine is also associated with significant toxicity the results from 0.3 
and 1 mg/kg nicotine groups are more reliable. In these groups the only significant response 
was an increase in DA in the PFC. Another factor that must be taken into consideration in 
the analysis of these results is that acute nicotine is anxiogenic, and the brain regions 
investigated respond to stress. This may change the interpretation of the results as it 
changes the assumption that any increase in neurotransmitter turnover is due to a nAChR 
mediated release in striatum or PFC, and raises the possibility of more global effects on the 
catecholaminergic pathways innervating these brain regions.  
3.7.3. DA release and metabolism  
Figure 3-17 illustrates DA release, reuptake and metabolism pathways. From the 
knowledge of these pathways the different profiles given by drugs with different 
mechanisms of action can be explained. The administration of d-Amphetamine increases 
3-MT and reduces DOPAC and DA due to a combination of DA release, and reuptake 
inhibition, forcing metabolism down the extracellular route. A DA reuptake inhibitor such 
as GBR-12909 will decrease DA turnover, leading to reduced DOPAC levels, and a 
monoamine oxidase inhibitor (MAOI) such as tranylcypromine leads to an increase in 3-
MT and a decrease in DOPAC and homovanillic acid (HVA). 
 
Figure 3-17 A schematic diagram of the release of DA and its metabolism  
Metabolism of DA by the intra- and extracellular routes. MAO - Monoamine oxidase, ADH - 
Aldehyde dehydrogenase, COMT – Catechol O-methyl transferase, TH – Tyrosine hydroxylase, DA 
– Dopamine, DOPA – Dihydroxyphenylalanine, DOPAC - 3,4-Dihydroxyphenylacetic acid, HVA – 
Homovanillic acid, 3MT - 3-Methoxytyramine 
3.7.4. Control of DA metabolism 
Tyrosine hydroxylase (TH) is the rate limiting enzyme is the formation of 
catecholamines. As the catecholamines can be toxic their formation is tightly regulated. 
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Tyrosine hydroxylase is regulated by many different mechanisms including feedback 
inhibition by the catecholamines (Kumer and Vrana, 1996). There are two DA binding sites 
on the tyrosine hydroxylase molecule, a high and a low affinity site (Gordon et al, 2008). 
The high affinity site has very slow dissociation kinetics and is generally fully occupied at 
physiological cytosolic dopamine concentrations. The low affinity binding site is thought to 
be the main regulator of catecholamine synthesis DA binding at this site reduces TH 
activity by around 12-fold (Gordon et al, 2008). 
Upon release of DA from the cell, vesicles are loaded from the cytosolic pool 
lowering the concentration of DA within the cell. This reduces the binding at the low 
affinity site, relieving the inhibition of TH and therefore increasing the production of DA. 
When DA levels increase binding occurs and TH activity is reduced. This dynamic 
regulation of TH activity gives close control of catecholamine levels within the cell, 
ensuring that a releasable pool is readily available, without the risk of toxicity from 
oxidized catecholamines. 
3.7.5. Tranylcypromine 
Tranylcypromine gives the expected results for its mechanism of action as a MAOI. 
This blocks the intracellular route of DA metabolism leading to a rise in DA, a fall in 
DOPAC and HVA which both depend on MAO for their formation, and a rise in 3MT. The 
MAO metabolism of 5HT to 5HIAA is also inhibited. 
In striatum tranylcypromine increased DA, reduced DOPAC, decreased HVA and 
increased 3MT (Figure 3.13). There was also a reduction in 5-HIAA. There was no 
significant change in NA or 5-HT, although there was a trend toward an increase in 5HT. 
There was a decrease in the DOPAC/DA ratio, indicative of a reduction in firing. There is 
also a reduction in the DOPAC/HVA ratio, which is due to the decrease in intracellular 
metabolism, as expected from the known mechanism of action of tranylcypromine. The 
increase in 5HIAA/5HT ratio is suggestive of an increased turnover of 5HT. 
In the PFC tranylcypromine again shows the effects that would be expected from 
its known MAO inhibition; however there is a decrease in NA, which is likely to reflect a 
marked reduction in synthesis with normal levels of release by exocytosis. Another 
explanation is that the decrease in NA is due to increased metabolism by COMT 
extracellularly, with insufficient synthesis to replenish cellular content. 
3.7.6. icotine 
The profiles of changes in metabolites differ between tranylcypromine and 
nicotine. The only significant response in the striatum with nicotine was an increase in 
DOPAC at the 3 mg/kg dose which as discussed above may be irrelevant due to the toxicity 
of nicotine at this dose (3.7.2). The ratio of DOPAC/DA is increased after 1 mg/kg nicotine 
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treatment, suggesting that there is increased DA turnover (a surrogate for increased firing), 
which is not seen as clearly by observing the individual compounds. The ratio of 
DOPAC/HVA is also increased after 1 mg/kg nicotine treatment as opposed to a decrease 
after tranylcypromine treatment and suggests that the increased DOPAC seen in this region 
is due to the increase in DA to DOPAC metabolism being faster than that of DOPAC to 
HVA, leaving a relative excess of DOPAC. 
In FC nicotine induced an increase in DA at both 1 mg/kg and 3 mg/kg. DOPAC 
only increased at 3 mg/kg. There are decreases in NA (at 3 mg/kg) and 5HIAA at 1 and 3 
mg/kg. Nicotine induced no significant changes in HVA or 5-HT levels. The ratios of 
transmitters and metabolites mostly show a similar profile of responses as seen in striatum; 
however DOPAC/DA is not significant, whereas HVA/DA is in FC. The ratio of 
DOPAC/HVA is strongly changed in favour of a relative increase in DOPAC. These 
changes to the ratio indicate that once again the increase in production of DOPAC due to 
higher turnover outstrips the increase in rate of HVA production, suggesting COMT as a 
rate limiting step in comparison with MAO/ADH action. The changes in 5HIAA/5HT are 
also significant in FC at 1 mg/kg nicotine where they were not in striatum; however the 
magnitude of the changes is similar. 
The changes in striatum in response to nicotine suggest an increased turnover of 
DA, which is to be expected upon nicotine administration as it elicits release. It may be 
expected to see increased HVA also as the end metabolite of DA; this is not seen possibly 
due to a rate limiting effects of COMT, or rapid clearance of HVA, preventing a buildup. 
In FC there is an increase in DA as well as DOPAC. Keeping in mind that the 
levels measured are total tissue content, and not extracellular content as for microdialysis, 
this is counter intuitive within the model of DA metabolism presented above where 
DOPAC is formed from DA that has been released and then taken back up into cells. A 
possible explanation for this may be a differing reuptake mechanism in FC from striatum, 
as has been previously postulated (see 2.6.2 and 3.7.7). 
3.7.7. Differences between PFC and striatum 
The changes induced differed between the two brain regions. There is evidence that 
the nAChR subtypes involved in DA release in FC and striatum differs with α4β2* 
nAChRs mediating release in FC and the striatum also containing around 30 % α-conotoxin 
MII sensitive α3/α6β2* nAChRs (Kulak et al, 1997; Grady et al, 2007; Livingstone et al, 
2009). Differentiating between these in this assay may be difficult due to a lack of selective 
ligands. α-conotoxin MII is a selective antagonist of α3/α6β2* containing nAChRs, 
however it does not cross the blood brain barrier and intracranial administration would not 
be feasible as it is invasive and the distribution of the drug may not be wide enough. As 
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both regions are mainly regulated by β2* containing nAChRs (Livingstone et al, 2009), it is 
unlikely that there are large enough differences in the subtypes involved to have caused the 
differences observed in these experiments. 
 
Figure 3-18 A schematic diagram of the release, and metabolism of DA and A in FC  
MAO - Monoamine oxidase, ADH - Aldehyde dehydrogenase, COMT – Catechol O-methyl 
transferase, TH – Tyrosine hydroxylase, NA – Noradrenaline, DA – Dopamine, DOPA – 
Dihydroxyphenylalanine, DOPAC - 3,4-Dihydroxyphenylacetic acid, HVA – Homovanillic acid, 
3MT - 3-Methoxytyramine 
The striatum is a region of the brain with dense dopaminergic innervation, whereas 
the dopaminergic innervation of the frontal cortex is sparser. It has been suggested that the 
reuptake mechanism of DA differs between FC and striatum, with the NET playing an 
important role in the FC (Williams and Steketee, 2004). Inhibition with nisoxetine which 
was shown to be selective for the NET over DAT by Wong and Bymaster, (1976), 
significantly reduces DA uptake at concentrations known to be selective for the NET. A 
possible model of the reuptake and metabolic pathways in the frontal cortex with a 
contribution of NET to DA uptake is shown (Figure 3-18). In this model DA is released as 
normal then taken up by NAdrenergic cells in the frontal cortex, within noradrenergic cells 
DA is metabolised to form DOPAC. This explanation leads to the assumption that the 
different route of uptake removes the inhibition on tyrosine hydroxylase DA production 
(3.7.4) in the initial dopaminergic cells; however as tyrosine hydroxylase is also the rate 
limiting enzyme in the production of NA, the DA taken up into noradrenergic cells may 
inhibit NA production. This model explains the concomitant rise in both DA and DOPAC 
after nicotine administration in this region as well as the reduction in NA. 
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The different reuptake mechanism between cortical regions and striatum may be 
due to the different levels of DAergic innervation. DAT levels vary between these regions 
both in terms of number of terminals and transporters per terminal (Sesack et al, 1998a; 
1998b) meaning that once DA has diffused away from its releasing cell it is more likely to 
be taken up by the NET as they are more prevalent. This mechanism has also been recently 
suggested to play a role in DA regulation in HC (Borgkvist et al, 2011). Another 
transporter mechanism that is widespread within these regions is the plasma membrane 
monoamine transporter (PMAT) which is a high volume, low affinity transporter with 
selectivity for DA and 5-HT over NA, epinephrine and histamine (Engel et al, 2004; Dahlin 
et al, 2007). This may provide an additional mechanism for monoamine clearance in those 
regions where spill over from the synapses is expected. 
The use of a selective NA uptake inhibitor (such as atomoxetine) in the current 
paradigm would allow the contribution of NET in DA clearance in FC compared to 
striatum to be assessed. Atomoxetine is known to be an effective treatment for ADHD, 
which is primarily treated with stimulant medications which increase DA levels. Stimulant 
medications also increase NA in PFC, as well as increasing DA in PFC and striatum. It has 
also been shown that the most efficacious drugs clinically increase both NA and DA 
transmission (Heal et al, 2008). Atomoxetine has been shown to increase both NA and DA 
in the PFC (Bymaster et al 2002). The rise in DA levels only happens in the FC (Swanson 
et al, 2006) whereas NA levels rise in all regions tested, suggesting that a different method 
of DA regulation (with significant uptake by NET) exists in PFC as suggested in Figure 
3-18. This paper however did not find detectable baseline levels of DA in HC, and so 
comparison with the suggestion of Blomkvist et al (2011) that HC DA is also taken up by 
the NET is not possible. To the author’s knowledge there are no selective inhibitors of 
PMAT available yet, and so assessing the contribution of this transporter would not be 
possible at the present time. 
3.7.8. Further experiments 
Use of selective agonists to assess regional differences in nAChR subtype 
involvement may not reveal many differences as both known to mainly be regulated by β2* 
nAChRs as far as DA release is concerned. The use of antagonists is limited due to lack of 
selectivity, and poor blood brain barrier penetration of conotoxins. The use of α7 nAChR 
selective drugs may be possible in this paradigm, especially with the ability of a selective 
positive allosteric modulator such as PNU-120596 to increase the α7 nAChR mediated 
portion of the effect. 
The assay could also be extended to the HC to attempt to measure differences in the 
subtypes involved to link with in vitro work. This may pose problems as the HC is more 
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difficult to dissect within the time frame needed to prevent post-mortem changes in the 
metabolite profile. To see if there are differences between FC and HC (as for in vitro 
preparations from rat see 2.3.2) a selective drug such as 5IA would be used, this drug has 
been shown to be systemically active only recently and so the doses that would activate one 
population of nAChR selectively are difficult to estimate. As a smaller subset of nAChRs 
would be activated by 5IA there may be a smaller risk of toxicity than for nicotine. 
The administration of atomoxetine would allow the contribution of different 
reuptake mechanisms between striatum and FC to be assessed. Based on Bymaster et al 
(2002) differences in the profile of changes in the two regions would be expected, with 
little change to DA metabolites in striatum and larger changes in FC. There is also evidence 
that the HC, again relatively sparsely innervated by DAergic neurons also has a proportion 
of DA reuptake mediated via NET (Borgkvist et al, 2011).  
Another modification to the assay would be to observe the changes in NA 
metabolites. The system used was optimised for the DA metabolites as well as NA and 
5HT, to analyse the NA metabolites in more detail would mean losing the detail for the DA 
metabolites. As NA is generally at lower concentrations within the brain due to sparser 
innervation the metabolites are also likely to be at lower concentrations and so there may be 
issues with the sensitivity of detection for this type of analysis. 
3.8. Summary and implications 
The data presented in this chapter suggest that the regulation of monoamines varies 
across the brain. NA release in response to local β2* nAChR stimulation varies between FC 
and HC, with greater responses that are cleared more quickly in FC. The regulation of DA 
in FC is different to that in striatum, with evidence to suggest that a model including 
clearance by NET may be appropriate, although this has not been tested in this study.  
The use of nicotinic ligands as therapeutics has been discussed in sections 1.4 and 
2.6.3. The data presented in this chapter show that there are many factors to consider when 
attempting to optimise neurotransmitter function. Both release and reuptake affect 
transmitter levels, with the regulation of metabolism of drug and transmitters also a factor. 
This emphasises the need for drugs to be tested in a variety of paradigms. The precise 
mechanisms of action of some drugs that have been shown to be behaviourally and 
clinically efficacious are not well known. Elucidating these mechanisms by the use of 
microdialysis and examination of the neurotransmitter metabolite profile may help define 
pharmacological targets for the future.  
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4. Summary and Future Directions 
4.1. Summary of results 
4.1.1. In vitro 
The use of a high throughput 96-well plate based filtration assay in Chapter 2 
allowed the assessment of [3H]-NA release from rat brain prisms. This thesis presents 
evidence that the regulation of [3H]-NA release from FC prisms is regulated by β2* 
nAChRs. This is contrasted with the HC, where results are in agreement with α3β4* 
nAChRs as the main subtype involved in modulating NA release. This difference is in spite 
of the fact that both regions contain primarily α4 and β2 subunits although HC does indeed 
contain a higher proportion of β4 nAChR than does the cortex (Gotti and Clementi, 2004). 
A proportion of the response in both regions was mediated indirectly via the actions of 
GABA, possibly acting in an excitatory manner through GABAA receptors. Interaction with 
the GABA system has previously been postulated by Barik and Wonnacott (2006) and 
Leslie et al (2002). 
Neither acute nor chronic in vivo nicotine treatment altered the profile of in vitro 
nicotinic responses in FC or HC. This is in agreement with Barik and Wonnacott (2006), 
although that paper found α7 nAChR mediated NA release from HC prisms which was 
increased during withdrawal. In the current study basal [3H]-NA efflux was increased in 
HC during withdrawal from chronic nicotine treatment but there were no differences in 
response to choline. [3H]-epibatidine binding was increased in tissue from chronically 
treated animals, and this upregulation persisted during early nicotine withdrawal. 
A number of analogs of cytisine were tested for their ability to displace 
[3H]-epibatidine binding from P2 brain membranes. Most of the compounds tested 
displaced the binding with similar or lower potency to cytisine itself. A number of the 
compounds were selected for trial in neurotransmitter release assays. Most of the selected 
compounds showed little or no ability to elicit neurotransmitter release, suggesting they act 
as weak partial agonists or competitive antagonists. None of the compounds were more 
efficacious in eliciting neurotransmitter release than cytisine showing that they remain 
partial agonists. 
4.1.2. In vivo 
In vivo microdialysis was used to monitor NA levels in the brain. Local 
administration of nomifensine increased the level of NA, showing that administration of 
drug via the perfusate flow is efficacious. In FC significantly increased NA in response to 
local administration of selective β2* nAChR agonist 5IA was observed. Increased DA 
levels in this region during 5IA administration have previously been reported (Livingstone 
et al, 2009). In HC with administration of the same concentrations of 5IA the increase in 
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NA level was not significant. Full differentiation of FC and HC responses was difficult, 
although the HC responses seemed to be blunted in comparison with FC. Overall the 
differences in responses may support in vitro work suggesting differing nAChR subtypes in 
the terminal field in these two brain regions, although further work is needed to confirm 
this. 
The profile of neurotransmitters and their metabolites 15 min after systemic 
administration of nicotine was observed in homogenates of mouse brain. In striatum, a 
richly dopaminergic region, nicotine produced a profile of responses consistent with 
increased turnover of DA. In FC the profile was broadly similar, although there is an 
increase in DA as well as its metabolites, indicating increased production. It is proposed 
that differences in the reuptake of DA within the FC may account for this as some DA is 
taken up by the NET in FC (Williams and Steketee, 2004). 
4.2. Comparison of techniques 
As discussed the main drawback of the 96-well in vitro assay is the very fact that it 
is in vitro, therefore lacking the connectivity and tonic innervation present in vivo. Its main 
advantage is to greatly increase throughput and allow the rapid construction of 
concentration response curves. In vivo techniques such as microdialysis are not good for the 
construction of dose-response curves as only 1-2 concentrations per animal can be reliably 
assayed for most drugs. The technique is costly in terms of time and animals used and so 
one of the aims of these assays was to confirm the translatability of the in vitro release 
assay for guidance to design microdialysis studies and define the questions to be asked. 
Validation of the translatability of in vitro to in vivo assays is difficult due to the small 
number of conditions examined in the microdialysis study, however finding differences in 
the terminal field responses of FC and HC as seen in vitro is encouraging. The difficulty in 
accurately determining the concentration of drug in the tissue due to diffusion gradients 
makes direct comparison of the concentrations administered by the two techniques 
complicated. A true test would be to examine full dose-response curves, but of course the 
point of the in vitro work is to reduce the number of animals used in vivo. 
Overall the results from both techniques indicate that the nAChR subtypes involved 
in NA release differ between the HC and FC. This shows that the in vitro assays are a good 
indicator of terminal field responses in vivo. Extension of the microdialysis work to include 
systemic injection of agonist may show that the extensive interactions between brain 
regions have modulatory influences and so that targeting particular regions is less 
straightforward than simply targeting selected nAChR populations. Dopaminergic inputs 
into the HC from the VTA may increase their firing after stimulation by β2* agonists, so 
although the terminal field is not stimulated directly HC responses may be affected. 
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4.3. Subunit differences 
The majority of noradrenergic projections in the brain arise from the LC. Although 
all cells examined in the LC contain β2 nAChR mRNA (Lena et al, 1999) the present work, 
in agreement with previous studies, has found a lack of involvement of β2 selective ligands 
on NA release in HC. The finding that FC NA release is influenced by β2* nAChRs shows 
that the mRNA can be translated and form functional receptors in the terminal regions of 
these cells. Hill et al (1993) showed that expression of the β2 subunit is widespread, and 
greatly in excess of that which arrives the plasma membrane as functional receptors. This 
may explain the relative abundance of β2* mRNA. Alternatively the β2 subunits may not 
be expressed in the terminal field of noradrenergic neurons in HC. Gotti and Clementi 
(2004) immunoprecipitated nAChRs from various brain regions and found high levels of β2 
in both cortex and HC, indicating that this subtype are indeed expressed in this region 
although the neuronal type was not identified. As discussed in Chapter 2 it is possible that 
the nAChRs on noradrenergic terminals in the HC contain β2 subunits, but in combination 
with β4 subunits. As occupation of two binding sites on the receptor is required for optimal 
function the lower affinity binding site may determine the perceived affinity of the receptor 
as a whole. This would give a much less sensitive receptor in HC if β2 is found in 
combination with β4 subunits.  
Overall, no matter the reason, β2* nAChRs are more important in the modulation 
of NA release in FC than HC, and this difference could open therapeutic avenues. 
4.4. Importance of differences 
As discussed earlier the differences in subtypes of nAChR involved in NA release 
between FC and HC may be important for targeting certain functions, or enhancing 
function whilst avoiding side effects. Many of the side effects of nicotinic drugs (nausea 
etc) are mediated by α3β4 nAChRs, therefore HC responses would be difficult to enhance 
as this is a major subtype involved in the release of NA in this region. FC NA could be 
more effectively targeted by use of β2* nAChR agonists, however striatal DA is also 
strongly influenced by β2* and so full agonists may have some abuse liability. Indeed the 
β2 subunit is important for drug discrimination and self-administration (Besson et al, 2006; 
Smith et al, 2007). 5IA is self administered by rats previously trained to administer cocaine 
(Liu et al 2003) and so may have abuse potential. Partial agonist therapy has been used 
with some success as a smoking cessation therapy however selectivity is often an issue still. 
The novel compounds presented here seem to show similar or reduced efficacy and potency 
at heteromeric nAChRs; however the selectivity profile has not been ascertained. 
Systemic administration of drugs (as would be required for a therapeutic 
application) may give differing profiles of responses to local administration whether in 
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vitro or in vivo. The many interconnections between cortical areas and the midbrain in 
particular suggest powerful feedback loops that may influence responses to drugs. The HC 
also has extensive connections with other brain regions and is innervated by midbrain 
dopaminergic neurons. These are likely to be sensitive to β2* selective ligands, and so there 
may be extensive modulation of HC activity not seen in the current experiments. 
Another way to target neurotransmitter levels is with selective reuptake inhibitors. 
Atomoxetine is in use for ADHD to increase FC NA levels. It also increases FC DA due to 
the uptake by NET in this region (Williams and Steketee, 2004). It has recently been 
demonstrated that the NET regulates DA uptake in the HC also (Blomkvist et al, 2011). 
Atomoxetine does not target the FC selectively and has a range of side effects. Nicotinics 
may be a useful adjunct as they could increase the release of NA and DA in FC, which 
would then remain elevated for longer due to the reuptake inhibition. This may allow usage 
of lower doses of atomoxetine and of the nicotinic agents than would be effective alone, 
assuming that the side effect profile is due to effects in other brain regions. 
The usefulness of animal models must also be considered. Whilst giving a good 
surrogate for some aspects of behaviour, many animal models require much inference to 
extrapolate to clinical models. Models of many disorders only characterize some of the 
deficits seen in the clinic. Modelling complex neurodegenerative disorders such as 
Parkinson’s disease for example requires the acute administration of neurotoxin, which 
whilst potentially providing an excellent model for neurotoxic lesions may not accurately 
reflect the progression of a disorder. Another drawback is the existence of species 
differences. Whilst for many cellular processes these are of minimal importance there is 
evidence that the predominance of different nAChR subtypes, for example, varies greatly 
between species with very little expression of α2 in mice, some expression in rats and 
widespread expression in primates. This means that some ligand interactions or prospective 
targets may not be discovered in rodent based animal studies, potentially risking side 
effects or missing an important therapeutic target. 
4.5. Future directions 
The development of lines of nAChR knockout mice has allowed the separation of 
some aspects of the function of nicotine, but it is difficult to know to what extent the 
remaining subunits compensate for those removed. This may mean that conclusions drawn 
from the use of knockout mice about the effect of the loss of a specific subunit may be due, 
in part, to increased expression of another (Champtiaux et al, 2003). The absence of some 
subunits may affect brain development; extensive signalling with α7 nAChRs is known to 
be important for the maturation of GABAergic system (Liu et al, 2007; Campbell et al, 
2010). 
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The development of more selective ligands for each possible subunit combination 
may help address these issues, however they would not be able to separate the more 
complex subtypes with two (or three) distinct binding sites. The generation of concatamers 
of nAChR subunits can allow the investigation of how more complex subtypes respond to 
ligands, however this expression will be in heterologous systems, and so may not represent 
subunit compositions that exist in vivo. 
Although targeting subtypes more effectively can help overcome side effects and so 
improve drug tolerability ligands that are more selective may not be the answer as 
therapeutics, for example the actions of antipsychotic drugs are across a broad range of 
receptor types, and the balance of these actions appears important for their efficacy. 
Investigation of the effect of targeting two or more known nAChR subtypes in combination 
may show synergistic effects and give new strategies for improving unmet treatment needs 
in many conditions. 
Whilst the work in this thesis goes some way to improving the definition of the 
nAChR subtypes involved in the regulation of NA release in the rodent brain, there is still 
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Appendix 1 
 
Reproduced from Smit et al, 2003 with permission 
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Appendix 2 
 
Probe and screw implantation 
Holes are drilled for the probe and two anchor screws. For the frontal cortex anchor 
screws are placed in the contralateral anterior and ipsilateral posterior skull plates to ensure 
firm fixing, for the hippocampus the two posterior skull plates have screws implanted. The 
microdialysis probe is lowered into position and a copper wire tether is attached to one 




After surgery the rat is attached to inlet and outlet tubing with aCSF flow driven by 
a syringe pump. Inlet tubing passes through a liquid swivel to allow free movement of the 
animal without twisting of the tubing. Samples are collected from the outlet tubing just 
below the level of the liquid swivel into polypropelene vials. A counterbalanced arm is 
used to take the strain of the animal’s movement via a tether spring, which is attached to a 
copper wire tether implanted within the dental cement on the animal’s skull. Bedding is 
provided and food and water are available ad libitum to the animal. 
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Appendix 3 
 
Example chromatogram for A and DA together 
Trace is the first nomifensine sample from one animal containing 17.5 fmol NA and 5.5 fmol DA. 
Basal sample DA levels were below 2 fmol, with some below the limit of detection. This was the 
case for each set of samples analysed with the mix method, and detection of NA was sometimes 
compromised by the shifting of peaks between sample sets. 
 
 
Example chromatogram for A alone 
Trace is a representative example of analysis for NA alone. Peak is 64 fmol NA and is well resolved 
from neighbouring peaks. 
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Example standard chromatograms 
A) monoamine and B) 3MT system. Five µl of calibration standard was injected onto each 
HPLC system. This equates to 0.2 ng of 3-MT, 0.5 ng of NA, DHBA, DA, DOPAC, 5-
HIAA and 5-HT and 1.0 ng of HVA on column. Peak area is calculated from integration of 
the curve above baselines. 
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Appendix 4 
FC pilot data 










   
Transformation: Log        
         
ANOVA table for   FcDa      
Source df ss ms F p    
Group 3 0.12454 0.04151 1.49 0.29    
Residual 8 0.22363 0.02795      
Shapiro-Wilk test for normality  p= 0.087    
         
ANOVA table for   FcNa      
Source df ss ms F p    
Group 3 0.04598 0.01533 5.7 0.022*    
Residual 8 0.02151 0.00269      
Shapiro-Wilk test for normality  p= 0.614    
         
ANOVA table for   FcDopac      
Source df ss ms F p    
Group 3 0.00602 0.00201 0.36 0.784    
Residual 8 0.04468 0.00558      
Shapiro-Wilk test for normality  p= 0.71    
         
ANOVA table for   Fc5hiaa      
Source df ss ms F p    
Group 3 0.0542 0.01807 7.49 0.010*    
Residual 8 0.01931 0.00241      
Shapiro-Wilk test for normality  p= 0.871    
         
ANOVA table for   FcHva      
Source df ss ms F p    
Group 3 0.05295 0.01765 2.29 0.155    
Residual 8 0.06169 0.00771      
Shapiro-Wilk test for normality  p= 0.286    
         
ANOVA table for   Fc5ht      
Source df ss ms F p    
Group 3 0.00247 0.00082 0.23 0.875    
Residual 8 0.02903 0.00363      
Shapiro-Wilk test for normality  p= 0.5    
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% 95 % CI t p 
A 3 32.215 13.55      
B 3 29.657 0.549 A 92.1 44.6,190.0 -0.26 0.799 
C 3 41.126 5.511 A 127.7 61.8,263.5 0.78 0.46 
D 3 54.134 2.678 A 168 81.4,346.9 1.65 0.137 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
      







% 95 % CI t p 
A 3 368.79 26.96      
B 3 276.81 23.13 A 75.1 59.9,94 -2.94 0.019* 
C 3 268.64 17.93 A 72.8 58.2,91.2 -3.25 0.012* 
D 3 256.06 12.07 A 69.4 55.5,86.9 -3.74 0.006** 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         







% 95 % CI t p 
A 3 43.355 7.308      
B 3 39.155 3.135 A 90.3 65.3,124.9 -0.73 0.489 
C 3 44.88 1.554 A 103.5 74.9,143.1 0.25 0.812 
D 3 43.582 2.563 A 100.5 72.7,139.0 0.04 0.971 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         







% 95 % CI t p 
A 3 111.97 9.661      
B 3 78.87 1.529 A 70.4 56.9,87.2 -3.79 0.005** 
C 3 80.721 4.727 A 72.1 58.3,89.2 -3.54 0.008** 
D 3 76.197 5.808 A 68 55.0,84.2 -4.17 0.003** 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks 
         







% 95 % CI t p 
A 3 121.55 5.821      
B 3 83.557 10.06 A 68.7 47.0,100.6 -2.27 0.053 
C 3 83.651 12.72 A 68.8 47.0,100.7 -2.26 0.053 
D 3 93.124 11.26 A 76.6 52.4,112.1 -1.61 0.145 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         







% 95 % CI t p 
A 3 837.17 42.27      
B 3 765.04 79.48 A 91.4 70.4,118.7 -0.8 0.449 
C 3 812.71 24.2 A 97.1 74.8,126.1 -0.26 0.8 
D 3 815.82 87.2 A 97.5 75.1,126.5 -0.23 0.825 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
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Striatum Pilot data 
Dependent variables StrDa StrNa StrDopac Str5hiaa StrHva Str5ht Str3mt 
Treatments: Group A  Saline B 10 min C     15 min 
D 
30 min 
   
Transformation: Log        
         
ANOVA table for   StrDa      
Source df ss ms F p    
Group 3 0.0065 0.00217 2.43 0.14    
Residual 8 0.00712 0.00089      
Shapiro-Wilk test for normality  p= 0.053    
         
ANOVA table for   StrNa      
Source df ss ms F p    
Group 3 0.02868 0.00956 1.64 0.255    
Residual 8 0.04651 0.00581      
Shapiro-Wilk test for normality  p= 0.234    
         
ANOVA table for   StrDopac      
Source df ss ms F p    
Group 3 0.02691 0.00897 1.7 0.243    
Residual 8 0.04212 0.00527      
Shapiro-Wilk test for normality  p= 0.249    
         
ANOVA table for   Str5hiaa      
Source df ss ms F p    
Group 3 0.0188 0.00627 2.02 0.189    
Residual 8 0.02479 0.0031      
Shapiro-Wilk test for normality  p= 0.151    
         
ANOVA table for   StrHva      
Source df ss ms F p    
Group 3 0.00321 0.00107 0.32 0.808    
Residual 8 0.02642 0.0033      
Shapiro-Wilk test for normality  p= 0.017*    
         
ANOVA table for   Str5ht      
Source df ss ms F p    
Group 3 0.00258 0.00086 0.41 0.751    
Residual 8 0.01683 0.0021      
Shapiro-Wilk test for normality  p= 0.577    
         
ANOVA table for   Str3mt      
Source df ss ms F p    
Group 3 0.01613 0.00538 0.11 0.951    
Residual 8 0.38808 0.04851      
Shapiro-Wilk test for normality  p= 0.154    
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Means and comparisons (The LSD test) for    StrDa  
Treatment n Adj mean SEM compared to % 95 % CI t p 
A 3 7722.1 585.2      
B 3 7824.3 135.3 A 101.3 89,115.30 0.23 0.821 
C 3 8731.2 72.85 A 113.1 99.4,128.7 2.19 0.06 
D 3 8549.1 114.4 A 110.7 97.3,126 1.81 0.107 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    StrNa  
Treatment n Adj mean SEM compared to % 95 % CI t p 
A 3 277.65 51.99      
B 3 217.29 10.12 A 78.3 56.2,108.9 -1.71 0.126 
C 3 245.22 8.306 A 88.3 63.5,122.9 -0.87 0.411 
D 3 207.97 10.85 A 74.9 53.8,104.2 -2.02 0.079 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    StrDopac  
Treatment n Adj mean SEM compared to % 95 % CI t p 
A 3 713.07 124.9      
B 3 813.38 31.08 A 114.1 83.3,156.2 0.96 0.363 
C 3 964.35 62.79 A 135.2 98.7,185.2 2.21 0.058 
D 3 785.2 22.96 A 110.1 80.4,150.8 0.71 0.5 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    Str5hiaa  
Treatment n Adj mean SEM compared to % 95 % CI t p 
A 3 331.14 42.45      
B 3 271.06 6.055 A 81.9 64.3,104.2 -1.91 0.092 
C 3 261.13 6.566 A 78.9 61.9,100.4 -2.27 0.053 
D 3 278.21 18.34 A 84 66,107 -1.66 0.135 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    StrHva  
Treatment n Adj mean SEM compared to % 95 % CI t p 
A 3 1625.9 241.9      
B 3 1520.7 20.11 A 93.5 72.9,120 -0.62 0.553 
C 3 1681.8 27.52 A 103.4 80.6,132.7 0.31 0.763 
D 3 1570.3 43.73 A 96.6 75.3,123.9 -0.32 0.756 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    Str5ht  
Treatment n Adj mean SEM compared to % 95 % CI t p 
A 3 632.8 64.21      
B 3 583.38 21.38 A 92.2 75.6,112.5 -0.94 0.373 
C 3 633.51 11.13 A 100.1 82.1,122.1 0.01 0.99 
D 3 622.67 33.68 A 98.4 80.7,120 -0.19 0.856 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    Str3mt  
Treatment n Adj mean SEM compared to % 95 % CI t p 
A 3 370.44 110.8      
B 3 320.66 95.2 A 86.6 33.3,224.9 -0.35 0.736 
C 3 313.46 88.03 A 84.6 32.6,219.9 -0.4 0.697 
D 3 294.09 86.44 A 79.4 30.6,206.3 -0.56 0.593 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
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FC main study 
Dependent 
variables 
    FcDa FcNa FcDopac  







E 3 mg/kg   
Blocks: Study        
Transform: Log        
       




p      
Study 1 0 0.968      
Group 4 41.46 <0.001***      
         
Extreme observations with | Studentised residual|>3     
Subject Group Value Z      
p3A A 75.8 4.136926      
4 A 61.2 3.1316453      
Shapiro-Wilk test for normality  p= 0.096    
         




p      
Study 1 1.02 0.313      
Group 4 46.72 <0.001***      
         
Extreme observations with | Studentised residual|>3     
Subject Group Value Z      
28 B 175.4 -3.807218      
14 D 219.9 -3.92188      
Shapiro-Wilk test for normality  p=<0.001***    
         




p      
Study 1 0.97 0.326      
Group 4 36.68 <0.001***      
         
Extreme observations with | Studentised residual|>3     
Subject Group Value Z      
24 A 3.2 -4.784402      
Shapiro-Wilk test for normality  p= 0.032*    
         




p      
Study 1 1.64 0.201      
Group 4 35.12 <0.001***      
         
Extreme observations with | Studentised residual|>3     
Subject Group Value Z      
20 A 169.9 4.7731595      
28 B 107 4.3241555      
7 C 137 3.5308075      
19 D 157.1 5.5924255      
Shapiro-Wilk test for normality  p=<0.001***    
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p      
Study 1 0.54 0.461      
Group 4 3.18 0.528      
         
Extreme observations with | Studentised residual|>3     
         
Subject Group Value Z      
20 A 158.9 4.699276      
Shapiro-Wilk test for normality  p= 0.139    
         




p      
Study 1 7.16 0.007**      
Group 4 6.45 0.168      
         
Extreme observations with | Studentised residual|>3     
         
Subject Group Value Z      
14 D 449 -3.078997      
Shapiro-Wilk test for normality  p= 0.295    
         
Means and comparisons (The LSD test) for    FcDa  
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 31.97 3.958      
B 8 67.195 4.411 A 210.2 161.6,273.3 5.73 
<0.001
*** 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    FcNa  
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 340.01 7.818      
B 8 258.78 17.35 A 76.1 68.6,84.5 -5.3 
<0.001
*** 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    FcDopac  
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 13.532 2.37      
B 8 8.0104 1.144 A 59.2 41.2,85 -2.93 
0.006*
* 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    Fc5hiaa  
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 103.26 5.505      
B 8 68.064 4.45 A 65.9 56.8,76.5 -5.69 
<0.001
*** 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
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Means and comparisons (The LSD test) for    FcHva  
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 74.293 7.404      
B 8 68.613 5.992 A 92.4 73.1,116.6 -0.69 0.494 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    Fc5ht  
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 553.01 12.6      
B 8 575.55 16.88 A 104.1 95,114 0.89 0.379 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The Williams test) for   FcDa   
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 31.97 3.958      
C 8 34.24 1.737 A 107.1 81.6,140.6 0.53 0.6 
D 8 42.458 4.7 A 132.8 100.0,183.6 2.19 0.039* 
E 9 47.023 3.397 A 147.1 108.8,198.9 3.19 
0.003*
* 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The Williams test) for   FcNa   
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 340.01 7.818      
C 8 352.91 16.74 A 103.8 93.2,115.6 0.72 1 
D 8 328.33 18.48 A 96.6 86.7,107.6 -0.68 0.599 
E 9 294.75 9.719 A 86.7 76.9,97.7 -2.98 
0.006*
* 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The Williams test) for   FcDopac   
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
         
A 11 13.532 2.37      
C 8 14.099 1.452 A 104.2 71.6,151.7 0.23 0.82 
D 8 18.331 2.746 A 135.5 93.1,197.2 1.7 0.113 
E 9 23.143 1.717 A 171 112.8,259.4 3.22 
0.003*
* 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The Williams test) for   Fc5hiaa   
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 103.26 5.505      
C 8 94.465 5.508 A 91.5 78.4,106.7 -1.21 0.232 
D 8 87.849 6.81 A 85.1 72,100 -2.15 0.043* 
E 9 88.552 5.191 A 85.8 72,100 -2.3 0.031* 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
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Means and comparisons (The Williams test) for   FcHva   
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 74.293 7.404      
C 8 77.432 4.663 A 104.2 81.8,131.2 0.36 0.853 
D 8 84 7.847 A 113.1 82.2,131.2 0.4 0.853 
E 9 72.643 3.641 A 97.8 83.6,131.2 0.43 0.853 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The Williams test) for   Fc5ht   
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 553.01 12.6      
C 8 537.43 15.56 A 97.2 88.4,106.8 -0.64 1 
D 8 583.13 26.74 A 105.4 96,115.90 1.18 0.292 
E 9 593.19 23.27 A 107.3 98.2,117.1 1.68 0.124 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
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Striatum main study 
Dependent 
variables StrDa StrNa StrDopac Str5hiaa StrHva Str5ht Str3mt  
Treatments: Group        
Blocks: Study        
Transformation: Log        
         
Robust regression tests for  StrDa     
Source df 
Chi 
squared p      
Study 1 18.22 <0.001***      
Group 4 7.71 0.103      
         
Extreme observations with | Studentised residual|>3     
Subject Group Value Z      
p3A A 7221.4747 -3.876681      
34 A 6403.4791 -3.883954      
27 E 6747.3646 -3.166531      
Shapiro-Wilk test for normality p= 0.023*    
         
Robust regression tests for  StrNa     
Source df 
Chi 
squared p      
Study 1 0.2 0.653      
Group 4 8.36 0.079      
         
Extreme observations with | Studentised residual|>3     
Subject Group Value Z      
p10A A 461.2 3.0678656      
20 A 494.1 3.8165179      
Shapiro-Wilk test for normality p= 0.023*    
         
Robust regression tests for  StrDopac     
Source df 
Chi 
squared p      
Study 1 23.17 <0.001***      
Group 4 185.31 <0.001***      
         
Extreme observations with | Studentised residual|>3     
Subject Group Value Z      
p3A A 537.9 -3.547477      
Shapiro-Wilk test for normality p= 0.228    
         
Robust regression tests for  Str5hiaa     
Source df 
Chi 
squared p      
Study 1 0.22 0.636      
Group 4 7.92 0.095      
         
Extreme observations with | Studentised residual|>3     
Subject Group Value Z      
19 D 420.9 4.3998556      
Shapiro-Wilk test for normality p=<0.001***    
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Robust regression tests for  StrHva     
Source df 
Chi 
squared p      
Study 1 14.26 <0.001***      
Group 4 14.88 0.005**      
         
Extreme observations with | Studentised residual|>3     
Subject Group Value Z      
p3A A 1216.6 -3.329819      
21 D 1030.1 -3.045726      
Shapiro-Wilk test for normality p= 0.171    
         
Robust regression tests for  Str5ht     
Source df 
Chi 
squared p      
Study 1 0.18 0.668      
Group 4 7.52 0.111      
         
Extreme observations with | Studentised residual|>3     
Subject Group Value Z      
19 D 979.6 5.1294179      
Shapiro-Wilk test for normality p= 0.006**    
         
Robust regression tests for  Str3mt     
Source df 
Chi 
squared p      
Study 1 1.17 0.279      
Group 4 29.71 <0.001***      
         
Shapiro-Wilk test for normality p= 0.064    
         
Means and comparisons (The LSD test) for   StrDa  
Treatment n Adj mean SEM 
compared 
to % 95 % CI t p 
A 11 7753.5 222.7      
B 8 8326.4 96.24 A 107.4 101.5,113.6 2.57 0.014* 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks 
         
Means and comparisons (The LSD test) for   StrNa  
Treatment n Adj mean SEM 
compared 
to % 95 % CI t p 
A 11 291.21 20.77      
B 8 331.14 24.7 A 113.7 97,133.40 1.63 0.111 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks 
         
Means and comparisons (The LSD test) for   StrDopac  
Treatment n Adj mean SEM 
compared 
to % 95 % CI t p 
A 11 611.83 40.59      
B 8 292.65 15.9 A 47.8 40.9,56 -9.5 <0.001*** 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks 
         
Means and comparisons (The LSD test) for   Str5hiaa  
Treatment n Adj mean SEM 
compared 
to % 95 % CI t p 
A 11 260.72 14.52      
B 8 218.16 17.57 A 83.7 71.4,98.1 -2.27 0.029* 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks 
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Means and comparisons (The LSD test) for   StrHva  
Treatment n Adj mean SEM 
compared 
to % 95 % CI t p 
A 11 1401.4 78.43      
B 8 1180.6 50.8 A 84.2 72.8,97.6 -2.37 0.023* 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks 
         
Means and comparisons (The LSD test) for   Str5ht  
Treatment n Adj mean SEM 
compared 
to % 95 % CI t p 
A 11 626.4 23.3      
B 8 701.27 39.19 A 112 98.8,126.8 1.84 0.074 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks 
         
Means and comparisons (The LSD test) for   Str3mt  
Treatment n Adj mean SEM 
compared 
to % 95 % CI t p 
A 11 306.55 34.47      
B 8 580.4 52.41 A 189.3 135.2,265.2 3.84 <0.001*** 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks 
         
Means and comparisons (The Williams test) for  StrDa   
Treatment n Adj mean SEM 
compared 
to % 95 % CI t p 
A 11 7753.5 222.7      
C 8 8145.7 136.7 A 105.1 97.2,108.7 1.06 0.351 
D 8 7913.3 147.5 A 102.1 97.2,108.7 1.06 0.351 
E 9 7910.1 191.4 A 102 97.6,108.7 1.14 0.332 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks 
         
Means and comparisons (The Williams test) for  StrNa   
Treatment n Adj mean SEM 
compared 
to % 95 % CI t p 
A 11 291.21 20.77      
C 8 316.35 17.09 A 108.6 92.1,128.2 1.05 1 
D 8 288.09 15.93 A 98.9 83.9,116.7 -0.14 1 
E 9 265.67 7.133 A 91.2 78.2,106.4 -1.25 0.276 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks 
         
Means and comparisons (The Williams test) for  StrDopac   
Treatment n Adj mean SEM 
compared 
to % 95 % CI t p 
A 11 611.83 40.59      
C 8 705.62 29.86 A 115.3 98,135.70 1.84 0.074 
D 8 753.78 28.61 A 123.2 99,137.10 1.97 0.064 
E 9 678.48 27.89 A 110.9 100.0,139.6 2.11 0.048* 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks 
         
Means and comparisons (The Williams test) for  Str5hiaa   
Treatment n Adj mean SEM 
compared 
to % 95 % CI t p 
A 11 260.72 14.52      
C 8 259.45 13.2 A 99.5 84.4,117.4 -0.06 0.951 
D 8 226.71 18.96 A 87 77.5,106.6 -1.28 0.246 
E 9 244 9.809 A 93.6 77.5,105.4 -1.38 0.222 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks 
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Means and comparisons (The Williams test) for  StrHva   
Treatment n Adj mean SEM 
compared 
to % 95 % CI t p 
A 11 1401.4 78.43      
C 8 1508.9 57.59 A 107.7 92.7,125.6 1.05 1 
D 8 1515 83.13 A 108.1 92.7,125.6 1.05 1 
E 9 1349 66.19 A 96.3 83.5,110.9 -0.57 0.734 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks 
         
Means and comparisons (The Williams test) for  Str5ht   
Treatment n Adj mean SEM 
compared 
to % 95 % CI t p 
A 11 626.4 23.3      
C 8 616.16 21.99 A 98.4 86.5,111.9 -0.27 0.79 
D 8 598.68 41.23 A 95.6 85.8,110.2 -0.53 0.734 
E 9 613.46 16.91 A 97.9 85.8,109.2 -0.56 0.734 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks 
         
Means and comparisons (The Williams test) for  Str3mt   
Treatment n Adj mean SEM 
compared 
to % 95 % CI t p 
A 11 306.55 34.47      
C 8 322.95 41.19 A 105.3 74.3,149.4 0.31 1 
D 8 259.51 12.95 A 84.7 59.9,120 -1 0.386 
E 9 254.13 29.86 A 82.9 59.9,114.8 -1.21 0.296 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks 
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E 3 mg/kg   
Blocks: Study        
Transform: Log        
         




p      
Study 1 11.08 <0.001***      
Group 4 321.34 <0.001***      
Shapiro-Wilk test for normality  p= 0.574    
         




p      
Study 1 3.01 0.083      
Group 4 23.04 <0.001***      
Shapiro-Wilk test for normality  p= 0.927    
         




p      
Study 1 4.29 0.038*      
Group 4 371.87 <0.001***      
Shapiro-Wilk test for normality  p= 0.087    
         




p      
Study 1 0.15 0.702      
Group 4 33.1 <0.001***      
Shapiro-Wilk test for normality  p= 0.771    
         




p      
Study 1 0.34 0.558      
Group 4 87.68 <0.001***      
         
Extreme observations with | Studentised residual|>3     
         
Subject Group Value Z      
24 A 0.1230769 -4.106303      
19 D 0.959375 3.5884041      
Shapiro-Wilk test for normality  p= 0.179    
         




p      
Study 1 0 0.985      
Group 4 35.36 <0.001***      
Shapiro-Wilk test for normality  p= 0.219    
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p      
Study 1 0.54 0.462      
Group 4 50.21 <0.001***      
         
Extreme observations with | Studentised residual|>3     
         
Subject Group Value Z      
24 A 0.0626223 -3.889758      
Shapiro-Wilk test for normality p= 0.021*    
         




p      
Study 1 0.06 0.804      
Group 4 41.13 <0.001***      
         
Extreme observations with | Studentised residual|>3     
         
Subject Group Value Z      
28 B 0.2113789 4.1809265      
Shapiro-Wilk test for normality  p= 0.033*    
         
Means and comparisons (The LSD test) for    StrDaDopacRat 
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 0.0776 0.003      
B 8 0.0346 0.002 A 44.6 39.3,50.6 -12.9 
<0.001
*** 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    StrDaHvaRat 
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 0.1773 0.007      
B 8 0.1412 0.006 A 79.6 69.8,90.9 -3.49 
0.001*
* 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    StrDopacHvaRat 
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 0.4298 0.012      
B 8 0.2441 0.009 A 56.8 52,62 -13.1 
<0.001
*** 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    Str5hiaa5htRat 
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 0.4312 0.017      
B 8 0.3154 0.019 A 73.2 64.8,82.6 -5.21 
<0.001
*** 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
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Means and comparisons (The LSD test) for    FcDaDopacRat 
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 0.3757 0.06      
B 8 0.1238 0.018 A 33 24,45.3 -7.06 
<0.001
*** 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    FcDaHvaRat 
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 2.2079 0.28      
B 8 1.0198 0.1 A 46.2 34,62.7 -5.11 
<0.001
*** 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    FcDopacHvaRat 
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 0.1738 0.022      
B 8 0.1221 0.014 A 70.2 53.4,92.4 -2.61 0.013* 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The LSD test) for    Fc5hiaa5htRat 
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 0.1917 0.01      
B 8 0.1156 0.01 A 60.3 50.8,71.6 -5.99 
<0.001
*** 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The Williams test) for   StrDaDopacRat  
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 0.0776 0.003      
C 8 0.0865 0.003 A 111.5 100,100 1.74 0.09 
D 8 0.0936 0.003 A 120.6 100.134.3 2.39 0.024* 
E 9 0.0871 0.003 A 112.2 100.4,134.3 2.56 0.016* 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The Williams test) for   StrDaHvaRat  
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 0.1773 0.007      
C 8 0.1864 0.007 A 105.1 91.7,120.5 0.77 1 
D 8 0.1856 0.01 A 104.7 91.3,120 0.71 1 
E 9 0.1715 0.007 A 96.7 85.2,109.9 -0.54 0.751 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The Williams test) for   StrDopacHvaRat  
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 0.4298 0.012      
C 8 0.4677 0.009 A 108.8 99.4,119.2 1.95 0.058 
D 8 0.5033 0.015 A 117.1 105.1,130.5 3.65 
<0.001
*** 
E 9 0.5109 0.013 A 118.9 107.5,131.5 4.29 
<0.001
*** 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
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Means and comparisons (The Williams test) for   Str5hiaa5htRat  
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 0.4312 0.017      
C 8 0.424 0.013 A 98.3 86.7,111.5 -0.28 0.781 
D 8 0.3837 0.015 A 89 80,102 -1.77 0.097 
E 9 0.3913 0.014 A 90.8 80,101.10 -1.9 0.078 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
  
Means and comparisons (The Williams test) for   FcDaDopacRat  
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 0.3757 0.06      
C 8 0.4074 0.042 A 108.4 74.3,143.9 0.21 0.982 
D 8 0.3705 0.053 A 98.6 74.3,143.9 0.21 0.982 
E 9 0.4935 0.029 A 131.3 96.6,178.7 1.86 0.085 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The Williams test) for   FcDaHvaRat  
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 2.2079 0.28      
C 8 2.1944 0.13 A 99.4 72.4,136.5 -0.04 0.968 
D 8 1.8218 0.228 A 82.5 60.1,113.3 -1.27 0.25 
E 9 1.5359 0.125 A 69.6 48.9,98.9 -2.58 0.016* 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The Williams test) for   FcDopacHvaRat  
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 0.1738 0.022      
C 8 0.1805 0.012 A 103.8 78.2,138 0.28 0.782 
D 8 0.2091 0.015 A 120.3 90.5,159.8 1.36 0.214 
E 9 0.3216 0.02 A 185 135,253.50 4.88 
<0.001
*** 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
         
Means and comparisons (The Williams test) for   Fc5hiaa5htRat  
Treatment n Adj mean SEM 
compared 
to 
% 95 % CI t p 
A 11 0.1917 0.01      
C 8 0.1763 0.008 A 92 77,109.80 -0.99 0.327 
D 8 0.1567 0.01 A 81.7 66.2,100 -2.39 0.024* 
E 9 0.1533 0.01 A 80 65.7,97.3 -2.84 
0.008*
* 
Adj mean are back-transformed means adjusted for any unbalance in covariates/blocks  
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